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IV 
Abstract 
 
Background and research questions- Breast cancer is the most common cancer not 
only affecting Australian women, but women world-wide. Breast lymphoedema is a 
recognised complication of breast cancer treatment. Due to improved diagnosis and 
treatment, more women are surviving breast cancer. As a consequence, preventing 
and treating those complications associated with breast cancer, such as breast 
lymphoedema, are paramount. Yet a lack of standard diagnostic criteria and 
measuring procedures make identifying the prevalence and incidence of this 
condition challenging. As a result, initiating and comparing research is difficult and 
hampers evaluation of the effectiveness of treatment and translation into clinical 
practice. The objectives of this project were to: 
 
1. identify features of breast lymphoedema considered important in the literature, 
to clinicians, and to affected patients.  
2. incorporate those features, as items into a valid and reliable questionnaire, that 
would be simple and convenient to administer. 
3. develop a definition for breast lymphoedema. 
 
Methods- In the first part of the study a literature search and clinician interviews 
were conducted to identify a pool of items that may be relevant to include in a health 
status questionnaire for women with breast lymphoedema. Duplicate items were 
reduced and remaining items were integrated to form an item elicitation 
questionnaire. Next, 50 patients with medically diagnosed breast lymphoedema were 
interviewed to determine how breast lymphoedema affected their lives. The item 
elicitation questionnaire was used to facilitate these interviews. Items were evaluated 
against three criteria; severity, frequency and importance. Those items that satisfied 
the criteria were included in the first draft of the questionnaire. At this stage the 
questionnaire was formatted and then pilot tested with five clinicians and two groups 
of nine patients. 
 
Another 30 patients diagnosed with breast lymphoedema were invited to participate 
in the next part of the study. Reliability was determined using duplicate
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administration of the BLYSS questionnaire, with a 24 hour interval. Patients were 
also timed to determine the approximate length of time to complete the BLYSS 
questionnaire.  
 
Aspects of validity, including face, content, construct, discriminant and convergent 
validity were determined by administration of the General Health-12 Questionnaire 
(GHQ-12) (1) and evaluation of the cosmetic appearance of the breast following 
breast conservation therapy using the modified Harris scale (2). Harris Scale scoring 
was performed by two experienced health professionals from the Breast Clinic at 
Royal Perth Hospital. 
 
During the first part of the study, a group of experts in the area of lymphoedema was 
formed. The purpose was to develop a consensus definition for breast lymphoedema 
using methods based on the Delphi technique. This is a type of consensus method 
using group facilitation with experts in the given field. 
 
Results- Sixty six items were identified from the literature and 31 from the clinician 
interviews.  Nine items were retained after the 50 patient interviews and screening 
against the pre-determined criteria. Two additional items were identified during 
analysis of the first 10 interviews. As a result these items were added to the item 
elicitation questionnaire and satisfied inclusion criteria for questionnaire items. The 
questionnaire underwent several revisions before undergoing the first round of pilot 
testing. After two rounds of pilot testing, consensus was generated from all clinicians 
and patients and no further reviews were undertaken.  
 
Thirty seven articles on the use of the terms breast oedema and/or breast 
lymphoedema and whether and how this was defined, were identified from the 
literature. As no existing definition for breast lymphoedema was identified, a 
consensus group was formed. Seven experts were contacted, and agreed to 
participate. Three rounds of email correspondence were undertaken and a definition 
formulated, based on the location, nature, timing and differential diagnosis of breast 
lymphoedema. 
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Following this, the reliability and validity of the BLYSS questionnaire were 
determined. Reliability was established as excellent at 0.948. On average the 30 
patients took 2 minutes and 14 seconds (standard deviation of 0.72) to complete the 
BLYSS questionnaire. 
 
Discrimination, convergence and criterion validity were determined by considering 
the associations between the BLYSS questionnaire and two other forms of 
assessment. These were the modified Harris score (2) and the GHQ-12 (1). 
 
There were significant correlations between the BLYSS and GHQ-12 (1) scores 
(Spearman’s rho=0.58; p=0.05 at the first administration, and Spearman’s rho=0.50; 
p=0.05 at the second administration of the BLYSS questionnaire and GHQ-12 (1)). 
There was a significant association between the two clinicians’ modified Harris 
scores (2) (Kappa coefficient 0.59; percentage agreement 77%). There were poor 
correlations between the BLYSS questionnaire and both clinicians’ modified Harris 
scores. 
 
Discussion- The development of the BLYSS questionnaire was undertaken to 
measure health status in women with breast lymphoedema as a result of breast cancer 
treatment. This project has addressed two issues critical to the forward progression of 
research concerning breast lymphoedema. In particular, a working definition for 
breast lymphoedema was constructed using a consensus technique and applied to the 
validation part of the study. Also a patient self-reported health status questionnaire 
was developed. 
 
The approach to questionnaire development was designed to not only maximise the 
chances of developing a useful questionnaire that struck a balance between patients’ 
needs (that it contained items considered important to patients with breast 
lymphoedema), clinicians’ needs (that it would be simple and convenient to 
administer), and scientific needs (to establish its validity and reliability). 
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The BLYSS questionnaire will be useful for clinicians treating breast lymphoedema. 
It will also be useful as a condition specific outcome measure for research projects 
acquiring evidence for clinical practice. The definition not only can be applied to 
patients in clinical and research settings, but provides a template for further 
discussion and works.  
 
Conclusion- To date the BLYSS questionnaire is the only valid and reliable tool 
available to measure health status in women with breast lymphoedema as a result of 
breast cancer treatment. The design, development and validation of the BLYSS 
questionnaire has integrated and encompassed three concepts integral for the 
development of a health status measure; patient participation, scientific value and 
clinician acceptability. 
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Chapter 1.0 
Introduction 
 
Breast cancer is the most common cancer affecting Australian and western women. 
However with increased recognition of breast cancer risk, the advent of 
mammographic screening programmes, and advances in the treatment of breast 
cancer, early detection of breast cancer is associated with improved survival 
prospects. Women may now be offered breast conservation therapy (BCT) which 
includes neoadjuvant therapies (chemotherapy or hormonal), surgical removal only 
of the cancerous tissue and immediate surrounding breast tissue, lymph node 
dissection (sentinel node biopsy with or without axillary clearance) and adjuvant 
treatments (chemotherapy, radiotherapy, monoclonal antibody therapies and/or 
hormonal therapies). These treatments enable women to retain the breast without 
compromising survival prospects. Prior to these advances, mastectomy was the only 
option.  
 
However, as with any intervention, there are side effects associated with breast 
cancer treatment. One of these side effects is breast lymphoedema. Breast 
lymphoedema can not only affect the cosmetic appearance of the treated breast, but 
can impact on the patient’s physical function and quality of life. Some women will 
opt for a prophylactic mastectomy instead of BCT to avoid the physical, cosmetic 
and psychological effects of breast lymphoedema. This is not only distressing for the 
woman, but also those involved in breast cancer treatment, as BCT aims to offer a 
woman survival likelihood on par with mastectomy whilst salvaging the breast.  
 
Although a recognised complication of BCT compared with arm lymphoedema, there 
is a scarcity of research on breast lymphoedema. Rates of breast lymphoedema have 
been reported at 6-80% (3-8), which suggests breast lymphoedema can be a major 
complication of breast cancer treatment. However a lack of standard measuring 
procedures, reporting criteria and the lack of a definition for breast lymphoedema 
make comparing research studies difficult. This is also reflected when evaluating the 
effectiveness of treatment for breast lymphoedema.  
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1.1 The aim of the study 
The aim of this project was to develop a questionnaire for women with breast 
lymphoedema (the BLYSS questionnaire). This questionnaire will be useful for any 
clinician treating breast lymphoedema in addition to providing a condition specific 
outcome measure for research projects acquiring evidence for clinical practice. The 
definition will provide a template for further discussion and work.  
 
1.2 The study objectives 
The specific objectives of the study were grouped into two parts: 
 
Part A: Consisted of development of a questionnaire to measure health 
 status in women with breast lymphoedema (the BLYSS 
 questionnaire)  
Part B: Consisted of establishment of the reliability and validity of the 
 BLYSS questionnaire 
 
Prior to commencement of these studies, ethical approval was sought and granted by 
the Human Ethics Committee of Curtin University and Royal Perth Hospital Ethics 
Committee (see Appendices 1 and 2, pages 136 and 137). In addition, ethical 
approval was sought and granted for Part B of the study from the Sir Charles 
Gairdner Group Human Resource Ethics Committee (see Appendix 3, page 138). 
 
1.3 Resources 
Financial resources were allocated as part of the budget associated with the Masters 
study. This budget allowed for provision of stationery, purchase of a licence to use 
the GHQ-12 (1) and travel re-embursement for patients. Interviews were conducted 
by the principal researcher as part of the clinical load.  
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Chapter 2.0 
Literature review 
 
Breast cancer is not only the most common cancer in women in Australia but also 
women worldwide (9). As a result of improved detection and treatment of breast 
cancer, there are higher and longer survival rates and consequently the side effects 
related to treament are receiving more attention (9). One complication of breast 
cancer treatment is breast lymphoedema. However a lack of, or inconsistent standard 
measuring procedures and reporting criteria (4) not only makes comparing research 
difficult, but also hampers evaluating the effectiveness of treatment for clinical and 
research purposes. To address this, a questionnaire was developed to measure health 
status in women with breast lymphoedema. The development of this questionnaire 
was based on rigorous scientific method to create as comprehensive and robust a 
questionnaire as possible. In this chapter narrative review of the limited literature 
related to breast lymphoedema will be provided. 
 
2.1 Breast lymphoedema 
2.1.1 Breast cancer-prevalence and survival 
For Australian women, breast cancer is the most common to affect both them (10) 
and also Western women (11). In Australia in 1982 there were 5,289 newly 
diagnosed women with breast cancer compared with 12,614 women in 2006 (10). 
This number is expected to be 22% higher by 2015, with approximately 15,409 
women likely to be diagnosed with breast cancer (10). 
 
However there has been an increase in relative survival for women after breast cancer 
diagnosis. The five-year relative survival for Australian women increased from 
72.6% between 1982-1987, to 88.3% between 2000-2006 (10). Survival trends show 
relative survival improved during 1995-2007 for Australian women diagnosed with 
primary breast cancer and survival was persistently higher in Australia for these 
women during this period (12). 
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Increased survival results in more women who have been treated for breast cancer. In 
2006 there were an estimated 143,967 women diagnosed with breast cancer in the 
previous 25 years (10). 
 
2.2 Breast conservation therapy 
2.2.1 Treatment 
For early breast cancer (breast cancer restricted to the breast with or without 
ipsilateral lymph node involvement) (13), BCT consisting of breast surgery and 
adjuvant radiotherapy (with or without hormonal and/or chemotherapy), is a 
recognised alternative to mastectomy (14) that has survival outcomes equivalent to 
mastectomy (15-17). The advantage of this treatment option is a better cosmetic 
outcome with a high degree of local cancer control (18). However, the paradox of 
achieving successful treatment outcomes is the development of side effects (17,19). 
Since there are now many long term breast cancer survivors, side effects are of prime 
importance (20).  
 
2.2.2 Side effects 
As patients survive longer there is an increased likelihood for the development of 
long term radiation sequelae (21-23). Skin complications due to irradiation that occur 
within 90 days of treatment are considered acute, while those occurring subsequently 
are considered late (24). Acute side effects of breast irradiation can include fatigue, 
local inflammation, moist and dry desquamation (25) and oedema (26). Late 
complications of radiotherapy treatment include fibrosis (19,22,27), vascular damage 
(telangiectasia), tissue atrophy and skin pigmentation (25,28,29). These reactions can 
range from undetectable or minimal, to unacceptably severe (30). 
 
The effects of breast surgery may cause secondary problems after radiotherapy (31). 
Common complications from breast and axillary node surgery include breast 
oedema, seroma, haematoma, infection or scarring (31). Breast oedema has been 
characterised as occurring before or during external beam radiotherapy and is related 
to lymphatic flow disturbances as a result of axillary dissection (3). Although the 
lymph vessels themselves appear to be radioresistant, radiotherapy affects both the 
healing process by delaying the growth of lymphatic networks into repairing tissues, 
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and by hindering the proliferative response of normal lymphatic to inflammatory 
stimuli (4). 
 
When radiotherapy is given to a damaged breast and a damaged dermal lymphatic 
network (such as from the complications listed), the potential for partial or whole 
breast swelling is increased (8,31). Lymph nodes unlike lymph vessels “are 
radiosensitive to conventional doses of radiotherapy, initially responding with 
lymphocyte depletion, followed by fatty replacement, then usually by local fibrosis” 
(4)(p2794). 
 
2.3 The challenge of breast lymphoedema assessment 
Arm lymphoedema is more commonly described and reported as a complication of 
breast cancer treatment than breast lymphoedema (8). When lymphoedema occurs in 
the upper limb, volume changes can be objectively quantified through bioelectrical 
impedance spectroscopy (32), water displacement, serial circumferential 
measurements and optoelectric volumetry (4). However, volumetric measures alone 
are poor indicators of severity, prognosis and treatment response and do not provide 
information about other soft tissue changes associated with lymphoedema such as 
fibrosis (4,33). A limitation of volume circumferential measurements, based on 
current lymphoedema grading systems, is their inability to be used for non-limb 
oedema assessment (4,33). There is currently no method of quantifying 
lymphoedema in the breast (33-35). 
 
In clinical practice, qualitative descriptors and scales such as the Lymphoedema 
Quality of Life Inventory, the American Physical Therapy Association scale, the 
Casley-Smith lymphoedema staging scale, the Late Effects of Normal Tissue/ 
Subjective, Objective, Management and Analysis (LENT/SOMA) measure and the 
Common Toxicity Criteria version 2 are available lymphoedema ratings (33). 
However, the American Physical Therapy Association scale grades lymphoedema 
based on limb circumference discrepancy (33). The Casley-Smith scale consists of 
three-stage lymphoedema scale based on fibrotic and skin changes, the presence of 
pitting and the effect of elevation (33). As this scale does not have established 
validity and reliability (33) for patients with breast lymphoedema, its use is limited. 
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The LENT/SOMA measure contains objective and analytic components rated on a 
four-point scale, based on unspecified arm circumferential measurements (33). The 
American Physical Therapy Association scale, the LENT/SOMA measure and the 
Common Toxicity Criteria version 2 scales do not have established validity and 
reliability (33). The Lymphoedema Quality of life Inventory questions the way 
lymphoedema can affect quality of life and activities of daily living and has 
established validity and reliability in patients with upper and lower limb 
lymphoedema (36,37) but validity and reliability has not been established in patients 
with breast lymphoedema (33). The Common Toxicity Criteria version 2 grades 
lymphoedema on a four-point scale and although the Common Toxicity Criteria 
version 2 allows grading in non-limb oedema, validity and reliably has not been 
assessed (33). Sensitivity and specificity has been established in other lymphoedema 
questionnaires (38). These authors found that the visibility of swelling (as a method 
to assess the amount of swelling) was highly reliable and in agreement with ratings 
from experienced clinicians (38). None of these descriptors and scales have been 
specifically designed for breast lymphoedema, nor are they widely used in 
lymphoedema related research (33), probably because not all of these questionnaires 
have established reliability or validity. 
 
In patients treated with breast conservation, breast lymphoedema is reported to be the 
more frequently seen complication than arm lymphoedema (4,7,39,40). 
Lymphoedema of the breast is an often overlooked side effect of breast cancer 
treatment (5,41), and the resulting problems minimised (42,43). Rates of breast 
lymphoedema have been reported at 6-80% (3-8). However, the lack of standard 
measuring procedures and reporting criteria make comparing research reports 
difficult (7). 
 
2.3.1 Limitations in the literature 
As identified, measuring breast lymphoedema remains difficult. In addition to this 
further limitations exist when comparing the literature on breast lymphoedema. 
 
2.3.1.1 Definition of terms 
One barrier to research and reporting of breast lymphoedema is the lack of a clear 
and widely accepted definition of the condition. Not only is this a barrier for 
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research, failure to recognise the condition also contributes to the significant effects 
it has on the physical, emotional and psychological wellbeing of affected women. 
The creation of a definition for breast lymphoedema is discussed in Chapter Five, 
Defining Breast Lymphoedema, page 77.  
 
Most authors do not provide a definition of breast oedema or lymphoedema (as 
shown in Table 5.3, Chapter 5, Defining Breast Lymphoedema, page 86) which 
makes the articles difficult to compare and to apply in clinical practice. As illustrated 
in Table 5.3, Chapter 5.0, Defining Breast Lymphoedema, page 86, some authors use 
both and/or alternate between the terms breast oedema and breast lymphoedema in 
their texts. This makes it difficult to determine the true nature of the condition being 
discussed and assessed. Other unclear, undefined terms such as persistent oedema 
(45) are used in the literature adding further confusion in regards to what is being 
discussed.  
 
Few articles define the condition but of those authors who do, definitions are 
subjective in nature (3,5,31) or ambiguous; “such as palpation of a pasty oedema in 
the affected breast in comparison with the contralateral side” (43)(p646). Other 
authors try to define the topic clearly, including signs and symptoms as reported in 
the literature to be associated with breast lymphoedema (57-59). However these are 
only limited to that article, making it difficult to compare, interpret results and apply 
to clinical practice. As a consequence of this, the term breast lymphoedema will be 
used throughout this literature review, except where comment is made on the 
diversity of terms different authors use. 
 
2.3.1.2 Study design 
Although the majority of articles on breast lymphoedema are observational or 
retrospective in nature (3,8,49), there is at least one published prospective study (60). 
The best study design is dependent upon the research question. For example, a study 
identifying risk factors needs to be a prospective cohort in nature, not a randomised 
control trial, whereas if the effectiveness of an intervention is being questioned, a 
control group is necessary. Observational studies do not encompass direct 
intervention by the researcher, and usually involve survey instruments, interviews, or 
review of medical notes including documentation by the researcher on the natural 
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course of events, noting who is and who is not exposed, and who does and does not 
develop the disease (61). These types of studies provide a useful insight into a 
condition, allow researchers to study the long term effects of variables and sidestep 
the ethical and practical problems associated with establishing large and cumbersome 
medical studies (62). This type of study design lacks control over the experiment (in 
regards to control groups) and independent variable/s and randomisation, potentially 
creating bias and masking cause and effect relationships (62,63). Alternatively this 
type of research may suggest correlations where there are none (62,63). 
 
Retrospective research involves examining data that could have been collected 
previously, often from medical notes or surveys (61). The researcher has no direct 
control of variables as these events occurred in the past or these are no longer 
manipulable and the inferences from these studies are weaker than those studies in 
which the researcher can control variables (61). 
 
Other articles reported in the breast lymphoedema literature are case studies 
(50,56,64). A case study is an extensive report designed to analyse and understand 
those factors important to the cause, care and outcome of an individual’s health 
status (61). Case studies are the most practical approach to research due to the direct 
relevance to patient care and it provides insight into the totality of an individual’s 
experience which maybe missed in a group study (61). However these are also the 
least rigorous approach because of the lack of control, weak internal validity and 
limited external validity (61). 
 
Few breast lymphoedema articles are prospective in design (43). Prospective studies, 
such as that by Degnim et al (60), are more reliable due to the greater control of 
collection methods, involve examining variables through direct contemporaneous 
recording (61). 
 
2.3.1.3  Outcome measures 
The range and variety of outcome measures used in articles on breast lymphoedema 
also contribute to the difficulty comparing research, and evaluating the effectiveness 
of treatment for clinical and research purposes. Some authors use scales defining the 
appearance of breast lymphoedema as mild, moderate or severe (3,5) and within 
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these scales provide a description of what each term or oedema encompasses (3,58). 
Several authors use patient concerns, such as breast swelling, heaviness, redness 
and/or pain (7,42,43) as outcome measures. However, the origin of these reporting 
criteria and their association with breast lymphoedema were not identified by these 
authors (7,42,43). Clinical observation and palpation is commonly used as a way of 
evaluating an intervention for breast lymphoedema (7,8,42). The limitations of these 
are the lack of standardised measurement procedures and difficulty of their 
translation into clinical practice. 
 
2.4  Features of breast lymphoedema 
Many features of breast lymphoedema are described in the literature, yet swelling is 
the most consistently referred to (3-5,7,8,31,41,43,47,50,56,64).  
 
Swelling is described as intermittent, chronic or persistent (45), includes part of or 
the whole breast (6,31,55), engorgement or enlargement (58). It is unclear whether 
these terms all refer to swelling or relate to it. This ambiguity makes interpreting 
articles and applying results difficult. 
 
Some authors report that breast oedema is more likely to occur in large-breasted 
women (45,58) but only one author clarified what was considered large-breasted 
(59). Another author reported that the development of breast oedema was not related 
to breast size (32). Others have stated that swelling can be in part or all of the breast 
(6,31,55) or that engorgement (55,58) can be with or without pain (58). 
Pathophysiologically it is plausible that women with larger breasts are at greater risk 
of breast lymphoedema as during radiotherapy larger breasts receive higher doses of 
radiation at the extremes of the latitudinal field due to the radiation scatter, causing 
more damage to lymphatics (31). 
 
2.4.1 Characteristics of breast lymphoedema 
A number of characteristics of breast lymphoedema are frequently reported in the 
literature, as shown in Table 2.1, page 10. Other reported characteristics are that the 
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Table 2.1 Characteristics of Breast Lymphoedema 
Characteristic Author/s 
Pain Clarke et al 1982 (3), Kirshbaum 2000 (31), Goffman et al 
2004 (7), Stevenson et al 2005 (56),  Jahr et al 2008 (43), Fu et 
al 2009a (35) and Lawenda et al 2009 (41) 
Nipple pain Lawenda et al 2009 (41) 
Discomfort Clarke et al 1982 (3), Kirshbaum 2000 (31) and Jahr et al 2008 
(43) 
Erythema Stevenson et al 2005 (56), King et al 2001 (64), Loprinzi et al 
1996 (47) and Ronka et al 2004 (8)  
Heaviness Clarke et al 1982 (3), Kirshbaum 2000 (31), Goffman et al 
2004 (7), Fu et al 2009a (35) and Lawenda et al 2009 (41) 
Peau de orange Clarke et al 1982 (3), Loprinzi et al 1996 (47), Kirshbaum 2000 
(31), King et al 2001 (64), Goffman et al 2004 (7), Ronka et al 
2004 (8), Stevenson et al 2005 (56) and Lawenda et al 2009 
(41) 
Fibrosis Clarke et al 1982 (3), Fu et al 2009a (35) and Lawenda et al 
2009 (41)  
 
lymphoedematous breast is tight, tender (31), is larger (8,41), has induration (64), 
hyperpigmentation (31), skin thickening (8), distortion (42), skin changes (35, 41),  
and is non-pitting and red (31). 
 
However the literature also describes tightness (35), tenderness on palpation (8), ache 
(41), redness (7), atrophy/retraction (23), architectural distortion (64), skin colour 
changes (41), an increase in skin thickening (53), pitting or non-pitting (41) and 
discolouration (31). It is unclear whether these are separate entities to the previous 
similarly described characteristics, if these are the same, are these what patients 
report or whether it has been observed, or both. Although women’s perceptions of 
breast lymphoedema would seem important and relevant, there is little in the 
literature describing them. 
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Due to lymph stasis (4,65) and the impaired lymphatic proliferation responses, 
cellulitis (35) and repeated bouts of cellulitis (4) are common in the breast treated for  
breast cancer. However an absence of fever (67) and the lack of identifiable 
pathogens that occur in some patients are inconsistent with infection (36). Moreover, 
patients can be unresponsive to antibiotic treatment or prophylactic antibiotics fail to 
prevent attacks of cellulitis or acute inflammatory (55,56,67) episodes, which  
suggests another cause for the appearance of the breast (49, 66). Some authors have 
termed this pseudo-cellulitis (6,66) and delayed breast cellulitis (6,8,56) however 
breast lymphoedema must also be a consideration as the inflammatory changes 
associated with lymphoedema (erythema and oedema) can be mistaken for infection 
(55). This has received some but limited recognition by some authors (55,56,). 
 
Patients with breast lymphoedema may experience pins and needles (paraesthesia) 
(41), hyperaemia (7), burning (35), increased breast size (31), lymphangitis (35), 
firm and thickened subcutaneous tissues (43), numbness (35) and changes in skin 
texture and integrity (42). Lopsidedness (31), fullness (41) and uncomfortable (4) are 
other terms used to described the lymphoedematous breast. 
 
2.4.2 Consequences of breast lymphoedema 
The consequences of breast lymphoedema are significant. In regards to appearance, 
breast lymphoedema is said to detract from the cosmetic outcome (3,4,7). The 
serious emotional and psychological effects of breast lymphoedema are also 
addressed in the literature (35,55). Frustration, fear, negative body image, 
disfigurement, isolation (55), body image problems, depression, fear of recurrence 
and difficulties of adjustment (31) are all reported consequences associated with 
breast lymphoedema. Although identified in the literature, these consequences have 
not been explored by using previously established psychological tools, such as the 
General Health Questionnaire or the Hospital Anxiety Depression Scale. Both of 
these tools have established validity and reliability and have been used in other 
studies of patients with breast cancer (1,68). The use of such tools would have 
provided more quantitative evidence about the magnitude of impairment caused by 
breast lymphoedema.  
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Breast lymphoedema is reported to impair quality of life, impede in the ability to 
work, affect activities of daily living including performing chores and hobbies, and 
cause economic burden, delay in resuming previous social activities and sexual 
difficulties (31,35,43). Breast lymphoedema is also reported to cause difficulties 
involving clothing and underwear, especially a brassiere which is more likely to 
cause indents on the breast (42). 
The physical consequences of breast lymphoedema are also extensive. It has been 
reported that breast lymphoedema is associated with fatigue (69), loss of 
glenohumeral joint range of motion (43), and oedema that feels pasty on palpation 
(43). 
 
2.5 Diagnostic evaluation of breast lymphoedema 
The literature on diagnostic evaluation of lymphoedema usually focuses on upper 
limb lymphoedema, whilst breast lymphoedema does not receive this attention (43). 
Being able to accurately measure the breast is important, however problems are 
associated with measuring the female breast, including positioning of the patient and 
varying tissue mass and texture (70).  
 
Methods including bioimpedance spectroscopy, cosmetic and functional outcomes 
including software programmes, grids and scales, water displacement, casting, 
anatomical measures used to fit brassieres, thermoplastic moulding, the Grossman-
Roudner measuring device, photographs, breast magnetic resonance imaging, 
mammography and ultrasound are all proposed for the breast volume and cosmesis 
measurement (71).  
 
2.5.1 Bioimpedance spectroscopy and tonometry 
Bioimpedance spectroscopy and tonometry are measures that may enable the 
measurement of changes in the breast however neither has been properly validated, 
and still need to be established. Moseley and Piller (70) conducted a pilot study of 14 
women who had breast conservation surgery for breast cancer more than 12 months 
previously (70). This time frame permits exclusion of breast oedema due to 
anticipated causes, such as surgery and radiotherapy. Covariance ranged from 0.20-
0.86%, which indicated reliability, and although duplicate measures using the same 
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tester were performed, the time interval between tests was not specified, nor whether 
marks were visible from previous electrode and tonometer placement. Another 
barrier for the use of Bioimpedance spectroscopy maybe the relative cost of the 
machine and ongoing costs of the electrodes, particularly given the paucity of 
information in regards to breast lymphoedema.  
 
2.5.2  The Breast Retraction Assessment  
The Breast Retraction Assessment, created by Pezner et al (72), is an objective 
assessment of the amount of cosmetic retraction in patients who have had BCT as 
part of breast cancer treatment. The Breast Retraction Assessment involves “using a 
measurement grid determining values by locating the x-and y-co-ordinates for the 
nipple of each breast and values are then calculated by vector geometry employing 
the Pythagorean theorem” (72)(p327). These authors reported that in comparison to 
qualitative forms of cosmetic analysis, the Breast Retraction Assessment is a 
quantitative objective test that eliminates observer bias, is easily reproducible 
between observers, and the grid is simple to construct and can be employed at any 
institution. Although these authors did not discuss breast lymphoedema as a potential 
component of breast retraction, it was noted that each cosmetic change must be 
analysed separately for its own set of related factors (73). 
 
2.5.3 Cosmetic and functional scales 
Evaluations of the cosmetic and functional outcomes after BCT using a variety of 
scales have been studied by other authors (2,3,74-79). However the validity and 
reliability of these scales has not been determined (3,78,79), nor was breast 
lymphoedema considered as contributing to adverse cosmetic and functional 
outcomes (74-76). However one author did assess, grade, and acknowledge arm 
lymphoedema (77). 
 
Although the reproducibility of the subjective methods of cosmesis evaluation of 
BCT are questioned (even when completed by experts), these are still in use today 
(80). This is likely due to the utility and practicality of these methods. More objective 
methods (72,75) are based on breast symmetry evaluation (80). However these 
methods do not take into account other aspects of the appearance of the breast such 
scarring, colour or skin texture (80) which may be indicative of breast lymphoedema.  
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2.5.4 The Breast Symmetry Index and the Breast Cancer Conservative 
 Treatment Cosmetic software 
The Breast Symmetry Index with the use of the Breast Analysing Tool software 
(80,81) and the Breast Cancer Conservative Treatment Cosmetic software (82) 
evaluate breast cosmesis after breast cancer treatment. Both programmes show good 
inter-observer agreement (81,82). Despite this, these programmes are not used in 
routine clinical practice in Australia. It is not clear why this is the case; however lack 
of awareness of these programmes, cost and access to technologies necessary to use 
them may be prohibitive factors in both the public and private settings.  
 
2 .5.5  Water displacement, brassieres and the Grossman-Roudner cone 
Water displacement based on the Archimedes principle involving the displacement 
of water within a large calibrated cylinder has been used to assess breast volume 
(71,83). Limitations to this method are that it is only suitable for breast volumes that 
are less than 425cc. If breasts are firmer, this method overestimates the volume and 
patients do not find the method easy to perform (71,83). 
 
Brassieres are a logical assumption as a guide for breast size. Current brassiere sizing 
has its origins in 1935 and since then this has been based on two measurements; 
around the ribcage underneath the bust and the fullest part of the bust (84,85). Yet 
the female breast has a very complex three dimensional geometry (85) that brassiere 
sizing does not take into account which limits its value as an outcome measure for 
research. 
 
The Grossman-Roudner breast measuring device is a variable cone device that can be 
placed over the breast. Breast volume is then read from a scale at the overlap of the 
cut radius of the cone (71). This is a cost effective and reliable measure however 
validity is questionable as not the entire breast is contained in the cone (71,83). 
 
2.5.6 Breast magnetic resonance imaging  
Breast magnetic resonance imaging is used for the differential diagnosis of breast 
disease (86-88) and has been shown to be highly specific in the differentiation of 
fibrosis versus tumour recurrence (88). However there are limitations with the use of 
this modality as therapies such as surgery and radiotherapy (86,88) can induce 
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morphological changes and enhancement within the breast, mimicking recurrent 
disease (87,88). Chemotherapy may also suppress enhancement of breast magnetic 
resonance imaging and mask residual disease (86). Researchers and clinicians do not 
advocate the use of routine breast magnetic resonance imaging in the early (12-18 
months after the end of radiotherapy) post treatment period, because it is reported 
that the contrast enhancement linked with inflammatory changes caused by 
radiotherapy severely impairs interpretation of breast magnetic resonance imaging 
(88). Other limitations such as the cost, access and the inability to use this utility to 
measure breast lymphoedema may also be a limitation for use with this condition 
(83). However some authors have used magnetic resonance imaging when they 
found it difficult to be certain that breast induration developing many years after 
radiotherapy was solely explained by fibrosis or by fat necrosis (89). These authors 
found a close correspondence between breast oedema in magnetic resonance imaging 
and the severity of induration (89), and suggested that parenchymal oedema might be 
due to impaired lymphatic drainage (89). 
 
2.5.7 Mammography 
Mammography may also have a role in the assessment of breast volume (83) and 
breast lymphoedema. Although mammography shows good correlation with breast 
volumes, there is an associated risk with radiation exposure (71). Breast oedema 
presents as increased density and changes on mammography (46,90). Differential 
diagnosis needs to be established as increased breast density, skin thickening and 
architectural distortion may be due to a number of causes (88,89,91). These include 
post-surgical oedema, radiation induced oedema, lymphatic spread of cancer, 
congestive heart failure, infection, post surgical retraction, abscess formation, fat 
necrosis (88,89,91) and breast lymphoedema. 
 
2.5.8 Breast ultrasound 
Breast ultrasound has been identified as a useful quantitative measure of cutaneous 
oedema and cutaneous breast thickness for patients treated for breast cancer 
(52,59,92). Breast oedema is shown by changes on ultrasound (46) and has been used 
as an outcome measure in one study of breast lymphoedema (8). This method may be 
problematic because the diffuse acoustic shadowing caused by scar tissue may also 
represent recurrence of breast cancer (8). 
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Despite the overlap between changes as a result of treatment and tumour recurrence, 
characteristic appearances on breast magnetic resonance imaging, mammography 
and ultrasound can usually distinguish these two entities (88,91). This is recognised 
by comparing findings on previous and successive studies (88,91). 
 
2.6 Management of breast lymphoedema 
Evaluating the effectiveness of the management of breast lymphoedema can be 
particularly challenging, as it is hampered by the lack of standardised objective 
measurement methods (4,35,54). Current treatment for breast lymphoedema includes 
medical and physical options, but there is little consensus on the best management 
(34). As stated earlier, antibiotics are often prescribed due to the cellulitic appearance 
of the breast, suggesting an infective process. Physiotherapeutic intervention includes 
manual lymphatic drainage, a very gentle massage applying light pressure to the skin 
or superficial fascia in the direction of the venous and lymphatic drainage of the 
involved structures (93). It is used to facilitate the lymphatic system to increase 
lymph transport (5). Manual lymphatic drainage can produce dramatic responses to 
breast oedema (7,42) and is considered the treatment of choice for the management 
of breast lymphoedema (5,31). However, there is no high level evidence supporting 
the effectiveness of manual lymphatic drainage. Central to the limitation of breast 
lymphoedema research is that there are no outcomes available at present, with known 
validity and reliability, to objectively assess the efficacy of these interventions.  
 
 
The paradox of achieving successful treatment outcomes for breast cancer is the 
development of side effects (17,19). As there are now many long term breast cancer 
survivors, the side effects are of prime importance (20). Breast lymphoedema can be 
a complication of BCT. A lack of standard measuring procedures and reporting 
criteria make comparing research in the area of breast lymphoedema difficult. 
Moreover, evaluating the effectiveness of treatment for clinical and research 
purposes is hampered by the lack of standardised measurement methods. To address 
this we are developing an instrument to measure health status in women with breast 
lymphoedema.  
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A questionnaire design was chosen for this project, as breast lymphoedema 
evaluation is not only about measuring the size and shape of the lymphoedematous 
breast, but includes other factors about how a woman feels and how this condition 
affects activities of daily living. Most of the current measures are concerned with the 
diagnosis of breast lymphoedema, the size of the breast and are limited in terms of 
reliability and validity.  In the next section of this chapter the methods for 
questionnaire design will be reviewed. 
 
2.7 Questionnaire development 
A questionnaire is in essence “a vehicle for human communication, an activity that is 
both highly complex and prone to failure” (94)(p1264). Designing one is a 
sophisticated craft (94) and the process of developing a questionnaire is much harder 
and more time consuming than most people realise (61). Although a questionnaire 
has the potential to evaluate patient care, patient treament programmes and the 
effectiveness of these programmes, developing questionnaires can be an expensive, 
time consuming and an effort driven task (95). 
 
Some authors have delineated methods of questionnaire development into two types. 
The “Rolls Royce model” (96)(p890), or the sophisticated method is commended to 
those researchers who have sizeable resources and an interest in questionnaire 
development (96). Clinical investigators inexperienced in questionnaire development 
have responded by creating ad hoc measures described accordingly as the pragmatic 
approach or the “Volkswagon model” (96)(p890). As a result their questionnaire 
development is constrained by a failure to attend appropriately to what patients 
consider important, as well as to issues such as clinical credibility, reproducibility, 
responsiveness and validity (96).  
 
As discussed previously, there is no known valid questionnaire assessing the full 
spectrum of items associated with breast lymphoedema. Current measures are 
hampered by a lack of a consensus definition for breast lymphoedema, limited 
reliability and validity data and an absence of comprehensive assessment of items of 
health status (97). These considerations are important when developing and selecting 
an outcome measure (97). 
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Other important considerations for patient self reported questionnaires are to be 
comprehensive, psychometrically robust but brief enough to be of practical use in 
clinical settings (97). These issues are germane to evaluating comparative treatments 
(97). The value of an accurate health status assessment is that it permits an 
instantaneous comprehension of an individual patient’s present status and to measure 
change over time (97). Such a tool should be a multidimensional measure of health 
status, to provide a comprehensive understanding of the impact of (97,98) breast 
lymphoedema.  
 
In the area of psychology a lot of work has been undertaken on questionnaire 
development. In order to achieve adequate levels of reliability, validity and 
responsiveness, the questionnaire needs to be robust, rigorous and complete. In this 
area of health when the word instrument is used, it implies a structured questionnaire 
that has been formally tested (99). 
 
2.7.1 Style of questionnaire development 
Several concerns must be addressed before health status measures can be used for 
clinical purposes (99). Initially the design of the questionnaire followed by the 
evaluation of the method need to be established before the questionnaire can be used 
in the clinical setting (99). Steps in instrument development and testing are outlined 
in Table 2.2, page 19 (96,100,101). 
 
Using these methods, investigators have developed questionnaires for application in 
diverse conditions including asthma (102), breast cancer (103-104), chronic illness 
(105), chronic obstructive pulmonary disease (106,107), oncology (99,108,109), 
incontinence (110) and melanoma (111).  
 
2.8 Questionnaire and patient population 
The first, and critical step is to exactly define what the questionnaire is designed to 
measure (100). This initial definition will assist the investigator design appropriate 
development protocols, and will enable other users of the measure to recognise its 
applicability to their own patients and studies (100). Leading on from this, the 
precise clinical diagnosis and patient characteristics should be identified (100). At 
the time this study was commenced, there was no widely accepted definition of  
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Table 2.2  Steps in questionnaire development and testing  
A.  Development 
1. Specifying measurement goals and patient population 
2. Item generation  
3. Item reduction 
4. Questionnaire formatting 
B.  Testing 
5. Pretesting 
6. Reliability 
7. Validity 
8. Responsiveness 
9. Interpretability 
                      (96, 100,101) 
lymphoedema, either in the literature, or used by clinicians in Western Australia. 
This was raised as a potential limitation of the study at the 7th ALA Conference, held 
in Fremantle Western Australia in 2008. In response to this feedback a consensus 
group was formed to define breast lymphoedema. This is discussed in Chapter 5, 
Defining Breast Lymphoedema, page 77. 
 
2.9 Item generation 
The next task in questionnaire development is the generation of a list of all 
potentially relevant items (96,100). In a sophisticated questionnaire design model, 
the most frequently used method of item generation is a review of the disease 
specific literature, followed by discussion with health care professionals working in 
the area with this patient group (96,100,112). Items collated from these sources 
provide the basis for unstructured interviews with patients (96,112,113). During 
these interviews, the dimensionality or extent of all of the characteristics of the 
symptomology of items should be explored (96,114). 
 
Probing enables a description of experiences more fully (115) and using an item 
elicitation questionnaire facilitates this. The presence, frequency and importance of 
items provides a comprehensive probe to cover all possible areas of dysfunction 
associated with the disease being studied (96,114). There are various approaches to 
determining item importance (96). The easiest is to ask patients to rate on a Likert 
scale (from very important to not important at all) the importance of each item that is 
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a problem for them (96,116). A Likert scale assesses the degree to which the 
respondent expresses a particular point of view (61). However the nature of the 
probes will depend on the amount of detail required by the researcher and which 
questionnaire design approach is being applied (96). 
 
A random sample of patient participants will imply a sampling of the complete 
spectrum of disease severity under consideration and inclusion of patients from all 
subclasses such as age, sex and duration of the disease (96). In a refined approach, 
detailed semi-structured interviews with 50 to 100 patients should determine all areas 
of dysfunction (95). For 100 subjects the 95% confidence interval near a proportion 
of 50% will be from 40% to 60% and with 50 subjects the 95% confidence interval 
near a proportion of 50% will be approximately 35% to 65% (96,100). 
 
In a pragmatic approach existing questionnaires are reviewed as well as consulting 
with one or two experts in the field of interest (96). Items are chosen as the 
researcher thinks is appropriate (96). 
 
2.10 Item reduction 
The item selection phase of questionnaire development often generates a large pool 
of items (96,100). The researcher must reduce this list, retaining those items that will 
be most suitable for the final questionnaire (100). Two authors have expanded on the 
relevant issues in regards to item reduction and therefore are cited as the authoritative 
works (96,100). 
 
If investigators intend to apply the final questionnaire to subgroups within that 
population (e.g. mild, moderate and severe disease), then it is important to ensure 
that all of the subgroups are represented during development and validation (100). 
Essential elements for retaining items include how many patients who identified the 
items as a problem (item frequency) and the importance associated with each item 
(96). There are numerous approaches to item reduction.  
 
Rasch analysis is a commonly used statistical method for item reduction and 
validation of health status tools (117). This item response theory model identifies 
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those items of redundancy and poor fit, ensures the scatter of items (of less severe 
and more severe health status) and construct validity (117,118). However, Rasch 
analysis is not without its controversies including the need for a high degree of 
software insight, a large number of observations and an infinite data set with 
unidimensionality (117,118,119). If there are lots of items and refinement of items 
during Rasch analysis, questionnaires maybe very reliable but they are also much 
less valid. Moreover, this analysis has strong assumptions not easily matched by the 
observations (119). For these reasons we elected not to use the Rasch analysis 
method for item reduction. 
 
One method is to ask patients to name those items they have experienced as a result 
of their disease (100). For each positively named item, they rate the importance of 
that item on a Likert scale (100). This scale offers multiple options depending on the 
context of the scale e.g. strongly agree to strongly disagree or none to extreme 
(100,112,114). Some authors have defined the frequency not as the quantity of 
patients experiencing a specific item, but how often that item occurs e.g. none, daily, 
weekly, fortnightly, monthly or less (114). While mathematically simple, however, 
combining frequency and importance criteria is conceptually challenging (95). In a 
sophisticated questionnaire developmental model, factor analysis or principal-
component analysis can be used (61,112,114). The disadvantage of using this method 
is that items that are not strongly correlated with one another are excluded (61,100). 
These excluded items may be important to patients (100). Some authors believe that 
the priority should be on the relative importance one puts on the impact of an item 
and not its relationship with other items (100). Consequently these authors are 
reluctant to use factor analysis for item reduction (100). Other authors suggest 
researchers must be cautious how factors are interpreted (61). A simple approach is 
to multiply the frequency of each item by its mean importance (96,100). This results 
in having retained those items with the greatest frequency – importance product for 
the final questionnaire (96). 
 
Aspects such as the purpose of the questionnaire also need to be considered (96,100). 
If the measure is an evaluative questionnaire (a questionnaire measuring difference 
within subjects over time)(100,113), there is little point including items that are 
unlikely to change over time either as a result of an intervention or through the 
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natural progression of the disease (96,100). Including these items would compromise 
the questionnaire’s responsiveness and increase the time to complete the 
questionnaire (96,100). Exclusion of items because of apparent unresponsiveness 
may be unwise particularly if the questionnaire is to be used to assess an 
intervention, and the item is considered very important by patients (100). 
Furthermore, with future innovation in treatment, items that currently appear 
unresponsive may in the future be impacted in a positive way. 
 
In a discriminative questionnaire (a questionnaire measuring differences between 
subjects at one point in time)(100,113), if virtually all patients experience the item, 
then it will not be useful to be included (96,100). However, if the final questionnaire 
will be used to grade the extent to which a problem affects respondents, then items 
that the entire population find a problem may still prove very useful in discrimination 
(96). Although some questionnaires may be capable of being evaluative, 
discriminative or predictive, it is difficult to simultaneously achieve maximum 
efficiency in all three (96).  
 
A comprehensive set of items will inevitably include some redundancies (100). If 
two items have a high impact score, one approach to decide whether to include one 
or both, is to test whether the items are highly correlated, by using the Spearman rank 
order correlations (100). This strategy is particularly appropriate for a discriminative 
questionnaire, as highly correlated items will add little to distinguish varying severity 
of health status from one another (100). This approach is not as suitable for 
evaluative questionnaires (100). Although items correlate with one another at the 
item reduction phase, this does not guarantee that they will change in parallel when 
measured serially (100). A final consideration in item reduction is the way the items 
will be aggregated (96). Each dimension being measured requires adequate 
representation for two reasons; a) to decrease the variability in responses found in 
stable patients and b) to minimise the impact of idiosyncratic responses to individual 
questions (96).  
 
The item reduction phase results in the researcher having a suitable number of items 
for the questionnaire (100), sufficient for content validity, yet not excessive resulting 
in respondent burden or fatigue. These are then grouped into domains. 
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The easiest method to determine domains is to use common sense, clinical 
experience and previously described domains in established questionnaires to group 
items (100). However intuition has its limitations including differing intuitive sense 
amongst different people, investigator uncertainty to item placement and although 
people’s intuition may agree, they may be wrong (100). Previously described 
domains are not an option if the questionnaire is a new measure (100). 
 
Factor analysis is the most popular statistical correlation method used to create 
questionnaire domains (100). The disadvantage of this method is that if the emergent 
groupings are counterintuitive, how to proceed thereafter is not self evident (100). 
Factor analysis is not applicable in the pragmatic approach if only one item is 
generated or if too few subjects are used. Moreover it will not enable the 
identification of subscales, if this was an intent of this approach. Item reduction is 
not a consideration with a pragmatic approach to questionnaire development, as 
during this phase the investigator simply selects the number of items one chooses to 
use (96).  
 
2.11 Questionnaire formatting 
2.11.1 Response options 
Response options are the categories or scales available for responding to the 
questionnaire items (96,100). A closed or forced option is one in which respondents 
select one or more of the choices (112). These may be of a dichotomous response 
preference (e.g. yes or no, agree or disagree) or, where the questionnaire is designed 
to determine the degree of severity, a wide range of options must be available 
(96,100,112). There are three grading principles when developing response options-
exhaustiveness (or inclusiveness), exclusiveness and balancing categories (112). 
Exhaustiveness or inclusiveness ensures that the response choices provide a 
sufficient range to cover all respondents (112). Exclusiveness means that for each 
item, the patient can only pick one answer to the question (112). An evaluative 
questionnaire must be able to detect changes for each item, albeit small (96,100). To 
assure this researchers use a Visual Analogue Scale (VAS) or a Likert scale (61,112). 
A VAS is a line, usually 100mm in length, anchored by extremes of the item being 
measured, which participants mark indicating their status for that item (96,112). 
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Likert scales have been discussed previously. Although there is no evidence to 
support use of one scale over the other, the Likert scale is easier to administer and 
interpret (100). 
There is also no agreement in the literature in regards to the number of response 
options to use (61,100,112). The main justification for using a larger number of 
response categories is that fewer categories are insensitive to real differences (112). 
 
The items in the questionnaire need to include time specification (96,100,114). 
However it is unclear whether the time frame alters data interpretation (114). Some 
authors give a range of time frames (96,114). Others suggest two weeks on the basis 
of their intuitive impression that this time frame is near the upper limit of what 
participants can accurately remember (100). The time frame also needs to consider 
the likelihood that the participant will have experienced the situations described in 
the questionnaire. 
 
2.11.2 Access to prior results 
Whether participants should be shown their prior scores when repeating self 
assessment health status remains controversial (114). The traditional approach is not 
to permit participants to see their responses on previous occasions, so as to avoid 
bias-a tendency to score the same even if change has occurred (96,100). Some 
authors (96,100) have found that showing participants their earlier responses 
improves the validity of the questionnaire, without negatively affecting the 
responsiveness (96,100). Other authors have noted no difference between blind 
versus informed administration approaches (114).  
 
2.12 Pilot testing 
 
After a questionnaire has been developed, all aspects of the questionnaire-as whole 
and individual questions, need to be assessed thoroughly before final administration 
(112). This is referred to as pilot testing or pretesting (61,96,112). When 
questionnaires are first administered, there are envitably some problems with 
participants not correctly understanding items, and problems with the wording or 
format of the questionnaire (61,100,112). 
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It is essential to pretest the questionnaire in a small number of participants before 
embarking on the next stage of validation (61,100). The literature is inconsistent in 
regards to the size of this number in the literature. Some authors suggest somewhere 
between 75 and 100 respondents provide a useful pilot test (112), whereas in the 
sophisticated model of questionnaire development, a random selection of about 20 
participants may be considered sufficient (96). Yet other investigators suggest 
approximately five to 10 participants (61,100), whilst the pragmatic approach may 
involve only two or three subjects (96). 
 
During pilot testing participants are asked to explain how they understood each item, 
what the question meant to them, and why they chose a particular response option 
(61,100). Discrepancies between what was intended and what was understood are 
noted, as are any questions that made the subject feel uncomfortable or embarrassed 
(95,99). Consistent problems in wording are also recorded (100). As well as testing 
individual items, the questionnaire as a whole is assessed (112). The flow of the 
questionnaire, time to complete, respondent interest and attention should all be 
carefully checked with participants (112). Any necessary changes are implemented, 
and the revised version is pilot tested again using the same procedure, until no more 
changes are required (61,96,100).  
 
With the pragmatic approach the questionnaire is only changed if obvious problems 
arise (96). In the construction and pilot testing phases, most investigators will choose 
a strategy that falls somewhere between the sophisticated and pragmatic approach 
(96,100). The advice to pilot test is probably one of the most ignored suggestions 
regarding questionnaire design (112). Time constraints, over confidence combined 
with inexperience, and practical difficulties all too often cause investigators to skip 
this whole stage (112). Some authors consider this a risk not worth taking (112). 
 
2.13  Different types of questionnaires 
Another consideration with questionnaire development is the type of questionnaire 
being created. There are different major types of questionnaires (120,121) as 
illustrated in Table 2.3, page 26. 
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Table 2.3 Different types of questionnaires and examples 
• Disease specific: the Asthma Quality of Life Questionnaire, Karnofsky 
Performance Status Scale 
• Site or region specific: the Oxford Hip Score, the Shoulder Disability 
Questionnaire 
• Dimension specific: Beck Depression Inventory, McGill Pain 
Questionnaire 
• Generic: Short Form 36-item questionnaire, Nottingham Health Profile 
• Summary items: Question about limiting long standing illness in the 
General Household Survey 
• Individualised: McMaster-Toronto Arthritis Patient Preference Disability 
Questionnaire (MACTAR), Schedule for the Evaluation of Individual 
Quality of Life (SEIQoL) 
• Utility: Health Utility Index (HUI) 
                          (123)(p8) 
 
2.13.1  Disease specific questionnaires 
Disease specific questionnaires are designed for the diagnostic group, condition or 
population being investigated (98,120,121). As disease specific questionnaires have  
been exclusively developed to assess the particular health problem being studied 
(120-122), they have relevant and high content validity (120). Disease specific 
questionnaires have greater likelihood to identify important change over time in the 
disease being studied (120). In addition acceptability to patients and completion rates 
should be high as the questionnaire has clear relevance to the patient’s presenting 
problem (121). Disease specific measures may be advantageous in regards to ease of 
administration, cost and simplicity in scoring, making them ideal for use in clinical 
practice (120). 
 
An obvious disadvantage of these types of questionnaires is that they are not 
intended for use in the general population (120,121). Moreover, the nature of disease 
specific questionnaires prevents comparisons of responses between patients with 
different conditions. (121). Another drawback of disease specific questionnaires is 
that they may miss health problems not associated or anticipated with that disease, 
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unlike a measure with a broader range of items (121). This can be minimised 
dependent upon the approach taken for questionnaire development (96). 
 
2.13.2 Site or region specific questionnaires 
Some questionnaires have been created to assess health problems in a specific site or 
region of the body. The site-specific focus of these questionnaires is both an 
advantage and a negative feature. An advantage of a site specific questionnaire is that 
content items should be particularly relevant to patients with a disease in a very 
specific body region (121). These patients should also be particularly sensitive to 
changes associated with interventions in that region (121). However, their very 
specific focus means they are (121) not likely to detect (any) changes in broader 
health, overall quality of life or unexpected side effects of interventions (121).  
 
2.13.3 Dimension specific questionnaires  
Dimension specific questionnaires focus on one particular aspect of health status 
(124). The key advantage of these types of questionnaires concerns the level of 
detailed assessment associated with the topic of interest (121). These questionnaires 
are also clinically sensible and may be more responsive (113). 
The potential problem with dimension specific questionnaires is the exclusion or 
resultant  reduction of information on other dimensions, otherwise the size of the 
questionnaire could burden the patient (121). A cautious approach concerning the 
significance of the proposed specific dimension is therefore required (121). Other 
weaknesses are that these types of questionnaires may restrict some cross-condition 
comparisons and their applications may be limited in terms of populations and 
interventions (113). Also in order to retain their sensitivity and psychometric 
properties, these questionnaires are often long (125). 
 
2.13.4 Generic questionnaires  
Generic questionnaires are planned to describe a broad range of health states and the 
consequence of illness, summarising health related quality of life (113,120,121). 
Health related quality of life is a multidimensional concept that encompasses 
physical, mental, emotional and social functioning (120). 
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Generic measures allow for the comparison of different populations and different 
programmes, an important objective for policy making and decision analysis 
(98,120). These questionnaires permit comparing benefits of different health 
interventions and allocating resources (120). Cumulative knowledge ascertained by 
generic questionnaires establishes the relative burden of different diseases and the 
relative merit of different interventions (120). 
 
Generic questionnaires may reduce respondent burden, compared with combinations 
of a number of different questionnaires (98,121). A disadvantage associated with 
generic measures is a loss of detail (at some level) in regards to significance to any 
single illness, and consequently the risk of some loss of significance when applied in 
any specific context (121,122). Of particular importance to clinical trials is that these 
questionnaires have less pertinent items to the specific disease, and as a result maybe 
less sensitive to changes that could occur as a result of a condition-specific 
intervention (121). However a generic questionnaire maybe of some use when no 
disease specific questionnaire exists in a particular area (121). 
 
2.13.5  Summary items 
Summary items are single questionnaire items that request participants to summarise 
various aspects of their health status by the use of one, or a very small number of 
questions (113,121). The brevity of summary items is the most apparent advantage in 
that questionnaires of this type make the least demands on the participant’s time 
(121). Other advantages include evidence of validity and of the predictive value, and 
the reproducibility of summary item questionnaires (121).  
 
Although the brevity of a summary item questionnaire can be an advantage, it can 
also be disadvantageous. These types of questionnaires a) cannot show opposing 
trends in different health dimensions, b) response categories for summary item 
questionnaires are restricted and c) this type of questionnaire prohibits making more 
specific conclusions about specific health aspects from these answers (121). 
 
2.13.6 Individualised measures 
Individualised measures are questionnaires that allow the respondent to select issues, 
domains and concerns that are not pre-decided by the researcher’s list of 
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questionnaire items (121,124). This type of questionnaire addresses the respondent’s 
own concerns as opposed to standard questions that could be of less relevance to that 
individual (121,124). This in turn contributes to supporting the content validity of the 
questionnaire (121). 
 
The main disadvantage of individualised measures is that they need to be 
individually managed by experienced personnel to capture the depth of a 
respondent’s concerns (121). Other disadvantages are that individualised measures 
require greater resources and time commitments for both researchers and respondents 
and therefore can be less feasible than other questionnaire methods (121). Also as 
these measures relate to individuals, it may be less possible to draw comparisons 
between respondents (122). 
 
2.13.7 Utility measures 
Utility measures use preference based methods eliciting the personal preferences of 
individuals regarding health status (113,121,124). Strengths of this type of 
questionnaire are that a single number represents the net impact on quality and 
quantity of life, the measure provides the possibility of a cost-utility analysis and 
incorporates death as part of the questionnaire. However there is difficulty with 
interpreting utility values as this type of questionnaire does not allow assessment of 
the impact on different aspects of quality of life (113). Of ethical concern is the 
poorly understood judgement of quality of life and utility measures (126) and who is 
in the best position to provide the utility measures (125). A utility measure may lack 
responsiveness (113), there is disagreement over the methodology associated with a 
utility measure (126) and the need for skilled interviewer/s (125). 
 
2.14 Criteria for developing a questionnaire 
Eight dimensions are discussed when considering developing, examining and using a 
questionnaire (121). These are appropriateness, reliability, validity, responsiveness, 
precision, interpretability, acceptability and feasibility (96,98,100). Although 
discussed in the literature the aspects of appropriateness, precision and 
interpretability are less likely to appear (121). Despite being clear from the literature 
how important these dimensions are, there is no standardised method associated with 
these aspects, further limiting their use. Due to the time limitations associated with 
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the project, the dimensions of appropriateness, responsiveness and precision were not 
assessed. Therefore these criteria will not be discussed.  
 
2.14.1 Reliability 
 
Reliability is the degree to which a measure is consistent and free from random error 
(61,112,127). It is a very important property of any questionnaire because when used 
as an outcome based measure it is critical to confirm that any changes detected in 
research or treatment are due to the intervention and not due to problems in the 
questionnaire (121). An unreliable questionnaire therefore may underestimate the 
beneficial size obtained from an intervention (121). 
 
Reliability is assessed in regards to two different features: internal consistency and 
reproducibility (61,121,128). Internal consistency refers to the amount to which 
items measure the same characteristics (61). However it has been debated that 
extreme attention to internal reliability can lead to the exclusion of important items, 
especially those items that reflect the intricacy and variety of the condition (121). 
 
Reproducibility more directly evaluates whether a questionnaire is capable of 
measuring a variable with consistency (61,121,128). This is assessed by the test-
retest method (61,121). The degree of agreement is examined between scores of the 
same patient on two separate occasions (121,129). The postulation is that there is no 
change in scores, based on the reflection of no considerable change in health status of 
the patient (being measured) between tests (129). The time interval between tests 
needs to be considered carefully (61). There is no exact agreement on a suitable time 
interval (121). However intervals need to be sufficiently apart to avoid fatigue, 
learning or memory effects, but close enough to escape authentic changes in the 
underlying dimension of health (61,121). 
 
A common approach to assessing test re-test reliability is by means of a correlation 
coefficient (61,121,129). The ICC is a reliability coefficient that is determined by 
using variance estimates acquired through an analysis of variance (61,130). 
Consequently it reflects the amount of correspondence and agreement among ratings 
(61,130). Reliability is conveyed as a number ranging between zero and one 
(61,129). The larger the reliability coefficient, the more repeatable or reliable is the 
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test score (129). “A reliability coefficient value of 0.90 and greater is reported to be 
excellent; a reliability coefficient value of 0.80 to 0.89 is good; a reliability 
coefficient value of 0.70 to 0.79 is adequate, and a reliability coefficient value below 
0.70 may have limited applicability” (129)(p46).  
 
2.14.2 Validity 
Validity is another characteristic of a well designed questionnaire (61,112). Validity 
is an evaluation of the extent to which a questionnaire measures what it claims to 
measure (61,112,127). Types of validity are shown in Table 2.4, page 32. 
 
2.14.2.1 Face and content validity 
Face validity is an opinion of the content of the questionnaire (61,112,121). This is 
the weakest form of measurement validity (61). Content validity refers to how well 
the questionnaire comprises or samples the health factors to be measured 
(61,112,128). Together these aspects of validity focus on whether the items clearly 
assess the planned subject matter and if the range is sufficiently covered (121). As 
neither face nor content validity can be readily measured statistically, the 
questionnaire itself needs to be examined (121). How the questionnaire was 
developed and the rigor of this process will determine its scientific quality (96,131). 
 
A sophisticated design approach will maximise the chances of constructing a useful 
questionnaire (96). This format increases confidence in the validity of the index to be 
considered as the primary measure of outcome in subsequent studies (95). A 
pragmatically designed questionnaire only considers face validity and disregards 
reproducibility and responsiveness (96). 
 
The level of patient participation also needs to be considered (121). However 
knowledgeable about an illness, experts cannot entirely substitute the direct 
experience that patients provide of health problems (121). 
 
Several studies have shown that there is disparity between patients’, doctors’ and 
relatives’ ratings of the patients’ quality of life (132). Using measures that are not 
patient centered may not cover domains important to patients and therefore may not 
be valid measures (128,132,133). In a teleconference with N. Bellamy, Professor  
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Table 2.4  Types of Validity 
• Face validity:  
a judgment of the content of the questionnaire and the weakest form 
of measurement validity 
• Content validity: 
refers to how well the questionnaire comprises or samples the health 
factors to be measured 
• Criterion validity: 
reflects whether a questionnaire is valid insofar as its results are 
compatible to those of a criterion standard, or another gauge generally 
accepted as more precise or an established “gold standard” 
• Construct validity: 
refers to the ability of a questionnaire to measure an abstract concept 
• Convergent validity:   
this is where to measures will correlate highly or yield similar results 
if the two measures reflect the same underlying phenomenon 
• Discriminant validity:  
this is where measures of different traits will have low correlation or 
will yield different results 
(61, 112) 
 
(October 2010) if such measures do not capture the lived experience of the disease, 
they are unlikely to be responsive to change after treatment (132). This has 
implications for interpreting the validity of the measure, determining the 
effectiveness of interventions and consequently the relative quality of service and the 
allocation of resources (132). 
 
2.14.2.2 Criterion validity 
Criterion validity reflects whether a questionnaire is valid insofar as its results are 
compatible with those of a criterion standard, or another gauge generally accepted as 
more precise or an established gold standard (61,112,121). Criterion validity is often 
separated into two parts, concurrent validity and predictive validity (61). In the 
absence of a gold or criterion standard, researchers have used validation strategies 
from psychologists who have been labouring with the problem of how to determine 
whether questionnaires really measure what they are presume to measure (113). 
These strategies include establishing the content and construct validity of the 
questionnaire (113). 
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As there is not a good criterion variable against which to measure the questionnaire, 
criterion validity will not be explored in this study. 
 
2.14.2.3 Construct validity 
Construct validity refers to the ability of a questionnaire to measure an abstract 
concept (61, 112). It has been described as the most rigorous approach to establishing 
validity (113). 
 
The internal structure of a questionnaire can be thought of a set of supposed 
relationships between underlying concepts (121). Inclusion of subscales within a 
questionnaire implies that the questionnaire measures different underlying concepts 
by offering alternate subscale scores, rather than all items simply being added to 
produce one score of one fundamental concept (121). 
 
2.14.2.4 Convergent and discriminant validity 
These two types of validity are based on whether the questionnaire measures what it 
is designed to measure, as well as not measuring what it is not meant to measure 
(61). Convergent validity is where two measures will correlate highly or yield similar 
results if they reflect the same underlying phenomenon, whilst discriminant validity 
is where measures of different traits will have low correlation or will yield different 
results (61).  
 
2.14.3 Interpretability 
Interpretability is interested with how meaningful the scores of a questionnaire are 
(100,113,121). Researchers have commented on the difficulty faced by clinicians to 
decipher meaningful interpretation of results of questionnaires, as opposed to other 
measures e.g. interpreting blood sugar results (113,121). Not being familiar with use 
could possibly be the cause (100,121) but also because health professionals seldom 
use health related quality of life measures in clinical practice (100). 
 
Investigators have begun to make efforts to make scores more interpretable (121). 
One approach has been to express the scores in terms of the statistical distribution of 
the results of a specific study, the effect size  obtained from the degree of change; 
and the variability in stable subjects (100). The limitation with this approach 
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however is there is still no indication as to the level of impact on the patient (if any) 
(100). One method to address this is to ascertain a conceivable range within which a 
minimal clinically important difference sits (134). This is the minimum level of 
change of an outcome measure that is thought to be clinically relevant (100,129,134). 
 
A different approach to be considered is to compare scores (dependent on the 
availability) of representative data from the general population (121). There are other 
widely used questionnaires such as the Short Form-36, WOMAC osteoarthritis index 
and the Australian/Canadian hand osteoarthritis index (AUSCAN) functional 
subscales have normative data to compare results but this approach has limited scope 
of application for disease specific and condition specific questionnaires (121,135-
137). 
 
2.14.4 Acceptability 
It is critical that any questionnaire be acceptable to patients. This aspect of outcome 
measure development has received less investigation than other issues, such as 
reliability and validity (98,113,121) and consequently there is little agreement as to 
what represents acceptability (121). 
 
Ideally a measure should minimise distress to patients already living with health 
problems (121). This is also important in order to obtain high response rates to 
questionnaires, to make results easy to interpret, more generalisable and less prone to 
bias from non-response (121).  
 
Failure to complete questionnaires may be due to a variety of reasons including the 
health status of respondents, taking into account other disabilities, particularly 
cognitive or visual (121). Difficulty in understanding the questionnaire including the 
layout, appearance, legibility and use of language unfamiliar to the respondent are all 
reasons thought to contribute to incomplete or non-completion of questionnaires. The 
method of questionnaire delivery may also be a factor in incomplete or non-
completion of questionnaires (121). Poor or incomplete questionnaire response rates 
due to formatting and wording can be discovered and remedied during the early 
pretesting and pilot tests (61,121,138) included in a sophisticated questionnaire 
design approach.  
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One potentially ill conceived assumption of the acceptability of a questionnaire is its 
length and time to complete (121). There are numerous reasons influencing the time 
taken to complete a questionnaire. Such issues may include the characteristics of 
respondents and the format of the questionnaire (121). Some patients appreciate the 
chance to report on their experiences and concerns (98). 
 
In general, acceptability should be addressed at the design stage (113,121,138). This 
is considered in a sophisticated approach but neglected in a pragmatic approach to 
questionnaire design and development. However the easiest and most straightforward 
ways assess acceptability is the length and response rates of questionnaires (98,121).  
 
2.14.5 Feasibility 
Not only does patient burden need to be considered but so does staff, researcher and 
institutional burden in amassing and processing information (98,121). Data from 
patients is frequently gathered in the context of routine clinical patient care. To 
collect, administer and collate questionnaires requires additional staff effort and may 
jeopardise clinical care (121).  
 
However these burdens can be reduced by the content and appearance of 
questionnaires (121). Data collection procedures should be simplified and adapted to 
accommodate clinical routine (98). It is essential the questionnaire topic has an 
emphasis on answering questions relevant to the clinician (98). 
 
The real test of any health status measure is in its routine clinical use (128). An 
import concept for any researchers is that validation is an incremental process (113). 
A properly constructed measure establishes its validity with repeated use over time 
(113,139). The more often a questionnaire is used, and the more varied the situations 
in which it performs as expected, the greater the confidence in its validity can be 
(113). Guyatt et al (113) suggest it is better to conclude that strong evidence for 
validity of a questionnaire has been obtained in a number of different settings and 
studies than not to “conclude that a questionnaire has “been validated” (113)(p44). 
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Rates of breast lymphoedema have been reported at 6- 80% (3-8) however a lack of 
standard measuring procedures and reporting criteria make comparing research 
difficult. This is also reflected when evaluating the effectiveness of treatment for 
breast lymphoedema. The development of the BLYSS questionnaire was undertaken 
in response to the need for a clinically useful instrument aiming to capture all 
dimensions of breast lymphoedema. The objective was to identify items considered 
important to affected women and incorporate them into a valid and reliable 
questionnaire that would be simple and convenient to administer. 
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Chapter 3.0 
Methodology 
 
In the management of breast cancer, BCT can have better cosmetic outcomes than 
mastectomy without compromising survival outcomes (18). However, in some 
women BCT can be complicated by breast lymphoedema. Rates of breast 
lymphoedema have been reported at 6-80% (3-8), however a lack of standard 
measuring procedures and reporting criteria, make comparing research studies 
difficult. Moreover, evaluating the effectiveness of treatment for clinical and 
research purposes is hampered by the lack of standardised measurement methods. To 
address this, an instrument was developed to measure the health status in women 
with breast lymphoedema.  
 
3.1 Part A: Instrument development  
3.1.1 Ethical considerations  
Prior to commencement of the project ethical approval was sought and granted from 
the Human Research Ethics Committees, Curtin University, Western Australia; 
Royal Perth Hospital, Western Australia (see Appendices 1 and 2, pages 136 and 
137) and Sir Charles Gairdner Hospital, Western Australia (Appendix 3, page 138). 
 
All patients received written and verbal information regarding this study. Written 
informed consent was obtained before inclusion. There was no obligation for patients 
to participate in this study. Those patients who chose not to participate, or who 
withdrew from the study, were assured that this would not affect their on-going or 
future physiotherapy management. 
 
All interviews were conducted in a private consulting room in the Physiotherapy 
Department at Wellington Street Campus, Royal Perth Hospital, or in a private 
consulting room in the Breast Clinic at the Wellington Street Campus, Royal Perth 
Hospital. Privacy and confidentiality were maintained in accordance with standard 
clinical practice. All patients were offered travel re-imbursement of $10. No data 
enabling identification of individual participants was or will be used in publication or 
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other reports of the results. De-identified data will be stored at Curtin University for 
five years. 
 
3.1.2 Instrument development strategy 
As shown in Figures 3.1 and 3.2 (pages 39 and 40) a stepwise development and 
validation process was undertaken. The project comprised of two sections:  
• Part A: Instrument Development  
• Part B: Evaluation of the BLYSS questionnaire  
 
In this part of the study, questionnaire items were generated and reviewed. This 
process commenced with generating a pool of questions, followed by a process of 
item reduction to eliminate redundant or duplicate items. The resulting list of items 
was then formatted into a questionnaire and a method of scoring developed. Part A 
concluded by pilot testing the questionnaire. 
 
3.1.2.1  Generating a pool of questions  
The initial pool of questions was generated from three sources; i) relevant published 
material, ii) clinicians who treat patients with breast lymphoedema and iii) patients 
who have previously been treated for medically diagnosed breast lymphoedema at 
the Physiotherapy Department at Royal Perth Hospital. 
 
3.1.2.2 Literature review 
An initial literature search was conducted by entering key words and phrases into the 
electronic databases MEDLINE and CINAHL from January 1980 to February 2008. 
However given the paucity of literature identified in these databases, Google Scholar 
was added to the databases searched. This approach proved more successful. Search 
terms used are listed in Table 3.1, page 41. Published and unpublished studies were 
considered, including proceedings from lymphology and lymphoedema conferences. 
Reference lists of identified articles were also examined to identify relevant 
literature.  
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 Literature review  
 ↓  
 8 clinician interviews  
 ↓  
 Create item elicitation questionnaire  
 ↓  
 Recruit and interview 50 patients  
 ↓  
 Determine questionnaire items  
 ↓  
 Format questionnaire  
 ↓  
 Four patients and five clinicians 
to pilot test questionnaire 
 
 ↓  
 Modify questionnaire and pilot test 
again on another five patients 
 
 ↓  
 Final version of BLYSS questionnaire  
 
Figure 3.1 Part A- Instrument development 
 
As discussed in the literature review, the literature identifies numerous characteristics 
and consequences of breast lymphoedema. However the information derived from 
these needed to be put into the context of the study design (including whether and 
how breast lymphoedema was defined). Most of the papers identified reported 
retrospective or observational studies followed by case studies. Although these 
provide a useful insight into breast lymphoedema, they lack scientific rigor and 
cannot address questions of treatment effectiveness.  
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 Recruit 30 patients via postal 
invitation and telephone 
 
 ↓  
 Clinic visit-Patients to complete BLYSS 
questionnaire and the GHQ-12 
Two clinicians to assess patients using the 
modified Harris scale 
 
 ↓  
 Patients to complete BLYSS questionnaire 
24 hours later and return in mail 
 
 ↓  
 Assess and determine reliability and 
validity of BLYSS questionnaire 
 
 
Figure 3.2 Part B- Evaluation of the BLYSS questionnaire  
 
Sixty-six items were identified from the literature to be associated with breast 
lymphoedema, as shown in Chapter Four, Results, Table 4.1, page 57. These were 
grouped into five domains: signs; symptoms; physical dysfunction; psychosocial 
factors; and functionality.  
 
3.1.2.3 Interviews with clinicians treating patients with breast 
 lymphoedema  
Ten clinicians who treat patients with breast cancer were interviewed to determine 
their perceptions of breast lymphoedema. Although no formal sample size 
calculation was undertaken to arrive at a group of ten clinicians, it is reasonable to 
extrapolate from previous questionnaire development projects utilising the same 
design that 10 clinicians from various relevant professions should be more than 
ample to develop a comprehensive list of items. For example Professor Bellamy (the 
Associate Supervisor of this project) and Buchanan developed the list of items for the 
first stage of the WOMAC osteoarthritis index that proceeded down the following 
steps in this proposal to ultimate validation and is now included in 
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Table 3.1 Words and key phrases used for the literature search 
Breast lymphoedema/lymphoedema 
Breast oedema/edema 
Breast oedema after treatment for breast cancer 
Breast cellulitis following BCT 
Mastitis and BCT 
Breast oedema and axillary dissection and breast cancer and radiotherapy  
Factors influencing the cosmetic outcomes in BCT 
Post surgical changes of the breast after breast cancer surgery 
Skin and cosmesis and BCT 
Radiotherapy and BCT 
Acute toxicity in BCT 
Fibrosis and radiotherapy for breast cancer 
 
virtually all clinical studies of interventions for osteoarthritis of the hip and/or knee 
(140) . 
 
3.1.2.3 (i) Recruitment 
Clinicians in Perth who treat patients with breast lymphoedema were identified 
through professional networks and invited to participate in the study. Ten clinicians, 
two from each of the following professions, were invited to participate: breast clinic 
staff (medical physicians), breast surgery (consultant medical staff), radiation 
oncology (consultant medical staff), physiotherapy and occupational therapy. They 
were mailed a written invitation detailing the research project and their obligations if 
they agreed to participate (Appendix 4, page 139). A reply paid envelope addressed 
to the researcher and a consent form (Appendix 5, 141) accepting or declining 
project involvement was included in the package. Those who consented to participate 
were contacted to arrange a suitable time for an interview.  
 
3.1.2.3 (ii) Interviews 
Demographic information including gender, profession, number of years worked in 
their profession, the number of patients with breast cancer and the number of patients 
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with breast lymphoedema treated per year was collected from each clinician 
(Appendix 6, page 142). 
 
Semi-structured interviews were conducted with the clinicians (Appendix 7, page 
143). They were asked, based on their clinical interaction with patients with breast 
lymphoedema, how much of a problem breast lymphoedema was and if noted this 
was a problem, why. Clinicians were also asked if they were seeing more, fewer or 
unchanged numbers of patients presenting with breast lymphoedema. Reasons in 
regards to these responses were also explored. Clinicians were asked to identify, 
describe and comment on items they believed would be important to be included in a 
questionnaire to evaluate the health status of such patients. Initially, to avoid bias and 
to explore the range and dimensionality of all of what they considered to be related to 
breast lymphoedema, clinicians were not given any indications or examples of the 
sorts of items that may be included. They were also asked to indicate which items 
they considered most important.  
 
For each item a clinician identified to be associated with breast lymphoedema, they 
were asked if this item varied between patients, how frequently it occurred, how 
severe it was and how important it was. For all three situations (frequency, severity 
and importance), they were asked to comment from their perspective as a clinician 
and also to describe their perception of the patient’s perspective. For example, a red 
lymphoedematous breast may indicate an infection to a clinician, whereas may be 
considered as unsightly for a patient. Clinicians were provided a scale to rate their 
responses as shown in Figure 3.3, page 43.  
 
Once responses to the open-ended question were exhausted, any of the 66 items 
identified from the literature review that had not already been identified by the 
clinician were raised in turn. They were asked whether each additional item was one 
item they would associate with breast lymphoedema. If so, the severity, frequency 
and importance of that item was explored using the same rating scale. 
 
Items from the literature (Table 4.1, page 57) were collated with the 23 additional 
items identified by clinicians (Table 4.2, page 59), as a preliminary pool of items. 
This was used to develop an item elicitation questionnaire for the patient interviews.  
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Figure 3.3 Rating scale for clinicians 
 
An item elicitation questionnaire aims to understand the breadth and depth of the 
item (115) by asking closed ended, then open ended questions probing into all of the 
characteristics and properties associated with that item. Items identified were 
screened for duplication and sorted into five domains:  
 
• Symptoms (9 items) 
• Signs (7 items) 
• Physical limitations (6 items) 
• Emotional (14 items) 
• Social (7 items) 
Severity 
□  Not 
□  Somewhat 
□  Very 
Frequency 
□  Less than or monthly 
□  Fortnightly 
□  Weekly 
□  Daily 
□  Constant 
Importance 
□  Not 
□  Somewhat 
□  Moderately 
□  Very 
□  Extremely 
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3.1.2.4  Interviews with patients with breast lymphoedema 
This part of the study involved interviewing 50 previously treated patients with 
breast lymphoedema to determine signs and symptoms of breast lymphoedema. In a 
sophisticated approach to questionnaire development detailed semi-structured 
interviews with 50 to 100 patients should be sufficient to determine all areas of 
dysfunction (96). 
 
3.1.2.4 (i)  Recruitment 
Patients who had previously been treated for medically diagnosed breast 
lymphoedema at the Physiotherapy Department at Royal Perth Hospital and in the 
private sector were invited to participate in the next step of the item generation 
process. The inclusion criterion for these patients was a medical diagnosis of breast 
lymphoedema secondary to treatment for breast cancer (ductal and invasive only). 
Exclusion criteria were current adjuvant chemotherapy or radiotherapy; skin 
breakdown or open wounds; local, recurrent or metastatic disease; and inability to 
communicate sufficiently well in English to participate in the interview. Patients 
taking (adjuvant) hormonal therapy were not excluded. Patients who had previously 
been treated for breast lymphoedema at the Physiotherapy Department at Royal Perth 
Hospital were posted information and consent forms (see Appendix 8 and Appendix 
9, page 145 and page 147) in regards to the study. Patients recruited by private 
lymphoedema practioners were informed of the study and, with permission, contact 
details of interested patients were forwarded to the researcher. Interested patients 
were telephoned to explain the purpose and procedures of the study, and information 
and consent forms (see Appendix 8 and Appendix 9, page 145 and page 147) were 
posted to those who remained interested. 
 
At the time these data were collected there was no widely accepted definition of 
lymphoedema either in the literature or used by clinicians in Western Australia. This 
was raised as a potential limitation of the study at the 7th Australasian Lymphology 
Association (ALA) Conference, held in Fremantle Western Australia in 2008. In 
response to this feedback a consensus group was formed to define breast 
lymphoedema. As this was not part of the original project, being able to access a 
large number participants, less known to the researcher was not feasible. The 
limitation of this approach does have implications for the generalisability of the 
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definition adopted. This is discussed in Chapter 5, Defining Breast Lymphoedema, 
page 77. 
 
All 80 eligible patients were posted an invitation to participate (Appendix 8, page 
145) irrespective of whether they lived in the city or a rural area to enhance patient 
recruitment. It has been documented that many mailed questionnaires do not obtain 
return rates greater than 50% (95). Also whole population recruitment facilitates 
sampling of the complete spectrum of disease severity under consideration and 
inclusion of patients from all subclasses such as age, severity and duration of the 
disease (96). The invitation outlined the purpose of the study and what women would 
be asked to do if they volunteered. Included in the mail out was a consent form to 
complete and return if they were willing to be contacted by telephone for further 
information (see Appendix 9, page 147). If the form was not returned there was no 
further contact. Those who returned the form were telephoned to establish eligibility, 
and ongoing interest, and appointments were made for those who chose to 
participate.  
 
At the appointment patients received further information concerning the study. In 
particular the researcher’s interest in the area, and the aims and methods of the study 
were explained in detail. Patients with reservations were reassured that declining to 
participate, would not have ramifications on provision of future physiotherapy. If the 
patient agreed to participate, the interview began. Notes were taken during these 
interviews but no names were recorded. Twenty-nine patients were recruited with the 
first mail-out. At this stage all non- responders to the initial mail out were 
recontacted (with ethical approval as an amendment received from Royal Perth 
Hospital), asking for reconsideration in project participation, including a consent 
form (Appendix 10 page 148). Another 51 letters were sent and recruitment of 21 
patients was achieved, therefore reaching the target of 50 patients for Part A of the 
study.  
 
3.1.2.4 (ii) Interviews 
Interviews commenced with clinical and demographic questions (Appendix 11, page 
151). Royal Perth Hospital medical records were accessed to collect clinical 
information. Where the required information could not be retrieved from the medical 
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notes, patients were asked about the disease related characteristics of their breast 
cancer (such as tumour size, tumour grade, histological type and receptor status). 
Demographic information including age, martial status, handedness, country of birth 
and occupation were collected.  
 
This progressed to open-ended questions about how breast lymphoedema affected 
the patient’s life. When more detail was required about the identified item, the item 
elicitation questionnaire (Appendix 12, page 155) provided a resource for the 
investigator to encourage further responses and discussion by referring to the 
concepts and items identified from the literature and/or from clinical experience.  
 
Patients were asked whether or not they experienced an item. If a positive response 
was generated, the dimensionality of the item was explored to identify the extent of 
all of the characteristics and properties that patient associated with the item. If the 
patient reported experiencing an item she was asked how often it occurred 
(frequency), and how important it was to her. Patients were provided the same scale 
the clinicians had been provided in the earlier part of the study to rate their responses 
(see Figure 3.3, page 43). 
 
As any unforeseen items identified during the patient interviews could not be added 
to the questionnaire after completion of the patient interviews, the first 10 interviews 
were analysed prior to interviews 11 to 50. This enabled any unexpected items 
identified by patients as associated with breast lymphoedema to be incorporated into 
the remaining 40 interviews and helped to make sure that items deemed significant 
by the patients were not left out of the questionnaire rendering it less valid.  
 
Patients were also asked whether similar items had the same meanings or different 
meanings e.g. discomfort and uncomfortable. Patients were then asked the meanings 
of each item. This information was used to develop definitions explaining the 
meaning of the item, in words familiar to patients with breast lymphoedema to 
reduce any misunderstanding when completing the questionnaire. The use of 
definitions helps to ensure each patient is interpreting the question the same way 
when completing the BLYSS questionnaire so that scores can be compared between 
patients.  
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3.1.3 Item reduction 
At this stage, the pool of items identified from the item elicitation questionnaire was 
examined. Those items that were unclear, of questionable relevance or seen as 
duplication compared with other items e.g. swelling and bigger or hardness and solid, 
were deleted.  
 
All remaining items were screened against the following criteria determined a priori. 
Items that affected ≥ 60% of the patients were retained. In addition the items must 
have affected ≥50% of the patients at least once per week and ≥50% of the patients 
must have considered the item at least slightly important. The justification for 
retaining ≥60% and ≥50% of items was to have a suitable number of items for the 
questionnaire (100), sufficient for content validity. This also ensured those items that 
were infrequently reported, considered not important and/or irrelevant to the majority 
of participants were not included. This also limited respondent burden or fatigue by 
reducing an excessive number of items which may not be important to patients. 
Those items that satisfied all three criteria were included in the first draft of the 
questionnaire. Nine items were retained as shown in Chapter Four, Results, page 55.  
 
Consideration of the items retained suggested that the circumstances during which 
some items were experienced (rest, activity or during the night) may alter the way 
they impact on the patient with breast lymphoedema. This phenomenon is widely 
recognised in other conditions, for example, patients with osteoarthritis often report 
being stiffer when they wake in the morning than later in the day. Although not 
identified in the literature review or with the interviews with the clinicians, we had 
the opportunity to explore this with patients.  
 
To investigate this further, 20 patients who, during the interviews, had expressed 
their interest in any further participation in the study were recontacted on the 
telephone and verbal permission was granted to further discuss these and other 
issues. For those patients who were willing to be involved, a time suitable for 
discussion was made. All patients contacted were willing to participate.  
 
Patients were asked whether the symptoms (as shown in Appendix 13, page 171) 
occurred at rest, during activity and/or night. Only the prevalence of such situations 
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were asked, as neither the literature review, the clinician interviews nor patient 
interviews had identified these situations impacting breast lymphoedema. During the 
same conversation, patients were also asked whether diagnostic ultrasound or 
summer heat had any impact on their breast lymphoedema. The results of these 
conversations are presented in Chapter Four, Results, page 55.  
 
These patients were also asked to define the symptoms as described in Appendix 13, 
page 171. This was done, as despite being able to clearly differentiate whether items 
had similar or different meanings, patients could not consistently define these terms. 
This method had the benefit of ensuring each patient was interpreting the question 
the same way so that scores of the questionnaire could be compared between 
patients.  
 
During these interviews two additional items, diagnostic ultrasound and summer heat 
were also identified by patients as exacerbating breast lymphoedema. These two 
items were included in the BLYSS questionnaire. 
 
3.1.4 Questionnaire formatting 
Several questionnaires were reviewed to provide a conceptual basis for the BLYSS 
instrument. Questionnaires reviewed included the WOMAC Osteoarthritis Index 
(140), the Functional Assessment of Cancer Therapy-Breast (FACT-B) Scale (104), 
the Functional Assessment of Cancer Therapy-General (FACT-G) Scale (141), the 
Breast Project Questionnaire (142), the Incontinence Screening Questionnaire (110), 
the Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Measurement 
System (97), the Breast Related Symptom Questionnaire (143), The Lymphoedema 
and Breast Cancer questionnaire (144), the Clinical Chronic Obstructive Pulmonary 
Disease (COPD) Questionnaire (106), The Chronic Respiratory Questionnaire 
(CRQ)- Self Administered- Standardised Activities (145) and the Memorial 
Symptom Assessment Scale (109). 
 
The wording, layout and formatting of the BLYSS questionnaire underwent 
numerous considerations and alterations. Eleven items formed the basis of the 
instrument. The items were divided into three sections; i) the first section was 
symptom based, ii) the second section contained an item associated with the 
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psychological impact of breast lymphoedema and iii) the third section contained 
items including investigations and the impact of summer heat on breast 
lymphoedema. 
 
Seven response options were initially chosen for the questionnaire. Both Juniper et al 
(100) and Guyatt et al (96) suggest that a seven to ten response option is reasonable. 
However seven response options required quite small text to fit on the page and 
looked overwhelming. As there is little agreement in the literature in regards to the 
optimal number of response options (61,96,100,112) and the main justification for 
using a larger number of response categories is that fewer categories are less 
sensitive to real differences (112), the response options were reduced to five.  
A landscape format, consisting of two pages and 11 questions was adopted to display 
the questionnaire in an easy-to-read presentation (see Appendix 14, page 172). There 
are five response options in the first and second sections and six in the third section.  
 
3.1.5 Scoring of the BLYSS questionnaire 
The standard procedure for scoring questionnaires consists of summing the responses 
to the questions or to one or more subsets and subsequently standardising or 
otherwise transforming these sums (146). This is the simplest and most commonly 
employed approach (147). However there are impediments of a single score for the 
BLYSS questionnaire encompassing the different recall periods and the conceptual 
differences in each domain. Based on the identified conceptual differences within the 
BLYSS, four scores were created (BLYSS I-IV): 
 
BLYSS I- “Appearance and Experience” is the score for the first domain, which are 
those signs and symptoms to be associated with breast lymphoedema. The scores 
range from zero to four, resulting in a range of responses from zero to 28. 
 
BLYSS II- “Memory” is the score pertaining to the second domain. This domain 
asks if the symptoms of breast lymphoedema are a reminder of the breast cancer 
experience. The scores range from zero to four, resulting in a range of responses 
from zero to four. 
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BLYSS III- “Assessments” is the score for the first two items in the third domain. 
These two items question whether investigations are now more uncomfortable as a 
result of breast lymphoedema. The scores range from zero to five, resulting in a 
range of responses from zero to 10. 
 
BLYSS IV-“Weather” is the score for the third item in the third domain. This item 
asks if summer exacerbates the patient’s breast lymphoedema. The scores range from 
zero to five, resulting in a range of responses from zero to five. 
 
The scoring sheet to assist clinicians score the BLYSS questionnaire can be viewed 
in Appendix 15, page 174. 
 
3.1.6 Pilot testing 
Having created the questionnaire, the final step in Part A was to pilot test it on a 
small group of clinicians and patients and to check the applicability, 
comprehensiveness, relevancy, any ambiguities associated with the instructions and 
questions, to modify the questionnaire where required and to gain final agreement 
(95). Both groups were consulted, clinicians providing feedback regarding the 
relevancy and feasibility of the BLYSS questionnaire in a health care environment, 
while patient feedback added validity. These two components were integral to the 
design of the questionnaire. 
 
3.1.6.1 Recruitment 
Additional feedback was achieved by recruiting another sample of five clinicians and 
ten patients (who had previously been treated either at Royal Perth Hospital or in the 
private sector for breast lymphoedema) in the same manner as earlier in Part A of the 
study (Appendices 16, 17, 18 and 19, pages 175, 177, 178 and 180). 
 
3.1.6.1 (i) Clinicians 
Discussion was divided between the content and structure of the questionnaire 
(Appendix 20, page 181). A panel of five clinicians who had not been involved with 
item elicitation were asked to comment on the relevance of the items (including 
inclusion of non-mentioned items and exclusion of items within the questionnaire), 
and whether the questionnaire was comprehensive (61,96,100,112). All of the above 
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were explored in length. The clinicians were also asked to pass judgement and 
explain the rationale for their comments on the format of the questionnaire, 
encompassing the questionnaire’s length, structure, and the size of the text.  
 
3.1.6.1 (ii) Patients 
Demographic and clinical information was first gained from the patients. This used 
the same document in the first section of Part A, as seen in Appendix 11, page 151. 
Where the patient was unsure or unable to answer any medically related questions, 
the medical notes were accessed, if available. 
 
Patients were asked to complete the new questionnaire and then, in an unstructured 
open ended interview (Appendix 20, page 181), to provide feedback about the clarity 
of the questionnaire, the relevance of the questions and any inclusions or exclusions 
to the questionnaire that they considered important and why. Patients were asked to 
comment on what they perceived the question to be asking, what they meant by their 
answer and the wording of the questions (112). They were also asked for feedback 
about the layout, text size and the length of the instrument. The questionnaire was 
revised according to the feedback received. 
 
The BLYSS questionnaire was pilot tested again, on another sample of five patients 
only. Clinicians were not asked to participate in the second round of pilot testing due 
to consistency in responses in the first round, as further discussed in Chapter Four, 
Results, page 55. The same procedure as previously described was used, collecting 
demographic and clinical information, having the patients complete the questionnaire 
and discuss the content and structure of the questionnaire in open ended unstructured 
interviews. No further refinements were required after the second pilot testing. 
 
3.2 Part B: Instrument evaluation 
The purpose of Part B of this project was to evaluate the reliability and validity of the 
BLYSS questionnaire developed in Part A of the project. This was accomplished by 
administering the questionnaire to another 31 patients who had previously been 
treated for breast lymphoedema. Construct validity was assessed by correlating the 
results from the BLYSS questionnaire with other qualitative scoring tools; the 
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modified Harris scale (Appendix 21, page 185), with the original Harris scale (2) 
shown in Appendix 22, page 186 and the GHQ-12 (1) (Appendix 23, page 187) using 
Spearman’s correlation coefficients. Reliability of BLYSS was calculated using 
ICC’s. 
 
3.2.1 Ethical considerations 
Ethical considerations for this part of the study were essentially the same as in Part 
A. There were however, two additional ethical issues in this part of the study. The 
first relates to use of the GHQ-12 tool (Appendix 23, page 187). This tool can detect 
affective disorders but does not attempt to give a specific diagnosis (1). Therefore 
any patient who scored within a range suggestive of an affective disorder (1) was 
offered appropriate services. Eleven patients scored within this range and these 
results are discussed in the Chapter Four, Results, page 55. These patients were 
offered counselling or psychological services. 
 
The second consideration was that observation of both breasts by clinicians was 
required as part of the validation process. This level of exposure is standard for 
patients being assessed and/or treated for breast lymphoedema and within the scope 
of practice in both the Breast Clinic and Physiotherapy Department at Royal Perth 
Hospital. The need to undress for this part of the study was explained to patients 
prior to signing the consent form. 
 
3.2.2 Patients and recruitment 
Thirty-one patients were recruited from among patients at the Physiotherapy 
Department and Breast Clinic at Royal Perth Hospital, Western Australia, the 
Occupational Therapy Department at Sir Charles Gairdner Hospital, Western 
Australia and the private sector (see Appendices 24 and 25, pages 188 and 190). 
Inclusion criteria were breast lymphoedema secondary to treatment for breast cancer 
(ductal and invasive only). For this group a diagnosis of breast lymphoedema was 
defined on the location, nature, timing and discounted potential differential diagnoses 
(refer to Chapter Five, Defining Breast Lymphoedema, page 77 and Appendices 26 
and 27, pages 191 and 194). Exclusion criteria were the same as for Part A. 
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Patients were recruited in two ways. Hospital patients were posted an invitation to 
participate (see Appendices 24 and 25, pages 188 and 190) following the same 
procedures used in Part A of the study. Patients recruited by private lymphoedema 
practioners were informed of the study and, with permission, contact details of 
interested patients were forwarded to the researcher. Interested patients were 
telephoned to explain the purpose and procedures of the study, and information and 
consent forms (see Appendices 24 and 25, pages 188 and 190) were posted to those 
who remained interested. The same procedure used for hospital recruits with 
reservations, was also used for these patients. 
 
3.2.3 Procedure 
Patients attended the Breast Clinic at Royal Perth Hospital. Written consent was 
obtained and the same clinical and demographic information was collected as in Part 
A of the study (see Appendix 11, page 151). Patients then completed the BLYSS 
questionnaire and the GHQ-12. The GHQ-12 is a self-administered test that takes 
four minutes to complete and focuses on the inability to carry out normal functions 
and any distressing phenomena (1,148). The GHQ-12 has been shown to be reliable 
(0.73) on test retest evaluation, has a split half value of 0.83, specificity of 78.5 and 
is sensitive to change (93.5) (1). Time taken to complete the BLYSS questionnaire 
was recorded. 
 
The appearance of breast lymphoedema was independently assessed by a clinical 
nurse specialist and a senior physiotherapist from the Breast Clinic at Royal Perth 
Hospital, using a modified version of the scale proposed by Harris (shown in 
Appendix 21, page 185). This four category scoring system first described by Harris 
et al in 1979, as shown in Appendix 22, page 186 is widely used in breast cancer 
treatment related studies (149,150). The Harris scale is a subjective method of 
evaluating the cosmetic outcome of BCT, based on observer evaluation of the treated 
breast, classifying it into one of four scores: excellent- treated breast nearly identical 
to untreated breast; good- treated breast slightly different than untreated; fair- treated 
breast clearly different from untreated but not seriously distorted; poor- treated breast 
seriously distorted (2,149). Assessors were blind to the other assessor’s responses. 
The researcher did not view the appearance of the patients’ breast lymphoedema, and 
therefore unable to assist, determine or influence scoring by the assessors. 
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After review by the nurse and physiotherapist, each patient was given another copy 
of the BLYSS questionnaire and asked to complete it 24 hours later, and return it to 
the investigator in the replied paid envelope provided. A 24 hour interval was 
selected to minimise recall bias, without introducing a high risk of change in 
condition during the interval. Patients were offered a telephone call the following 
day, as a reminder to complete the second BLYSS questionnaire.  
 
3.2.4 Data analysis 
3.2.4.1 Reliability 
Data were analysed using Statistical Package for the Social Sciences version 18.0 for 
Mac. Reliability of BLYSS questionnaire was calculated from the initial (test) and 
follow up (re-test) completion of the BLYSS questionnaire using ICC’s. Duplicate 
administration in a sample of this size was sufficient to determine a reliability 
coefficient of 0.8 at alpha = 0.055 and beta = 0.02 (151). 
 
3.2.4.2 Validity 
The BLYSS questionnaire addressed face, content, discriminant, criterion, 
convergent and construct validity. Face and content validity were established by the 
design of the questionnaire and involvement of both clinicians and patients. This is 
further discussed in Chapter Four, Results, page 55. The results from the BLYSS 
questionnaire were correlated with qualitative scoring of the modified Harris scale to 
determine discriminant validity. The correlations between the BLYSS and GHQ-12 
scores were analysed to establish criterion and convergent validity. Construct validity 
was established based on the content of the questionnaire and if there was a positive 
correlation between the BLYSS and the GHQ-12.  
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Chapter 4.0 
Results 
The development of the BLYSS questionnaire was undertaken in response to the 
need for a clinically useful instrument aiming to capture all relevant clinical 
dimensions of breast lymphoedema. The objective was to identify items that 
reflected the areas affected patients considered important and incorporate them into a 
valid and reliable questionnaire that was simple and convenient to administer. The 
approach was designed to both maximise the chances of constructing a useful 
instrument and to vigorously test its validity and reliability (96). This chapter 
describes the results of Part A (instrument development) and Part B (evaluation of 
the BLYSS questionnaire).  
 
4.1 Part A: Instrument development 
This first stage involved gathering items to be considered for inclusion in the 
questionnaire. Based on this objective the initial pool of questions was generated 
from three sources; i) relevant published material, ii) clinicians who treat patients 
with breast lymphoedema and iii) patients who have previously been treated for 
medically diagnosed breast lymphoedema. 
 
4.1.1 Generating a pool of questions 
4.1.1.1 Literature review 
One hundred and sixty-six articles were identified from the literature review, using 
the search items described in Table 3.1, Chapter 3 Methodology, page 37. These 
articles were filtered to include only those articles that described BCT for breast 
cancer including breast lymphoedema and/or breast oedema, complications of all 
aspects of BCT treatment (especially chronically), characteristics associated with 
breast lymphoedema or breast oedema, assessment and treatment of these 
complications. Items that were mentioned in more than two articles were retained, 
including such terms as swelling, fibrosis, discomfort and distress. Sixty-six items 
reported to be associated with breast lymphoedema were identified from the 
literature. Any items that were, or appeared to be, repetitious or duplicative were 
reduced to one item (for example larger, bigger, fuller or engorged were considered 
synonymous with swelling). These items were then grouped into five domains; signs, 
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symptoms, physical dysfunction, psychosocial factors and functionality, seen in 
Table 4.1, page 57. 
 
4.1.1.2 Clinician interviews  
Of the ten clinicians invited to participate in Part A of the study, eight were willing to 
be involved. Two clinicians from each of the following professions were represented: 
breast surgery (consultant medical staff), occupational therapy, physiotherapy and 
radiation oncology (consultant medical staff). They had worked in their respective 
professions for a mean (SD) of 16.2 (9.3) years (range 7–33 years) and treated a 
mean of 486.2 (347.9) patients per year, of which 116.4 (134.6) patients had breast 
lymphoedema. 
 
All of the clinicians identified breast lymphoedema as a problem, both clinically and 
for patients. They reported that differential diagnosis could be difficult due to the 
absence of definitive diagnostic criteria and lack of objective assessment tools. 
Clinicians used their own rating scales to classify the severity of breast 
lymphoedema as mild, moderate or significant. Their severity ratings were based on 
the appearance of the breast and how badly it affected the patient, either physically 
and/or psychologically. Clinicians reported that specific therapy was not usually 
recommended for mild breast lymphoedema. However, if the condition was 
considered moderate to significant, patients would be referred to services such as 
physiotherapy and psychology for treatment. 
 
Clinicians’ responses about breast lymphoedema were associated with how often 
they treated these patients. Those who did not routinely review patients with breast 
lymphoedema reported a low prevalence, whereas those who routinely treated 
patients with breast lymphoedema reported breast lymphoedema as a significant side 
effect of breast cancer treatment. This was further explored by asking clinicians 
whether the incidence of breast lymphoedema had changed, particularly as a result of 
BCT. Responses varied from increased (25%), no change (37.5%), not sure (25%), to 
a decrease (12.5%) in the incidence of breast lymphoedema. 
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Table 4.1 Items identified in the literature to be associated with breast lymphoedema  
Symptoms 
Altered body image                                                   Increased breast size/increase breast weight 
Breast size discrepancy                                             Numbness 
Discomfort                                                                Distortion in shape 
Fatigue                                                                       Heaviness 
Hypersensitivity 
 
Signs 
Atrophy/loss                                                              Oedema  
Erythema                                                                   Peau de orange 
Fibrosis                                                                      Pigmentation  
Increased density/firmness                                        Pitting  
Induration                                                                  Retraction  
Lymphoedema of the arm                                         Telangiectasis 
Non- pitting                                                               Thickened skin 
 
Physical dysfunction 
Change in appearance                                               Skin appears shiny 
Change in fit of jewellery (rings)                              Skin appears tight 
Indentations from the brassieres                               Skin has fewer creases 
Limitations in arm range of motion                           Marking of brassieres 
 
Psychosocial 
Anxiety/social anxiety  
Avoids looking in the mirror when undressing 
Constant reminder of the breast cancer experience 
Fear 
Fear of recurrence  
Feels ashamed of body 
Feels less feminine 
Feels self conscious about physical appearance  
Psychological distress  
Uneasy about future health 
 
Functionality 
Inability to return to activities of daily living, as prior to breast lymphoedema 
Inability to return to paid occupational activities, as prior to breast lymphoedema 
Inability to return to social activities, as prior to breast lymphoedema 
Arm functioning interferes with daily activities 
Arm functioning interferes with social activities 
Difficulties involving clothing 
Difficulties involving underwear  
Difficultly sleeping 
Discomfort in brassieres 
Functional changes  
Reduced function  
The breast affects the frequency of having sex 
The breast affects the partner’s enjoyment of sex 
The breast affects the partner’s interest in sex 
The breast affects the patient’s enjoyment of sex 
The breast affects the patient’s interest in sex 
The breast interferes with daily activities  
The breast interferes with social activities 
Told by specialist that their breast swelling should resolve (over months to years) 
 
 58 
Clinicians reported that breast lymphoedema was a problem when mammograms 
were required. The swelling and discomfort associated with breast lymphoedema has 
the potential to limit the amount of breast compression possible during imaging, 
affecting the quality of the mammogram. As a result some patients with breast 
lymphoedema had ultrasonography as well as mammography as part of the review 
process. The responses of the clinicians to the open ended questions about the signs 
and symptoms they considered were associated with breast lymphoedema and how 
many clinicians identified each item can be viewed in Table 4. 2, page 59.  
 
Although all items were screened for prevalence, frequency and importance, only the 
four highest ranking items (as described as important to clinicians and patients) are 
discussed here. Clinicians reported the frequency of swelling ranging between daily 
(three clinicians) to constant (three clinicians). One clinician did not answer this 
question and the other reported that swelling fluctuated between daily and constant. 
In regards to the importance of swelling to patients, clinicians rated this as ranging 
from somewhat to very important to patients, and in regards to how important 
swelling was to clinicians, five clinicians considered swelling to be a very important 
item. 
 
Discomfort was reported to occur constantly to weekly in patients with breast 
lymphoedema. Four clinicians considered discomfort as very important and rated it 
between somewhat and very important to patients. Five clinicians reported heaviness 
to occur daily in patients with breast lymphoedema. They considered this item as 
very important whilst they interpreted it to be somewhat to very important to 
patients. Three clinicians reported constant redness in patients with breast 
lymphoedema. This item was rated by clinicians as somewhat to very important to 
patients and as very important by six clinicians. 
 
The next step in generating the pool of items was to integrate the responses from 
clinicians to the closed ended questions and the items identified in the literature 
review. All items in Table 4.2, page 59 were included at this stage. Where items 
contained the main word e.g. anxious or self-conscious but were in different 
derivatives (anxiety, feels conscious, self conscious of appearance), the main word 
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Table 4.2 Identified items and between-clinician responses to items considered to be 
associated with breast lymphoedema (N=8)  
Symptom                            Agreement within the group 
Swelling 8 
Discomfort 6 
Heaviness 6 
Redness 2 
Fibrosis 2 
Pain 2 
Peau de orange 2 
Tightness 2 
Tenderness 1 
Hardness 1 
Indentations from brassieres 1 
Fear of recurrence 1 
Uncomfortable 1 
Pinkness 1 
Aesthetics 1 
Physical reminder of breast cancer 1 
Breast changes 1 
Hypersensitivity 1 
Restriction in glenohumeral joint  
Range of motion 1 
Breast rubs or catches on brassieres 1 
Ache 1 
Distress 1 
Warmth 1 
 
was retained. The items were allocated to five domains which can be seen in the 
patient elicitation questionnaire (Appendix 12, page 155).  
 
4.1.1.3 Patient interviews 
Eighty patients were sent invitation letters to participate and 29 patients responded 
agreeing to be involved. Six patients returned the consent form declining to be 
involved and three telephoned to discuss their participation as they no longer felt that 
they had breast lymphoedema. Forty two patients did not reply to round one of the 
mail out. On the second mail out, 51 patients from the original mail out were sent 
invitation letters and the target of 50 patients was achieved.
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Patients with breast lymphoedema were predominantly postmenopausal (74%) with a 
mean age of 57.9 years at diagnosis of breast cancer (Tables 4.3 and 4.4, pages 61 
and 62). With respect to treatment, 96% of patients had a wide local excision and 
42% of patients had a grade II axillary clearance. The tumour was located in the right 
breast in 60% of patients and in the upper outer breast quadrant in 58% of patients. 
Histopathology for the majority of patients was a ductal (82%) grade II (56%) 
carcinoma without lymph node invasion (68%) that was positive for the hormone 
oestrogen (43%).  
 
Thirty-six (72%) of the patients experienced postoperative complications. Infection 
occurred in 24 (48%) patients, seroma in 18 (36%) patients and haematoma in four 
(8%) patients. Although the total of combined complications was greater than the 36 
identified patients, some patients had one or more post operative complications.  
 
Patients were predominantly right hand dominant (92%), pensioners (56%) and born 
in Australia (44%). Most patients were married (66%) and gave birth to an average 
of two children, with five patients nulliparous. The highest level of education of 50% 
of patients was less than or equivalent to an intermediate certificate from secondary 
school (Table 4.5, page 63).  
 
4.1.2 Item elicitation interviews  
Patients who reported experiencing an item were asked further questions regarding 
the frequency and importance of that item to them. Five response options for how 
often the item occurred ranged from “constantly” to “less than or monthly”. There 
were five response options for the importance of each item to the patient. Patients 
could choose from “not important” to “extremely important”.  
 
The first ten interviews were examined to see if there were any unexpected items 
associated with breast lymphoedema identified by patients. During this examination 
it became apparent that patients perceived mammography as an event that 
exacerbated breast lymphoedema. Therefore this item was incorporated into the 
interviews, and subsequent patients were asked if it was a problem for them.
 61 
Table 4.3 Characteristics of interview patients (N=50) 
Characteristics Mean (SD) Range 
Time since surgery (years) 5.4   (2.6) 1—11 
Age at diagnosis (years) 57.9 (9.06) 33—82 
Tumour size- first (mm) 
Second (mm) 
18.7   (8.9) 
12.4   (6.3) 
1—35 
3—20 
Age during interviews (years) 62.5   (8.5) 45—85 
Duration of breast lymphoedema (years) 3.7   (2.5) 0.1—9.0 
 
Patients were asked the similarities, or differences of items and meanings of each 
item. From the ten initial interviews, it became apparent that patients could clearly 
discriminate the meanings of different items but they could not adequately or 
consistently describe them. It was decided that patients would continue to be asked 
the similarities and differences between items and the meaning of each item. Once 
questionnaire items were determined, definitions of these items would be 
incorporated into the questionnaire. The remainder of the group was interviewed 
incorporating those additional items identified from the first ten interviews. 
 
Results were tabulated with prevalence, frequency and importance of each item 
(Table 4.6, page 64) to facilitate screening against the previously determined item 
retention criteria (affected ≥ 60% of the women at all; affected ≥50% of the women 
occurring at least once per week; and ≥50% of the women must have considered the 
item at least slightly important).  
 
The nine items retained were swelling, discomfort, heaviness, uncomfortable, 
hardness, discomfort in the breast when wearing a brassiere, indentations on the 
breast from the brassiere, breast lymphoedema is a reminder of breast cancer and 
mammograms were more uncomfortable now. 
Although not identified in the literature review, or clinician or patient interviews, 
during data collection the investigators questioned whether the items identified from 
the first round of interviews occurred during different scenarios (at rest, activity and 
at night). As a result 20 patients were recontacted and verbal permission was granted
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Table 4.4 Tumour, surgical, histopathological and treatment characteristics of 
interview patients (N=50) 
Features Numbers (%) 
Tumour location 
 Right breast 
 Left breast 
 
30 (60%) 
20 (40%) 
Position of Tumour (quadrant) 
 Upper inner 
 Upper outer 
 Upper inner/outer 
 Lower inner 
 Lower outer 
 Central 
 Axillary tail 
 
7 (14%) 
29 (58%) 
1 (2%) 
4 (8%) 
7 (14%) 
1 (2%) 
1 (2%) 
Surgical procedure  
 Wide local excision 
 Other 
 
48 (96%) 
2 (4%) 
Adjuvant treatments 
 Chemotherapy 
 Radiotherapy 
 Hormonal therapy 
 
23 (46%) 
 50 (100%) 
38 (76%) 
Tumour Grade 
 First tumour   
    I 
 II 
III 
 Second tumour  
    I 
 II 
III 
      Third tumours 
    I 
 
 
10 (20%) 
28 (56%) 
12 (24%) 
 
1 (2%) 
3 (6%) 
1 (2%) 
 
1 (2%) 
Histological Type  
 Ductal 
 Lobular 
 Mixed ductal and lobular 
 Special types 
 
41 (82%) 
4 (8%) 
2 (4%) 
3 (6%) 
Type of axillary surgery  
 Axillary clearance-grade I 
 Axillary clearance-grade II 
 Axillary clearance-grade III 
Sentinel node biopsy 
Sentinel node biopsy progressing 
to axillary clearance            
Unknown 
 
1 (2%) 
21 (42%) 
2 (4%) 
  9 (18%) 
 
11 (22%) 
6 (12%) 
Lymph node involvement 
 Positive 
 Negative 
 
16 (32%) 
34 (68%) 
Hormonal status  
 Oestrogen positive 
 
38 (76%) 
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Table 4.5 Demographic characteristics of patients (N=50) 
Features Numbers (%) 
Hand Dominance 
 Right hand 
 Left hand 
 
46 (92%) 
4 (8%) 
Country of Birth 
Australia 
United Kingdom 
Other countries 
New Zealand 
Other European countries 
Malaysia 
 
22 (44%) 
19 (38%) 
  4 (8%) 
  3 (6%) 
1 (2%) 
1 (2%) 
Marital Status 
 Single 
 Married 
 De Facto 
 Divorced 
 Widowed  
 
4 (8%) 
33 (66%) 
1 (2%) 
6 (12%) 
6 (12%) 
Child Bearing 
Nulliparous 
One child 
Two children 
Three children 
Four children 
Five children 
 
5 (10%) 
6 (12%) 
17 (34%) 
16 (32%) 
5 (10%) 
1 (2%) 
Breast Fed 
None 
One child 
Two children 
Three children 
Four children 
 
20 (40%) 
4 (8%) 
11 (22%) 
12 (24%) 
3 (6%) 
Education 
No school certificate 
School/Intermediate certificate 
High school/Leaving certificate 
Trade/Apprenticeship 
Certificate/Diploma 
University degree 
Postgraduate degree 
 
2 (4%) 
23 (46%) 
5 (10%) 
1 (2%) 
11 (22%) 
6 (12%) 
2 (4%) 
Primary Employment 
Pensioner 
Full time work 
Unemployed 
Home duties 
Part time work 
Student 
Voluntary work 
 Secondary Employment 
Voluntary work 
Pensioner 
Full time work 
Part time work 
 
28 (56%) 
 6 (12%) 
4 (8%) 
4 (8%) 
4 (8%) 
4 (8%) 
2 (4%) 
 
3 (6%) 
2 (4%) 
2 (4%) 
2 (4%) 
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Table 4.6 Prevalence, frequency, importance and inclusion of questionnaire items 
Variable Prevalence (%) 
Frequency 
Overall 
Importance 
Overall Include 
Signs     
Swelling 34 (68%) 32 (64%) 25 (50%) Yes 
Discomfort 31 (62%) 25 (50%) 31 (62%) Yes 
Heaviness 34 (68%) 34 (68%) 34 (68%) Yes 
Pain 27 (54%) 27 (54%) 27 (54%) No 
Hypersensitivity 27 (54%) 22 (44%) 21 (42%) No 
Tenderness 28 (56%) 28 (56%) 27 (54%) No 
Uncomfortable 30 (60%) 30 (60%) 30 (60%) Yes 
Ache 19 (38%) 20 (40%) 20 (40%) No 
Redness 14 (28%) 13(26%) 14(28%) No 
Symptoms     
Hardness 31 (62%) 31 (62%) 31 (62% Yes 
Peau orange 15 (30%) 15 (30%) 15 (30%) No 
Warmth 24 (48%) 21 (42%) 23 (46%) No 
Thickness 16 (32%) 15 (30%) 15 (30% No 
Pinkness 15 (30% 12 (24%) 13 (26%) No 
Heat 25 (50%) 23 (46%) 24 (48%) No 
Physical dysfunction     
Indentations 30 (60%) 30 (60%) 30 (60%) Yes 
Glenohumeral joint range of 
motion 12 (24%) 12 (24%) 12 (24%) No 
Reaching 18 (36%) 18 (36%) 18 (36%) No 
Taking brassieres on/off 13 (26%) 13 (26%) 13 (26%) No 
Hardness 31 (62%) 31 (62%) 31 (62%) Yes 
Appearance 10 (20%) 10 (20%) 10 (20%) No 
Fear of recurrence 22 (44%) 21 (42%) 22 (44%) No 
Psychosocial     
Reminder 37 (74%) 35 (70%) 34 (68%) Yes 
Anxious 15 (30%) 14 (28%) 15 (30%) No 
Fear 10 (20%) 10 (20%) 10 (20%) No 
Depressed 13 (26%) 12 (24%) 12 (24%) No 
Frustrated 21 (42%) 20 (40%) 20 (40%) No 
Embarrassed 10 (20%) 10 (20%) 10 (20%) No 
Self- conscious 14 (28%) 13 (26%) 13 (26%) No 
Affects clothing 19 (38%) 17 (34%) 18 (36%) No 
Tired 9 (18%) 9 (18%) 9 (18%) No 
Relationship with family 9 (18%) 9 (18%) 9 (18%) No 
Relationship with friends 0 (0%) 0 (0%) 0 (0%) No 
Functionality     
Difficulty wearing a brassiere 18 (36%) 18 (36%) 18 (36%) No 
Difficulty sleeping 22 (44%) 22 (44%) 21 (42%) No 
Discomfort in brassieres 30 (60%) 30 (60%) 30 (60%) Yes 
Affects activities of daily living 19 (38%) 18 (36%) 18 (36%) No 
Affects work 7 (14%) 10 (20%) 10 (20%) No 
Affects sport 8 (16%) 12 (24%) 11 (22%) No 
Affects intimacy 15 (30%) 21 (42%) 20 (40%) No 
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Table 4.7 Items and the frequency of occurrence during different scenarios 
(N=20) 
Item 
Scenario 
    Rest (%)                 Activity (%) Nocturnal (%) 
Swelling 19 (95%) 17 (85%) 17 (85%) 
Discomfort 18 (90%) 16 (80%) 18 (90%) 
Heaviness 17 (85%) 15(75%) 17 (85%) 
Uncomfortable 18 (90%) 17 (85%) 19 (95%) 
Hardness 14 (70%) 14 (70%) 14 (70%) 
Indents from brassieres 10 (50%) 14 (70%) 7 (35%) 
Discomfort in brassieres 10 (50%) 15 (75%) 7 (35%) 
Reminder of breast cancer 17 (75%) 15 (75%) 15 (75%) 
 
to further discuss these and other issues. The results of further exploration of 
different scenarios on the items, is illustrated in Table 4.7. As it was not expected 
that these scenarios would influence the prevalence or frequency of items, patients 
were only asked of its presence. As is illustrated in Table 4.7 a similarity in presence 
for the majority of the items during various scenarios can be seen. Only the 
indentations from the brassiere and discomfort in the brassiere occurred in half the 
patients (10/50%) at rest.  
 
Indentations from the brassiere and discomfort in the brassiere occurred in seven 
patients (35%) nocturnally. This result would not be considered unexpected however 
as patients would not routinely wear a brassiere to bed. As the prevalence for the 
remaining items ranged from 75% to 95% for the three scenarios, it was decided not 
to incorporate any of these situational qualifiers in the questionnaire.  
 
Patients were also asked whether they had ultrasound as a routine part of their 
investigations for breast lymphoedema and/or as part of ongoing investigations. Ten 
(50%) of the patients had routine ultrasound and seven of these patients (35%) said 
that ultrasound was more uncomfortable since developing breast lymphoedema.  
 
During the interviews one patient volunteered that her breast lymphoedema was 
worse in summer. The potential effect of weather or the seasons on breast 
lymphoedema had not been considered, as this had not been identified in the 
literature, by clinicians or other patients. Consequently patients in the subsequent 
 66 
interviews were asked if there was a season that more affected their breast 
lymphoedema. Of the twelve patients who were asked the above question, eight 
(66%) responded that summer exacerbated their symptoms of breast lymphoedema. 
As a result both ultrasound and summer heat were added to the questionnaire items. 
 
These patients were also asked to define eight of the questionnaire items (swelling, 
discomfort, heaviness, uncomfortable, hardness, indentations from the brassiere, 
discomfort when wearing a brassiere and breast lymphoedema is a reminder of breast 
cancer). Operational definitions were then based on the majority consensus of 
patients’ responses to these items.  
 
Discomfort and uncomfortable were identified by the interviewed patients as items 
associated with breast lymphoedema. However it is questionable whether these two 
items have the same or different meanings to patients. Patients who responded 
positively to experiencing both discomfort and uncomfortable, were asked further 
questions using the same format as previously described. 
 
Twelve patients reported these items had the same meaning and 11 patients reported 
that these items had different meanings. As this did not constitute an obvious 
difference, further analysis was undertaken. The absolute values and averages were 
examined and as 14 of the 18 responses met the criteria of frequency it was decided 
to retain both candidate items. 
 
4.1.3 Questionnaire formatting 
Fourteen reviews were undertaken to standardise and harmonise questionnaire 
wording and response options. This required several attempts due to the conceptually 
different dimensions identified in the earlier processes of Part A. 
 
Alternative templates of the questionnaire were considered using established 
questionnaires as examples. Revisions were made to the formatting of the BLYSS 
questionnaire until the final stage was considered acceptable for pilot testing.
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4.1.4 Pilot testing 
The questionnaire was initially pilot tested by five clinicians and nine patients. 
Cognitive interviews were conducted with these volunteers with a focus on content 
and structure of the questionnaire. 
 
4.1.4.1 Clinicians 
All clinicians agreed to participate reviewing the BLYSS questionnaire. Clinicians 
included two physiotherapists, a breast physician, a radiation oncologist and a 
masseuse. They had worked in their respective professions for a mean (SD) of 14 
(8.9) years (range 4–25 years) and treated 179 (88.1) breast cancer patients per year 
(range 100-300 patients), of which 16 (13.4) of these patients (range 6-40 patients) 
had breast lymphoedema. 
 
4.1.4.1.1 BLYSS questionnaire content 
All clinicians agreed that the content was relevant to the topic. Feedback included 
that the items were specific, the items described what they thought the common signs 
and symptoms of breast lymphoedema were and it was relevant not only to the 
clinician but also to the patient.  
 
Clinicians were asked whether any other items should be included or any item should 
be excluded in the questionnaire. Four clinicians identified other factors to be 
included in the battery of items. Discussion was entered into with all clinicians 
regarding the process of recruitment and selection of items contained within the 
BLYSS questionnaire. Several clinicians expressed a “doubling up” of items in the 
questionnaire, such as Items 2 (discomfort), 4 (uncomfortable) and 6 (discomfort 
when wearing a brassieres). Despite the perceived similarity of these items, patients 
had expressed distinct differences between them so they were retained.  
 
Clinicians were asked their thoughts about the definitions attached to each item. 
They agreed the definitions were important as they would improve consistency in the 
patients’ interpretation of the meaning of items. Two clinicians suggested that the 
response options should also be defined. Another clinician pointed out that it was not 
clear if the descriptors (none to extreme) were related to the severity or frequency of 
each item.  
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4.1.4.1.2 BLYSS questionnaire structure 
The structure and the layout of the BLYSS questionnaire was explored with 
clinicians. All of the clinicians agreed that the size of the text and the length of the 
questionnaire were appropriate. Other comments included that the alternate shading 
enhanced the clarity of the instrument. Clinicians thought the purpose of the BLYSS 
questionnaire needed improved explanation. 
 
Clinicians were invited to provide any further comments. One commented that Item 
7 (how severe are any indentations on the breast from the brassiere?) should be 
grouped with the rest of the items in the first box. The ultrasound item was suggested 
to be excluded, as a consequence maybe that patients would want an ultrasound to 
provide a diagnosis and/or the cause of the breast lymphoedema.  
Another suggested that mammograms are not uncomfortable when performed by an 
experienced professional. One clinician described the questionnaire as purely 
subjective. 
 
4.1.4.2 Patients 
Five patients who had previously been treated for breast lymphoedema were invited 
to participate in this part of the cognitive debriefing of the BLYSS questionnaire. 
Four of these patients were willing to pilot test the questionnaire. 
 
Demographic and clinical information was collected on these patients. Table 4.8, 
page 69 illustrates some of the characteristics of this group. Patients were mainly 
postmenopausal and who had undergone a wide local excision and axillary clearance, 
predominantly in the right breast for the surgical management of breast cancer. 
Although the four patients had differing tumour locations by breast histopathology, 
all patients had grade III ductal carcinomas in situ. Lymph node status was positive 
for two patients, and the tumour of one patient was positive for both the hormones 
oestrogen and progesterone. Three patients had been treated with chemotherapy and 
all patients had received radiotherapy. Three patients experienced postoperative 
complications including seroma, cording and haematoma. 
 
All patients were right hand dominant and half of the group were born in Australia. 
Three of the patients were married. All of the patients had reproduced and had breast 
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Table 4.8 Characteristics of pilot test patients (N=4) 
Characteristics Range 
Time since surgery (years) 2—3 
Age at diagnosis (years) 47—58 
Age during interviews (years) 50—60 
Tumour size (mm) 4—20 
Duration of breast lymphoedema (years) 0.3-1.6  
 
fed their infants. Half of the patients had graduated from University and three 
patients had some form of paid employment. 
 
4.1.4.2.1 Content 
All patients reported that the content of the instrument was relevant and that the 
questionnaire was understandable, facilitated by the definitions within the 
questionnaire. Four patients stated that the descriptors (none to extreme) were 
sufficient to answer the questions. Two patients reported completing other 
questionnaires (including the Pain Scale) and described words being easier to make a 
choice than numbers.  
  
All patients agreed that the items in the questionnaire represented those items they 
associated with breast lymphoedema. One patient reported that it was not obvious if 
the questions were being asked about the frequency and/or the severity of breast 
lymphoedema. None of the patients suggested any additional items for inclusion. 
One patient proposed removing item six (discomfort when wearing a brassiere), as 
this maybe due to a variety of situations, not just breast lymphoedema.  
 
4.1.4.2.2 Structure 
All patients liked the configuration of the instrument as it was simple to read, 
comprehend and answer. All patients reported that the text size and length of the 
questionnaire were appropriate. One patient suggested modifying page one of the 
questionnaire so that all of the first seven items were on this page. 
 
4.1.4.3 Revision of the questionnaire and further pilot testing 
The BLYSS was modified based on comments provided by clinicians and patients. 
Amendments included clarification of the purpose of the BLYSS questionnaire in the 
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introduction and reformatting of the instrument to accommodate the first seven items 
onto the first page of the questionnaire. 
 
4.1.4.3.1 Second round of pilot testing  
Five patients were invited and agreed to provide feedback on the revised BLYSS 
questionnaire. These patients were recruited using the same process and criteria as in 
previous parts of Part A of the study. Discussion followed the same format as in the 
first round of cognitive debriefing of the BLYSS questionnaire. 
 
Characteristics of the second cognitive debriefing patients can be viewed in Table 
4.9, page 71. All of the participants were postmenopausal and had undergone a wide 
local excision in a part of the upper outer breast quadrant as part of the surgical 
treatment of breast cancer. Of this group, three patients had a sentinel node biopsy 
progressing to a grade II axillary clearance. Three patients had based on 
histopathology a grade II ductal breast carcinoma located in the right breast, positive 
for the hormone oestrogen. Three of this group had developed seroma and infection 
as postoperative complications. All patients received radiotherapy and three patients 
took hormonal therapy as part of the adjuvant treatment for breast cancer. 
 
4.1.4.3.2 Content 
All five patients reported that the content of the questionnaire was relevant to the 
topic. They did not think that any of the items should be excluded from the 
questionnaire. Patients did not volunteer any other items for inclusion in the 
questionnaire. 
 
All patients considered the explanations associated with each item removed any 
ambiguity that could be associated with the meanings of the items. Patients also 
reported that the descriptors (none to extreme) were sufficient to answer the 
questions. Comments included that the range of choices was sufficient and that 
circling a word would provoke more of a response than choosing a number or 
crossing a line. One patient described that having to choose a word response gives 
the person filling in the questionnaire more of an idea what the question is asking. 
One patient described experience with questionnaires previously and identified 
completing pain scale questionnaires. This patient reported familiarity with
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Table 4.9 Characteristics of second cognitive debriefing patients (N=5)  
Characteristics Range 
Time since surgery (years) 1—4 
Age at diagnosis (years) 49—68 
Age during interviews (years) 50—72 
Tumour size (mm) 5.7—37 
Duration of breast lymphoedema (years) 0.5—4 
 
answering a questionnaire and alternative ways of answering a questionnaire. 
 
4.1.4.3.3 Structure 
All patients identified the alternative shading of items as an attractive feature of the 
BLYSS questionnaire. One patient reported that this made the questionnaire easier to 
read. Other remarks included that the BLYSS questionnaire was clear and 
understandable in this format. Patients described the layout of the questionnaire as 
simple. Patients went onto report that this made the instrument easy to complete and 
made the instructions very easy to follow. 
 
Patients were asked what could be improved with the layout of the BLYSS 
questionnaire. Only one patient suggested greater balance between the items section 
and the responses, and suggested expansion of the items section. Patients stated the 
size of the text and length of the questionnaire was appropriate. All patients reported 
that questionnaires of four pages or more started to become time-consuming, 
responses became less accurate due to length and doubted the value of the 
questionnaire. 
 
Patients were invited to provide additional comments with regards to the BLYSS 
questionnaire. Three patients took this opportunity. Comments included that the 
questionnaire was succinct and the length was appropriate.  
 
The ambiguity with response answers, identified in the first pilot testing seemed to 
have been removed by making clear in the introduction that the questionnaire was a 
symptom severity-based questionnaire. Consistent comments in both sections 
implied that no further adjustments of the BLYSS questionnaire were required.
 72 
4.2 Part B: Instrument evaluation 
The reliability and validity of the instrument was assessed in this part of the study. 
Thirty-one patients were recruited to participate in Part B using the same process as 
previously described in Part A. Thirty patients completed both the initial BLYSS 
questionnaire (test) and the follow up BLYSS questionnaire (retest). This group was 
predominantly postmenopausal (60%). Histopathologically the breast cancer tumours 
of the majority of these patients was grade II (53%) ductal carcinomas (80%) that 
were positive for the hormones oestrogen (87%) and progesterone (50%). Seventeen 
(57%) of the patients experienced post operative complications, with infection 
occurring in 12 (48%) of patients. Demographic and histopathological details can be 
seen in Tables 4.10, 4.11 and 4.12, pages 73, 74 and 75. 
 
4.2.1 Reliability of the BLYSS questionnaire 
Test re-test reliability of the BLYSS questionnaire was ICC=0.948 (95% CI=0.894 to 
0.975). This ICC score indicates that the score is excellent and that the BLYSS 
questionnaire is considered to be reliable (129). 
 
4.2.2 Validity of the BLYSS questionnaire 
4.2.2.1 Convergent validity 
There were significant correlations between the BLYSS and GHQ-12 scores 
(Spearman’s rho=0.58; p=0.001 between the first administration of the BLYSS 
questionnaire and GHQ-12; and Spearman’s rho=0.50; p=0.005 between the second 
administration of the BLYSS questionnaire and GHQ-12). 
 
4.2.2.2 Discriminant validity 
There were poor correlations between the BLYSS questionnaire and both clinicians’ 
modified Harris scores. For the first clinician the statistics were Spearman’s 
rho=0.15; p=0.043 between the first administration BLYSS questionnaire and the 
modified Harris scores; and Spearman’s rho=0.23; p=0.22 between the second 
administration of the BLYSS questionnaire and the modified Harris scores. For the 
second clinician, the statistics were Spearman’s rho=0.31; p= 0.1 between the first 
administration of BLYSS questionnaire and the modified Harris scores; and 
Spearmans’ rho=0.16; p=0.39 between the second administration of the BLYSS  
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Table 4.10 Characteristics of patients in Part B (N=30) 
Characteristics Range 
Time since surgery (years) 0—21 
Age at diagnosis (years) 468—912 
Age during interviews (years) 46—82 
Tumour size (mm) 1.9—35 
Duration of breast lymphoedema (years) 0.25—14 
 
questionnaire and the modified Harris scores. 
 
4.2.3 Other measures 
4.2.3.1 Time to complete the BLYSS questionnaire 
Patients were timed to determine the approximate length of time to complete the 
BLYSS questionnaire. On average it took the 30 patients 2 minutes and 14 seconds 
(standard deviation of 0.72) to complete the questionnaire. The time to complete the 
BLYSS questionnaire ranged from 0.53 seconds to 3 minutes and 41 seconds. 
 
4.2.3.2 Inter-tester reliability using the Modified Harris score 
There was a significant association between the two clinicians’ modified Harris 
scores (Kappa coefficient 0.593; 23/30 or percentage agreement 77%).  
 
4.2.3.3 GHQ-12 
Patients also completed the GHQ-12. Seventeen (56.3%) patients scored within a 
range that suggested no psychological component of ill health. Five patients (16.3%) 
recorded a score that was considered borderline of a psychological component of ill 
health and eight (26.3%) scored within a range indicating a high likelihood of a 
psychological component of ill health. 
 
Of the 13 patients who recorded borderline to high scores, (potential) causes were 
explored with these patients. The five patients who scored between 2 and 3 were 
asked to identify any reasons that may have contributed to their score. Four patients 
could not identify any factors that may have contributed to a borderline response. 
One patient was able to identify potential factors, including feeling worse than 
normal (which may have attributable to a breast cancer treatment related hormonal 
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Table 4.11 Tumour, surgical, histopathological, treatment and characteristics of 
patients in Part B of the study (N=30) 
Features Numbers (%) 
Tumour location 
 Right breast 
 Left breast 
 
14 (47%) 
16 (53%) 
Position of Tumour (quadrant) 
 Upper inner 
 Upper outer 
 Upper inner/outer 
 Lower inner 
 Lower outer 
 Lower inner/outer 
 Not documented 
 
2 (6.5%) 
14 (46.5%) 
2 (6.5%) 
  5 (16.5%) 
3 (10%) 
  1 (3%) 
3 (10%) 
Surgical procedure  
 Wide local excision 
 Other 
 
29 (97%) 
1 (3%) 
Adjuvant treatments 
 Chemotherapy 
 Radiotherapy 
 Hormonal therapy 
 
15 (50%) 
29 (97%) 
24 (80%) 
Tumour Grade 
  I 
 II 
III 
 Unknown 
 
6 (20%) 
16 (53%) 
5 (17%) 
3 (10%) 
Histological Type  
 Ductal 
 Special types 
 Not reported 
 
24 (80%) 
2 (7%) 
 4 (13%) 
Type of axillary surgery  
 Axillary clearance-grade II 
 Axillary clearance-grade III 
 Sentinel node biopsy 
 Sentinel node biopsy progressing  
 to axillary clearance 
        Not performed 
        Unknown 
 
 6 (20%) 
2 (7%) 
 7 (23%) 
 9 (30%) 
 
1 (3%) 
5 (1%) 
Lymph node involvement 
 Positive 
 Negative 
 
14 (47%) 
16 (53%) 
Hormonal status  
 Oestrogen positive 
 
26 (87%) 
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Table 4.12 Demographic characteristics of patients in Part B of the study 
 (N=30) 
Features Numbers (%) 
Hand Dominance 
 Right hand 
 Left hand 
 
28 (93%) 
2 (7%) 
Country of Birth 
Australia 
United Kingdom 
New Zealand 
South Africa 
 
22 (73.3%) 
6 (20%) 
1 (3.3%) 
1 (3.3%) 
Marital Status 
 Married 
 Widowed 
 Single 
 Divorced  
 
 23 (77%) 
  5 (17%) 
1 (3%) 
1 (3%) 
Child Bearing 
Nulliparous 
One child 
Two children 
Three children 
Four children 
 
3 (10%) 
5 (17%) 
13 (43%) 
5 (17%) 
4 (13%) 
Education 
School/Intermediate certificate 
High school/Leaving certificate 
Trade/Apprenticeship 
Certificate/Diploma 
University degree 
Postgraduate degree 
 
22 (73%) 
 4 (13%) 
1 (3%) 
 9 (30%) 
 3 (10%) 
 1 (3%) 
Breast Fed 
One child 
Two children 
Three children 
Four children 
 
5 (17%) 
8 (27%) 
5 (17%) 
  2 (7%) 
Primary Employment  
Pensioner 
Home duties 
Part time work  
Fulltime work 
Student 
Unable to work 
Secondary Employment 
Voluntary work 
Pensioner 
Part time work 
Home duties 
Tertiary Employment 
Part time work 
 
11 (37%) 
 7 (23%) 
 6 (20%) 
 4 (13%) 
1 (3%) 
 1(3%) 
 
 6 (20%) 
1 (3%) 
1 (3%) 
1 (3%) 
 
2 (7%) 
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drug, having a current cold or a recent birthday), that may have contributed to a 
borderline response. This patient declined any form of psychological assistance that 
was offered. 
 
Five of the eight patients, who recorded a score of 4 or more on the GHQ-12, were 
able to identify current situations that may have reflected this score. This included 
family situations (members with a diagnosis of metastatic breast cancer and being a 
carer for a partner deteriorating both physically and cognitively), breast cancer 
treatment related issues (the side effects associated with hormonal therapy) and other 
non-breast cancer related health issues (chronic back pain requiring surgery).  
 
Three of the eight patients were not able to identify any factors that may have 
contributed to their score. However one patient had a past medical history of 
depression that could have influenced these results.  
 
All of these patients were offered access to a variety of services to assist with these 
psychological situations. Seven of the eight patients declined services, citing being 
able to access their own avenues or resources to assist with their current 
psychological situations. One patient accepted information and a pamphlet for access 
to the Western Australian Breast Cancer Psychology Service. 
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Chapter 5.0 
Defining breast lymphoedema 
 
5.1 Introduction 
At the time of this study, there was no widely accepted definition of breast 
lymphoedema either in the literature or used by clinicians in Western Australia. 
Because of the difficulty in evaluating the literature due to the wide range and 
variance between definitions (if a definition was supplied), a group of experts in the 
area of lymphoedema was formed, with the purpose of developing a consensus 
definition for breast lymphoedema. 
 
5.2 Literature review 
5.2.1 Definitions 
Objective, accurate and reliable measures and standardised clinical definitions are 
essential to the generation of evidence, and the development of practice guidelines 
fundamental for evidence-based practice (152). However, little attention has been 
paid to defining disease in clinical medicine (153). Although it has been argued that 
patients can be treated without one, the importance to patients, clinicians and society 
cannot be argued (153). The true prevalence and incidence of breast lymphoedema 
has been difficult to elucidate, and is likely to be under-estimated due to the lack of 
consensus pertaining to a clinical definition (38,152). The necessity “to describe 
precisely how the disease is defined” (154)(p300) has been reiterated by other 
authors. Other researchers have continued to explore this theme. Although the impact 
of lymphoedema is extensive, it is largely unrecognised and under diagnosed, partly 
because of a lack of uniformity in diagnostic criteria (144). These inconsistencies in 
the scientific literature consequently lead to confusion surrounding clinical practice 
in the prevention and management (155) of breast lymphoedema. 
 
In 2009 Norman and colleagues revisited this discussion, stating that the 
inconsistencies in measuring and defining lymphoedema still remained a barrier to 
research and reporting (156), as results cannot be generalised since study populations 
may differ. Although the conclusions of this research were limited to lymphoedema 
of the arm and hand, the authors did acknowledge that breast lymphoedema was not 
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assessed (156). When provided, the terminology used to define breast lymphoedema 
is inconsistent (7,8,31). As a result, the lack of this understanding hinders patient 
care (157). 
 
It has been identified that information regarding the assessment and treatment of 
breast lymphoedema is lacking (41). The lack of a definition for this condition 
maybe be contributing, and compounding these matters. 
 
A definition that is consistent, bone fide and agreed to allows for assessments within  
and between groups (154). “Whilst definitions are essential to determine the 
consistency of measurement, lymphoedema is rarely defined in precise terms” 
(154)(p300). However, establishing a definition of breast lymphoedema, will 
facilitate uniformity in identifying patients with breast lymphoedema, and will be 
advantageous in clinical and research settings (32).  
 
5.2.2 Consensus techniques 
Consensus methods provide a means of synthesising information from a wide range 
of sources, frequently via insights provided by appropriate experts. They are 
particularly useful where purely quantitative methods are inappropriate or 
impossible. The three most commonly known consensus methods are the Delphi 
technique, the nominal group technique and the consensus development conference 
(158). The resources to orchestrate the consensus development conference were 
beyond this project, and is beyond that of most researchers (158). The Delphi 
technique and the nominal group technique involve measuring and developing 
consensus (158). Both approaches have been used in medical, nursing and allied 
health. 
 
5.2.2.1 The Delphi technique 
The Delphi technique uses group facilitation to achieve agreement of the opinion of 
experts in the field, typically through a series of sequential structured questionnaires 
in rounds (158-160). The process allows respondents to be exposed to the 
anonymous opinion of their peers. It enables researchers with limited resources to 
contact a large group of experts cheaply (via mail or electronic mail) with a self 
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administered questionnaire with few geographical barriers (158). Table 5.1, page 80 
illustrates the areas for reporting using the Delphi technique. 
 
5.2.2.2 The Nominal group technique 
The Nominal Group Technique originated in the 1960’s with the aim of facilitating 
effective group decision making in regards to social psychological research (161). As 
with the Delphi technique, this technique also uses experts, has at least two rounds of 
balloting but also includes face to face meetings from the beginning to identify issues 
associated with the topic to reach consensus (163). This method can be adapted and a 
modified nominal group technique involves only one meeting (163). 
 
There are similarities in both techniques. These include the generation of a large 
number of ideas, avoidance of a single train of thought, brainstorming to help explore 
the concept, encouragement of equal expert input, highly structured processes, 
avoidance of quick decision making, high degree of task completion and 
measurement of the relative importance of generated ideas (158,161).  
 
However significant differences exist as well. The nominal group technique involves 
a face to face meeting (usually of one to two hours length), whereas the Delphi 
technique does not (158, 161). The nominal group technique provides immediate 
feedback to participants, the Delphi Technique does not (158,161). 
 
A predominantly Delphi technique was used in this part of the project as this 
technique has demonstrated its value in previous health studies (158-160) and it 
integrates qualitative and quantitative approaches. However due to time limitations 
associated with a Masters degree, the desire to apply the definition to the project, and 
the economic constraints of the project, this initiative did not start with a 
questionnaire asking experts what should constitute a definition of breast 
lymphoedema. The components were provided to experts, who were asked to express 
their opinions of the merits of these components. In light of the time and economic 
constraints, a face to face meeting was not feasible. 
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Table 5.1 Areas for reporting on the Delphi technique 
Research problem Clearly defined 
Research rationale Topic and method justification 
Literature review Topic under study 
Methodology 
Data collection: clear explanation of the Delphi method employed 
Rounds: number employed, outline of each 
Sample: experts selection process and characteristics described in 
details 
Reliability and validity issues identified 
Statistical interpretation: guidelines for the reader 
Ethical responsibilities: towards “expert” sample and research 
research community 
Data Analysis 
Response rate for each round 
Round 1: presentation of total number of issues generated 
Round 2: presentation of results indicating the strength of support 
Further rounds (if applicable):  presentation of results 
Discussion and 
conclusions 
Issue of consensus 
Interpretations of consensus gained/not gained 
Direction of further research leading to conclusions 
Appendices Copy of each round of questionnaire illustrated 
                                                   (162)(p1009) 
 
5.2.3 Factors for consideration 
There are considerations for establishing and determining a consensus group. The 
success of the consensus group depends upon the combined know-how of the experts 
(160). The qualifications of the experts and the size of the panel are two fundamental 
features, as are the meaning of consensus, data analysis, reliability and validity (160). 
 
5.2.3.1 Experts 
The most appropriate experts will be those practicing in the area (158), which also 
provides credibility with the target audience (158). Yet experts should be relatively 
impartial (160), as those with a direct interest in the area could cause bias (159). 
Another consideration is that experts ideally should not be chosen on the basis of 
acquaintance with the researchers, as this too may introduce bias into the process 
(160).  
 
What constitutes an expert and how to identify one is controversial (159). The 
selection of experts usually involves non-probability sampling techniques, either 
purposive sampling or criterion sampling (159). Either technique means that experts 
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are not randomly selected therefore representativeness is not assured (159). This is 
also a potential cause of bias (154) as experts are chosen for a selected purpose.  
 
A heterogeneous group of experts should include those with a wide knowledge base 
(160). This will potentially lead to better performance due to differing perspectives 
on a problem (leading to a wider range of alternatives) and has the promise of 
producing a substantially higher proportion of high quality, highly acceptable 
outcomes than a homogenous group (160).  
 
5.2.3.2 Numbers 
The numbers of experts in the group will affect the generation of ideas and the 
amount of data to be analysed (159). In the Delphi technique there is a wide variation 
in the panel sizes from 10 to 1685 although this technique does not call for panel 
sizes to be representative samples for statistical purposes (160). However, time and 
money constraints associated with projects, maybe more influential and important 
considerations in regards to the number of participants (160). Intuitively it seems 
reasonable that the more experts the better because as the number of experts 
increases (160), so does “the reliability of a composite judgement” (164)(p37). 
 
5.2.3.3 The meaning of consensus 
There are no level or firm rules that determine consensus in the Delphi technique 
(160), nor is there any uniform or consistent way of measuring this. Although the 
final round will show “convergence of opinion with the dispersion of experts views 
lessening with each round” (160)(p379).  
 
A clear definition of acceptable levels of consensus (158) must be identified and 
justified within the methodology. Consensus can be defined in several different 
ways. Establishing a percentage level is a common way of clarifying the meaning of 
consensus (159,160), however this percentage can be construed at different levels 
(160). In one author’s review of the literature (160), this inconsistency of the 
meaning of consensus is evident in some studies. Some studies suggested consensus 
was implied by the results, other studies reported it was most participants’ 
agreement, others defined consensus based on stability of responses between rounds, 
or the interpretation of consensus was left to the reader (160).  
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5.2.4 Data analysis 
The Delphi Technique includes qualitative and quantitative methods (159,161) . The 
first round of the Delphi technique is often qualitative (159). Following rounds are 
then assessed to determine convergency and change of participants’ opinions (159). 
 
Scrutiny of statements can be summarised by using the median (158,159), modes and 
means (159), and levels of dispersion using interquartile ranges and standard 
deviations (158,159). Some authors have used a very precise methodological 
quantitative analysis involving ranking and scoring on a nine point scale, where 
scores represented levels of total disagreement through to levels of total agreement 
(158).  
 
5.2.5 Reliability and validity 
There is no evidence for the reliability of the Delphi technique (159) however aspects 
of validity can be assessed. Face validity can be determined by how consensus was 
achieved and the rigor of this process will determine its scientific quality (96,131). 
Content validity may be established using experts with knowledge and interest in the 
topic (159). Predictive and concurrent validity of a Delphi technique can be 
evaluated by comparing findings with data from alternative sources (160). 
Concurrent validity can also be helped to be developed by successive rounds using 
the instrument developed (159).  
 
5.3 Methodology 
Initially the literature was searched for information related to breast lymphoedema in 
breast cancer patients, the use of the term and whether and how this was defined. The 
literature was also reviewed for standards for what should be included in a definition.  
 
Databases searched included Medline, AMED (Allied and Complimentary 
Medicine), PsycINFO, Health and Psychosocial instruments and the Ovid Nursing. 
Given the success with Google Scholar earlier in the project, this was also searched. 
As identified in other parts of this thesis, the literature review identified that 
uniformity in the use and terminology of breast lymphoedema is limited. As a pre- 
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existing definition could not be used, it was decided to create a definition for breast 
lymphoedema (112). 
 
Experts working in the field of lymphoedema were invited to participate in a 
discussion group (Table 5.2, page 84). These people were known to the researcher 
through professional affiliations and collaborations. At the commencement of this 
project there was no widely accepted definition of breast lymphoedema. During a 
discussion at the 7th ALA Conference held in Fremantle, Western Australia in 2008, 
this was identified as a potential limitation of the study. Therefore a complimentary 
study was introduced to the project with the aim of developing a definition of breast 
lymphoedema. As this was not part of the original project, being able to access a 
large number participants, less known to the researcher was not feasible. The 
limitation of this approach does have implications for the generalisability of the 
definition adopted. Experts were contacted via electronic mail, explaining why they 
specifically had been approached, the aims, requirements and expected outcomes of 
the project. The purpose of this project (as an adjunct to a Masters degree) was also 
discussed. Participation was requested of the experts and it was explained that all 
contact would be via electronic mail (email) due to logistics, time and budgetary 
constraints. They were reassured that participation in the project was entirely 
voluntary and choosing not to participate would not affect any future professional 
interactions or affiliations. If experts wanted to be involved in the study, a reply 
email was requested. If no response was indicated by the expert, no further contact 
was pursued. Experts were directed to contact the researcher in regards to any 
questions or concerns about the project, either by email or telephone.  
 
In the first round of discussion, 12 issues were generated and presented as 
suggestions for the requirements for a definition of breast lymphoedema to panel 
members. No standards for what should go in a diagnostic definition were revealed 
during the literature review. However general requirements suggested that a vigorous 
definition should be based on the nature, location and the timing of breast 
lymphoedema. 
 
Differentiating true breast lymphoedema is a process of identification of a possible 
cause of lymphatic vessel or node damage (in this case potentially surgery and/or 
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Table 5.2 Experts who participated in the breast lymphoedema consensus 
definition group 
Expert Position and affiliation  
Dr. Sandi Hayes 
Senior Research Fellow,  
School of Public Health,  
Queensland University of Technology, Australia 
Dr. Monika Janda 
Senior Research Fellow,  
School of Public Health,  
Queensland University of Technology, Australia 
Louise Koelmeyer 
Senior Occupational Therapist,  
Westmead Breast Cancer Institute,  
Westmead Hospital, New South Wales, Australia 
Dr. Helen Mackie ALA Medical Adviser,  Australia 
Mr. Alex Munnoch Consultant Plastic Surgeon,  Ninewells Hospital, Dundee, Scotland 
Professor Neil Piller 
Director Lymphoedema Assessment Clinic, Department of 
Surgery, School of Medicine, Flinders University, 
South Australia, Australia  
Dr. Leigh Ward 
Reader in Nutritional Biochemistry,  
Department of Biochemistry,  
University of Queensland, Australia 
 
radiotherapy for treatment of breast cancer treatment), and elimination of other 
systemic or local causes (165). An initial document containing other criteria 
including location, nature, timing, differential diagnosis and risk factors for 
developing breast lymphoedema was sent to experts for their contribution. For each  
section, criteria derived from the literature review were provided, as a starting point 
for discussion amongst the group. For example in regards to location of the breast 
tissue, a description of the position of the breast, with references, was provided. 
Using a dichotomous scale experts were asked whether they agreed or disagreed with 
the statements, and to provide their rationale for this.  Results were then collated. As 
there is no widely recognised level of consensus required, it was decided that a 
minimum of 80% agreement from the group would be required for further 
consideration of inclusion in the definition. Anonymous responses from the group 
were fed back to the experts, along with the rationale as to why certain decisions and 
choices had been made and the consensus document was changed to reflect these 
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suggestions. This process continued for three rounds until all experts were satisfied 
with the content of the definition for breast lymphoedema. 
 
5.4 Results 
Thirty- seven articles on breast oedema and/or breast lymphoedema were identified 
from the literature review. Table 5.3, page 86, identifies those authors that define and 
do not define breast lymphoedema and breast oedema. Although these articles were 
not shown to the panel of experts, it identified the inconsistency in regards to 
definitions. Reviewing these articles informed the development of the criteria 
provided to the panel during the first round of data collection. Seven experts were 
contacted. All (as shown in Table 5.2, page 84) accepted the invitation to participate 
in the consensus group. 
 
5.4.1 Data collection 
5.4.1.1 Round one 
5.4.1.1.1 Experts comments 
An initial document was emailed to each of the expert panel members who provided 
feedback including verification of provided material, ideas for further development 
or components that required clarification. Analysis involved identifying whether an 
expert agreed or disagreed with statements in each section, by reviewing the 
comments they provided. The responses for round one are summarised in Table 5.4, 
page 87. One hundred per cent agreement was achieved during this round. 
 
5.4.1.1.2 Location 
Three experts questioned whether the discussion of breast lymphoedema, included 
chest wall lymphoedema following mastectomy. Another expert questioned naming 
the breast a round eminence where the breast has been modified or tissue removed. 
An expert suggested components of definitions should include the breast quadrant/s 
involved. This expert’s proposal was to term the breast quadrants as lateral superior, 
lateral inferior, medial superior and medial inferior. This idea was supported by 
another two experts. No expert reported that the criteria in this section were not of 
value to the definition. 
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Table 5.3 Authors that defined and did not define breast lymphoedema and breast 
oedema 
Characteristic Author/s 
Defined breast lymphoedema  Kirshbaum 2000 (31), King et al 2001 
(64), Falagas et al 2005 (67), Lawenda et 
al 2009 (41), Fu et al 2009 (35), Degnim 
et al (60) 
No definition of breast lymphoedema Mertz et al 1998 (49) 
Defined both breast lymphoedema and 
oedema 
Clarke et al 1982 (3), Mondry et al 2002 
(5), Goffman et al 2004 (7), Ronka et al 
2004 (8), Stevenson et al 2005 (56), Jahr 
et al 2008 (43) 
No definition of either breast 
lymphoedema or breast oedema 
Sarin et al 1993 (77), Loprinzi et al 1996 
(47), Meek 1998 (4), Majeski et al 2000 
(50) 
Defined breast oedema Carl et al 2001 (90), Fehlauer et al 2003 
(23), Moffatt et al 2003 (57), Kwak et al 
2005 (65), Jeffs 2006 (42), Wratten et al 
2007 (59) 
No definition of breast oedema Habibollahi et al 1988 (44), Senofsky et 
al 1991 (45), Mendelson 1992 (46), Carl 
et al 1998 (48), Martlew 2000 (51), 
Wratten et al 2000 (52), Kurtz 2002 (26), 
Lopez et al 2002 (30), Wratten et al 2002 
(53), Zippel et al 2003 (6), Back et al 
2004 (15), Parbhoo 2006 (40), Williams 
2006 (54), Linnitt et al 2007 (55) 
  
5.4.1.1.3 Nature 
The experts provided points for consideration in this section. These included 
description of skin and tissue quality using the terms pitting, fibrotic, indurated 
and/or painful. The staging of lymphoedema created by the International Society of 
Lymphology (ISL)(166) was also provided as a consideration and can be viewed 
(Table 5.5, page 88).  
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Table 5.4 Summary of experts’ comments in round one. 
Expert Opinion Comment 
1 Agree Discussion of breast lymphoedema, included chest wall 
lymphoedema following mastectomy 
2 Agree Discussion of breast lymphoedema, included chest wall 
lymphoedema following mastectomy 
3 Agree Discussion of breast lymphoedema, included chest wall 
lymphoedema following mastectomy 
4 Agree Discussion of breast lymphoedema and questioned naming the 
breast a round eminence where the breast has been modified or 
tissue removed 
5 Agree Discussion of breast lymphoedema, suggesting inclusion of the 
breast quadrant/s involved 
6 Agree Agreed with expert 5 for inclusion of breast quadrant/s involved 
7 Agree Agreed with expert 5 for inclusion of breast quadrant/s involved 
 
5.4.1.1.4 Timing 
During discussion of the diagnosis of breast lymphoedema at the 2008 ALA 
Conference, it was suggested by an audience member that a definitive diagnosis of 
breast lymphoedema could not be made until breast swelling had been present for a 
minimum of three years. Five of the seven experts questioned the need to have breast 
considered this to be extreme and questioned its basis. The relevance of the time after 
breast surgery and the completion of radiotherapy were also queried. One expert 
questioned the need to have breast lymphoedema for a minimum of three years as a 
criterion for the definition. The panel considered this to be extreme and questioned 
its basis. The relevance of the time after breast surgery and the completion of 
radiotherapy were also queried. One expert suggested this was an unsound 
recommendation, as earlier detection can result in more favourable outcomes. 
 
One expert pointed out the need to be clear about distinguishing between timing 
related to development of breast lymphoedema, and timing with respect to how long 
someone has had breast lymphoedema. This expert thought that there was a general 
consensus that normal post-operative or post-radiotherapy swelling is resolved within 
three months. The expert suggested encompassing this concept with this, even if only 
on the basis that there is nothing better to go by. Whilst wanting to ensure a diagnosis 
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Table 5.5 International Society of Lymphology lymphoedema staging 
Stage Definition 
Stage 0 or Ia 
A subclinical state where swelling is not evident despite impaired 
lymph transport. This stage may exist for months or years before 
oedema becomes evident 
Stage I 
This represents early onset of the condition where there is 
accumulation of tissue fluid that subsides with limb elevation. The 
oedema may be pitting at this stage  
Stage II 
Elevation alone rarely reduces swelling and pitting is manifest. ISL 
late stage II- there may or may not be pitting as tissue fibrosis is more 
evident 
Stage III 
The tissue is hard (fibrotic) and pitting is absent. Skin changes such 
as thickening, hyperpigmentation, increased skin folds, fat deposits 
and warty overgrowths 
                                      (166)(p53) 
 
of breast lymphoedema as opposed to other conditions, alternative causes could be 
ruled out using other diagnostic tools. This expert also discussed the issue about 
whether someone has acute (meaning transient or short-term) lymphoedema, 
compared with chronic lymphoedema (which is persistent – could be stable persistent 
or fluctuating, but persistent). Accepting the theory that swelling from an event (e.g. 
surgery) goes within three months, Moffat’s definition of persistent “lymphoedema 
of greater than three months duration” (57)(p732) may be appropriate. 
 
5.4.1.1.5 Differential diagnosis 
This section achieved consensus by the group. One expert suggested lying on the 
same side continually to be included in this section. 
 
5.4.2 Responses and recommendations 
5.4.2.1 Location 
In response to whether breast lymphoedema included chest wall lymphoedema 
following mastectomy, it was clarified that this definition at present was restricted to 
those female patients who had BCT for breast cancer treatment. As a result at this 
stage the definition would also not include other areas such as the axilla, lateral chest 
wall, inferior clavicle, superior clavicle or the arm. 
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One expert questioned naming the breast a round eminence as removal of breast 
tissue could potentially change breast shape. Although it is acknowledged that the 
appearance and structure of the breast may be altered or changed as a result of breast 
cancer treatment and breast lymphoedema, the anatomical location will still be on the 
anterior chest wall and there is a need to clearly identify the organ that is being 
discussed and defined. Changes in the shape of the breast in the location section were 
made to reflect these suggestions. 
 
The terms for breast quadrants provided uniformity and consistency when describing 
locations on a breast. This suggestion was adopted as it is anatomically based. 
Therefore, these descriptors should be recognisable across different health 
professions working with women with breast lymphoedema. 
 
5.4.2.2 Nature 
Experts were asked to consider using the terms for breast quadrants, the descriptions 
of skin and tissue quality, the lymphoedema staging created by the ISL and/or both. 
There were several reasons for this suggestion. There is repetition of the terms pitting 
and fibrosis in the descriptions of skin and tissue quality and the lymphoedema 
staging created by the ISL. Although induration and pain may be important items 
associated with breast lymphoedema, there are many items identified in the literature 
associated with breast lymphoedema. As explained by one expert “the information 
derived from studies needs to be put in the context of study design, and comments 
about the strength of the study need to be described”. Another expert pointed out that 
detectable swelling may be a comparatively late development.  
 
The ISL staging is a familiar and established grading system in the assessment of 
lymphoedema, in the lymphology community. Therefore it was suggested to the 
group, as a basis for assessment of grading for breast lymphoedema. 
 
5.4.2.3 Timing 
Rationale for the basis of the three year suggestion was that if breast oedema was still 
present, differential causes of breast oedema could be disregarded. Regardless of 
what timeframe was decided upon by the group, experts were reassured by the author 
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there was no implication that if a patient had breast oedema/lymphoedema, they 
would not be denied any sort of lymphoedema management.  
 
All of the above suggestions were incorporated in the document as risk factors 
associated with the development of breast lymphoedema. These risk factors were 
identified from the literature review and included suggestions from experts. A list of 
risk factors was included in the second document for comment by the experts. The 
second revised version was distributed among experts.  
 
5.4.3 Round two 
5.4.3.1 Experts comments 
All experts (100%) expressed their support for information in this section. 
 
5.4.3.1.1 Location 
One expert interpreted the base of the breast as being the bottom of the breast as 
opposed to the top and questioned whether this is what was being described. Two 
experts suggested a diagram to supplement the breast quadrant Table. One expert 
questioned the effect of aging on the breast and another whether this only applied to 
a female breast (as breast cancer is seen in males). Other than these comments 
experts expressed their support for information in this section. 
 
5.4.3.1.2 Nature 
General consensus of agreement was achieved within this section. 
 
5.4.3.1.3 Timing 
General consensus of agreement was achieved within this section. 
 
5.4.3.1.4 Differential diagnosis  
One expert suggested that in this section it may be useful, depending on the context 
that the definition would be used, to provide a brief summary detailing the 
differential diagnoses. Other experts of the group supported this.  
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5.4.3.1.5 Risk factors  
There was also discussion about whether a section on risk factors for breast 
lymphoedema should be included in the definition. A list of these factors, with 
references was provided to the experts to review. One expert suggested considering  
breast scar direction and breast scar length to be considered as a potential risk factor. 
However another expert responded to this comment by suggesting these scars (the 
breast incision and the node dissection scar) were two individual factors to be 
considered separately. Experts’ comments can be seen in Table 5.6, page 92.  
 
5.4.3.2 Responses and recommendations 
5.4.3.2.1 Location 
As a result of the feedback, a diagram to supplement the breast quadrant terms was 
added. The effect of aging on the breast was included as part of the definition and a 
statement that the definition was only applicable to female breast lymphoedema was 
added. 
 
5.4.3.2.2 Nature 
One expert queried if other items (such as heaviness, tightness and hardness) should 
be included in this section. Although heaviness, tightness and hardness may be items 
associated with breast lymphoedema, there are many items identified in the literature 
associated with breast lymphoedema. One expert clearly explained that information  
derived from studies needs to be put in the context of study design and comments 
about the strength of the study need to be described. Therefore at this time, based 
upon study design and strength, these items were not included. 
 
5.4.3.2.3 Timing 
Based on the comments provided by experts in this section it was suggested that 
breast lymphoedema consists of breast swelling that persists greater than or equal to 
three months post surgery and/or radiotherapy.  
 
5.4.3.2.4 Differential diagnosis 
Definitions were provided for the differential diagnoses and were included as an 
appendix to the main document. This can be seen in Appendix 27, page 194. 
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Table 5.6 Summary of experts’ comments in round two 
Expert Opinion Comment 
1 Agree Discussion of breast lymphoedema, included risk factors for 
breast lymphoedema 
2 Agree Discussion of breast lymphoedema, included the effect of aging 
on the breast 
3 Agree Discussion of breast lymphoedema, included risk factors for 
breast lymphoedema 
4 Agree Discussion of breast lymphoedema, included description of breast 
location, differential diagnosis and risk factors for breast 
lymphoedema 
5 Agree Discussion of breast lymphoedema, included rationale for timing 
section and limitations risk factors for breast lymphoedema 
6 Agree Discussion of breast lymphoedema, included discussion of 
genders of breast cancer patients 
7 Agree No comments provided 
 
5.4.3.2.5 Risk factors 
Four experts provided feedback in this section. A concern of one expert, with listing 
the risk factors, was that the information derived from studies was not put in the 
context of study design (including how breast lymphoedema was defined). This 
expert suggested making some comment about the strength of the study design that 
informs in regards to risk factors, to help recognise whether these are facts or 
possibilities. Other experts conferred that without describing study designs, it would 
be very difficult to determine the strengths and weakness of the research that 
identified risk factors.  
 
The references that supported the risk factors listed were either low (observational 
studies) or very low (any other evidence) level evidence. None of the risk factors are 
diagnostic, nor are risk factors themselves diagnostic. Therefore there is a need to be 
careful how to incorporate risk factors into the definition. Consequently, risk factors 
for developing breast lymphoedema, were removed from the definition. 
 
5.4.3.3 Round three 
5.4.3.3.1 Experts comments 
All experts (100%) agreed to this version of the consensus document. The consensus 
document for defining breast lymphoedema is seen in Appendices 26 and 27, pages 
191 and 194.  
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5.5 Discussion 
Currently there are no objective measures used for breast lymphoedema. Although 
there are treatment modalities that appear to be effective, any research involving 
these modalities will be limited, if a definition for breast lymphoedema is not 
developed. There were no requirements that a definition should be a clinical 
diagnosis or involve laboratory tests. 
 
This exercise aimed to establish consensus among a group of experts in the field of 
lymphoedema to provide a definition for breast lymphoedema (167). Despite the 
literature demonstrating the need for lymphoedema to be clearly defined 
(38,152,154), this has not yet been translated into breast lymphoedema research. As a 
result, the absence of a generally accepted definition for this condition makes 
research projects difficult to compare and constrains application of findings to 
clinical practice.  
 
Where high quality research evidence is unable to answer clinical questions, 
recommendations from scientific consensus evidence is advocated due to its 
structured procedures involve (163,168). These methods are increasingly important 
(163) and are being used to define key aspects of health care (164). Studies using the 
Delphi technique have been published in the medical, allied health and nursing 
literature (168). Consensus groups have been criticised as a method that does not 
provide high level evidence (169), which is understandable in light of the dominant 
paradigm. Nevertheless, consensus methods are argued to lead to guidelines that are 
more clinically useful, than guidelines based purely on systematic review of the 
evidence (163). Consensus techniques are familiar, have previously been and 
continue to be used in the lymphoedema community. The document “Best Practice 
for the Management of Lymphoedema” (34) was created by consensus techniques. 
However which techniques and how this was done is not described in the document.  
 
Although a questionnaire was not circulated to experts at the commencement of the 
process, the first round was still structured, required open responses from the experts, 
and allowed them to discuss issues raised, and elaborate on their views, therefore 
increasing the diversity of data collected (160,162). This allowed the experts 
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relatively free scope to elaborate on breast lymphoedema. The qualitative analysis of 
the experts’ comments provided basis to construct subsequent rounds (160, 162).  
 
As recommended in the literature experts were informed where their responses sat in 
relation to other experts in the group and the overall picture (164). This feedback 
gave the opportunity to revise responses that had been identified as important 
elements contributing towards consensus (169). 
 
Major themes for defining breast lymphoedema were identified from the literature. 
This approach has been used by other authors, as it provides a point of reference for 
the experts, and limits the randomness of an open ended dialogue (170). Being 
quantitative in design, subsequent rounds were analysed using rating or ranking 
techniques (160) and central tendencies and levels of dispersion about collected 
opinion (167). The technique is described as part of data analysis for consensus 
techniques, as it enables experts to compare their responses in relation to that of the 
group (162). 
 
It has been described that “by their very nature, definitions are neither true nor false, 
only more or less useful” (112)(p41). This project has commenced development of a 
definition of breast lymphoedema. The acceptance and application of this definition 
is to be seen, but it addresses a need in the area of breast lymphoedema. Justification 
of how this process was undertaken (112), and how this project was started has been 
documented. Although consensus techniques are designed to capture collective 
knowledge they are also vulnerable to collective ignorance (164). In view of these 
issues, definition of breast lymphoedema developed in this project should be 
considered as making the best use of available information, and it does not 
necessarily mean that the correct answer has been found. 
 
In practice, the process of clarification continues as data is analysed (112), and it is 
envisaged that this will continue as more is learnt about breast lymphoedema. 
“Clarification is not a once-and-for-all process; it is an ongoing process of interaction 
between analysing data and clarifying concepts” (112)(p45). “As a result of 
analysing data, we are often in a better position to say what we mean by a concept, 
than before we began” (112)(p 45).  
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The current breast lymphoedema definition is a working definition which was used 
in this project (112). It provided a focus for this and potential future research (112). 
This will enable researchers and clinicians to draw conclusions as to whether the 
research is applicable to their patients, clinical practice and research. 
 
There is no consensus in the literature for defining timelines of post operative breast 
oedema, or breast lymphoedema as a result of breast cancer treatment. However, 
some authors have identified post operative and radiotherapy events within 
timeframes (3,8), and have further defined oedema as early onset (developing within 
the first two months after surgery and/or radiotherapy), and late onset occurring 
about 20 months after surgery and/or radiotherapy. Other authors have categorised 
the oedema response into acute (less than six months after radiotherapy) and late 
(from six months to several years after radiotherapy)(172,173), or have defined 
chronic oedema as greater than three months duration (57). It has been recognised by 
these authors that lymphoedema may occur in the late oedema response (172,173). 
One of these authors also acknowledges that chronic oedema is synonymous with 
chronic lymphoedema (57). 
 
Discussion continues on this issue regarding whether a patient has acute (meaning 
transient or short-term) lymphoedema, compared with chronic lymphoedema (which 
is persistent – could be stable persistent or fluctuating, but persistent). Therefore 
accepting the theory that swelling from an event (e.g., surgery or radiotherapy) 
should be resolved within three months, the definition of persistent “lymphoedema of 
greater than or equal to three months” (57)(p732) was considered most appropriate 
by the group.  
 
To ensure breast lymphoedema is the condition being addressed, as opposed to other 
differential diagnostic conditions, other causes could be ruled out using appropriate 
diagnostic tools. The list of differential diagnoses and the associated definitions 
assist in this process. 
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5.5.1 Strengths and limitations 
The Delphi technique allows the generation of consensus opinion to begin to answer 
clinical questions unanswered by research (163), by drawing on the opinion of a 
group of experts over a series of rounds interspersed with feedback, to gain the most 
reliable consensus (163). Strengths of the project design include the clarity of the 
purpose of the consensus group and the high degree of methodological precision and 
research rigor including insight into the process of the methodology, sequential data 
collection and analysis (160, 162,163). 
 
A potential limitation of this project concerns the panel of experts. The limited 
number of experts, their relationship to the author and the lack of random selection 
could potentially introduce bias to the project, and limit generalisability. However, 
the panel members represented the diversity of professions working in the field of 
lymphoedema. The experts are also recognised for their contributions and 
achievements in this field, therefore providing credibility to not only the group but 
the outcomes proposed by the group. 
 
5.6 Conclusion 
There is an urgent need for a definition of breast lymphoedema. This will facilitate 
uniformity in identifying patients with breast lymphoedema that will be both 
advantageous in clinical and research settings (32). In this part of the study a working 
definition was established using expert opinion in a three-round Delphi exercise, and 
based on the location, nature, timing and exclusion of differential diagnoses. This 
definition has immediate application in research and clinical settings. The success of 
this definition (172) will require a broader consensus and more widespread uptake 
among those working with breast lymphoedema (157). 
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Chapter 6.0 
Discussion 
 
The development of the BLYSS questionnaire was undertaken to measure health 
status in women with breast lymphoedema. Breast lymphoedema is a recognised 
complication of BCT and rates have been reported at 6-80% (3-8). However a lack of 
standard diagnostic criteria and a definition for breast lymphoedema make 
comparing research difficult and hampers evaluation of the effectiveness of treatment 
and translation to clinical practice. This project has addressed two issues critical to 
the forward progression of research around breast lymphoedema. In particular, a 
working definition for breast lymphoedema was constructed using a consensus 
technique, and a patient self-reported health status questionnaire was developed. The 
approach to questionnaire development was designed to not only maximise the 
chances of developing a useful questionnaire that struck a balance between patients’ 
needs such as containing items considered important to patients with breast 
lymphoedema, clinicians’ needs that it be simple and convenient to administer and 
scientific needs for validity and reliability to be determined. 
 
6.1  Breast cancer and breast lymphoedema 
Breast cancer is the most common cancer affecting Australian women (9), with one 
in nine Australian women diagnosed with breast cancer before the age of 85 years 
(174). As breast cancer treatments become more effective and patients’ survival 
longer, the importance of morbidity is increased (30). The categorisation of possible 
side effects such as breast lymphoedema according to scoring systems like the 
BLYSS questionnaire will facilitate monitoring the quality of care (30). 
 
For women with early diagnosed breast cancer, the current paradigm of treatment is 
BCT. This treatment option not only gives women survival outcomes equivalent to 
mastectomy (14,16,17), but salvages the breast. Lymphoedema, as a result breast 
cancer treatment, is recognised as one of the most significant survivorship issues and 
is reported to have significant consequences including physical, functional, quality of 
life and financial (175). Lymphoedema has been referred to as the dreaded sequela of 
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breast cancer treament (35) and some consider it to be worse than the cancer itself 
(35). 
 
In patients treated with breast conservation, breast lymphoedema is reported to be a 
more frequently seen complication than arm lymphoedema (4,7,39,40). As 
approximately 15,400 Australian women are expected to be diagnosed with breast 
cancer by 2015 (10), an increase in breast cancer survivors and those living with the 
burden of breast lymphoedema, is probable. 
 
Advances in surgical and adjuvant treatments for breast cancer, such as sentinel node 
biopsy, targeted intraoperative radiotherapy and brachytherapy (176), have the 
potential to reduce the likelihood of developing lymphoedema. Regardless, 
secondary lymphoedema can still occur after less invasive surgical procedures, such 
as wide local excision and/or sentinel node biopsy (176). As a result effective 
outcome measures are required to monitor the frequency and severity of breast 
lymphoedematous changes. 
 
Targeted radiotherapy offers a single high dose of radiation to the tumour bed 
performed in the operating theatre (176). However, as this technique is relatively 
new, longer monitoring is required before the effects of this treatment on the risks 
and severity of breast lymphoedema can be determined (176). Valid and reliable 
measuring procedures, definitions and reporting criteria for breast lymphoedema are 
critical for monitoring these changes and ultimately determining whether the risk and 
severity of breast lymphoedema are reduced.  
 
Despite recognition that breast lymphoedema is occurring more frequently (39), it is 
often an overlooked side effect of breast cancer treatment (41) and the resulting 
problems are minimised (43). Factors related to the lack of knowledge regarding 
breast lymphoedema include the historical focus on upper limb lymphoedema and in 
regards to this, predominantly on acute treatment and lack of a definition (144, 177). 
Not only does the lack of a definition and reporting criteria make interpretation of 
lymphoedema of the breast difficult, it may misinform clinicians, researchers and 
patients regarding the actual incidence and risk factors for breast lymphoedema. 
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It has been stated that the cause of breast lymphoedema is less well known than its 
signs and symptoms (8). This statement however, is open to question. Despite 
defining breast oedema and breast lymphoedema, like many other authors 
(4,5,43,50), Ronka et al (8) alternates between the terms breast oedema and breast 
lymphoedema. 
 
One of these authors does recognise that the incidence of breast lymphoedema does 
vary depending on how it is defined (4). Some researchers have differentially defined 
breast oedema and breast lymphoedema (8), whilst others have not (4,47,49,50). As 
these are two different conditions, it is difficult to determine what condition is being 
assessed, and although lymphoedema occasionally becomes apparent immediately 
after surgery, it most often appears after a latent period (35,175,176). 
 
In reference to signs and symptoms, it is not explained in the literature, how they 
have been attributed to breast lymphoedema. It is unclear whether they are anecdotal 
findings, based on clinicians’ and/or patients’ reports or if they have been 
extrapolated from research in the upper limb and applied to breast lymphoedema 
(7,31,42,56). Methodological evaluation of modern oncoplastic and radiotherapeutic 
techniques require standardised instruments to measure outcomes (177). As the 
ability to measure breast lymphoedema is difficult, most studies have used the 
dichotomous choices of present or not (15). As a result, thorough documentation of 
the severity of breast oedema is not possible from these data (15). For studies in 
other conditions, authors have chosen response categories other than dichotomous 
choices, as it gives further knowledge into the severity of patients’ conditions (110). 
It has been stated that diffuse breast lymphoedema is the most obvious symptom up 
to one year after radiotherapy, with close to zero incidence in the second year of post 
treatment review (178). These authors also reported that evidence based results 
regarding “other possible risk factors for lymphoedema of the breast should be able 
to be obtained from the meta-analysis of large randomised studies (such as the 
NSABP-B-06, Milano III, Ontario, Uppsalla-Orebro, and Scottish trials) evaluating 
the outcome of breast conserving surgery with and without radiotherapy” 
(174)(p240). Nevertheless, a search of Ovid Medline and Google Scholar failed to 
find any published results from those studies (the NSABP-B-06, Milano III, Ontario, 
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Uppsalla-Orebro, and Scottish trials) in regards to risk factors for breast 
lymphoedema and BCT, inclusive or exclusive of radiotherapy. 
 
There are still few simple objective methods for evaluating post treatment symptoms, 
especially in the breast (8), which may be due to the complexities in valid and 
reliable breast measurements (144). Technologies such as MRI, the Breast Symmetry 
Index and Bioimpedance spectroscopy may have a role in the diagnosis of breast 
lymphoedema, however, access to these technologies may not be readily available 
and/or expensive. Other modalities such as cosmetic and functional scales and the 
Breast Retraction Assessment (73) are not routinely used, perhaps as the validity and 
reliability of these scales has not been determined, or because of a lack of awareness, 
or availability. Water displacement and brassiere size have also been considered as 
objective measurements but they too have limitations due to the logistics of water 
displacement and the imprecision of brassiere size for use as an objective outcome 
measure of breast size. 
 
Due to limitations in assessment of breast lymphoedema, other assessment options 
needed to be considered. The literature identifies that there is no disease specific 
questionnaire available to measure health status in patients (37) with breast 
lymphoedema. This could also be contributing to the lack of research in patients with 
breast lymphoedema. Changes in signs and symptoms over time may suggest breast 
lymphoedematous changes (144). Due to the unique symptoms and problems of 
patients with breast lymphoedema and the reported increased occurrence (39), it was 
important to create a health status questionnaire designed especially for this group 
(37). The primary aim of this project was to create a questionnaire to measure the 
health status in women with breast lymphoedema. 
 
At the commencement of this project there was no widely accepted definition of 
breast lymphoedema. During discussion at the 7th ALA Conference held in Fremantle 
Western Australia in 2008, this was identified as a potential limitation of the study.  
Therefore a complementary study was introduced to the project with the aim of 
developing a definition of breast lymphoedema. The development of a definition of 
breast lymphoedema gave a clear understanding of what constituted a definition of 
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this condition applied in the study. This component of the project is described and 
discussed in Chapter 5, Defining Breast Lymphoedema, page 77. 
 
6.2  BLYSS questionnaire development and validation 
Measurements of health status provide important information about the humanistic 
and economic benefits of clinical medicine (179), however data collected using 
questionnaires may not be considered as robust as more objective outcome measures 
(179). Regardless, questionnaires are important resources for the evaluation of 
patient care and the effectiveness of patient treatment programmes (95). 
 
The BLYSS questionnaire is a comprehensive, multidimensional measure of health 
status that provides an understanding of the impact of breast lymphoedema. A 
questionnaire design was chosen as an assessment tool as the impact of breast 
lymphoedema is not just about measuring the size and shape of the 
lymphoedematous breast, but includes other factors about how a woman feels and 
how this condition affects activities of daily living, including functional aspects 
associated with the wearing of a brassiere. The BLYSS questionnaire incorporated 
those domains (appearance and experience, memory, assessments and weather) 
identified as important by patients with breast lymphoedema as a result of breast 
cancer treatment (180). 
 
Due to the unique symptoms and problems of patients with breast lymphoedema and 
the reported increased occurrence (39), it was important to create a health status 
questionnaire designed especially for this group (37). Sophisticated and complex 
approaches to questionnaire development can result in valid and reliable 
questionnaires that are suitable as outcome measures for clinical trials (94). The 
methods used to develop the BLYSS questionnaire addressed those considerations 
identified in the literature as important in the development of patient self reported 
questionnaire. An example of this is the use of an item elicitation questionnaire that 
provided the structure to further explore the dimensionality of symptoms experienced 
and identified by patients (140). Although this type of questionnaire development 
required more substantial resources than improvised measure development (96), the 
methods used ensured that the BLYSS questionnaire addressed issues that patients 
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considered important, and as well as those issues important to clinicians, such as 
reliability, validity, clinical credibility and feasibility. 
 
Part A of the study identified that patients had previously been exposed to and 
completed questionnaires/scales. During pilot testing two patients reported 
completing other questionnaires. These patients described how the word options in 
the BLYSS questionnaire made it easier to make a choice than numbers such as in 
the Pain Scale. All of the patients in the pilot testing phase reported that the content 
of the instrument was relevant and that the questionnaire was understandable, 
facilitated by the definitions within the questionnaire. This acceptability to patients 
(121) may be advantageous in regards to completing the BLYSS questionnaire, 
making the BLYSS questionnaire ideal for use in clinical practice (120). 
 
As our interviews with women with breast lymphoedema began with open-ended 
questions about how breast lymphoedema affected their lives we do not believe our 
use of an item elicitation questionnaire introduced bias into their responses. When 
more detail was required about the identified item, the item elicitation questionnaire 
provided a resource for the investigator to encourage further responses and 
discussion by referring to the concepts and items identified from the literature and/or 
from clinical experience. The item elicitation questionnaire permitted probing into all 
of the characteristics and properties associated with that item.  
It is also important to note that women did identify items that related to image and 
psycho-social issues, however these were not considered important enough by 
sufficient numbers of the women to warrant inclusion in the final questionnaire. 
 
The justification for retaining ≥60% and ≥50% of items also may have resulted in a 
narrower focus. Yet the aim was to have a suitable number of items for the 
questionnaire (100), sufficient for content validity. The priori ensured those items 
that were infrequently reported, considered not important and/or irrelevant to the 
majority of participants were not included. This approach also limited respondent 
burden or fatigue by reducing an excessive number of items which may not be 
important to patients. 
 
A different methodological approach taken during the initial stages with women may 
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have generated different results. A different approach could have involved using 
Rasch analysis. However this approach is not without its controversies including the 
need for a high degree of software insight, a large number of observations and an 
infinite data set with unidimensionality (117-119). If there are lots of items and 
refinement of items during Rasch analysis, questionnaires maybe very reliable but 
they are also much less valid and this analysis has strong assumptions not easily 
matched by the observations (119). 
 
6.2.1 Reliability of the BLYSS questionnaire 
6.2.1.1 Test- retest method 
The test-retest method (61,121), which evaluates whether a questionnaire is capable 
of measuring a variable with consistency (61,121,128), involves comparing scores of 
the same patient on two separate occasions (121,129). The assumption is that there is 
no change in scores, if there is no substantial change in health status of the patient 
being measured between tests (129). However the time interval between tests needs 
to be considered carefully (61). There is no exact agreement on a suitable time 
interval (121). Whichever interval is used it needs to be far enough apart to avoid 
fatigue, learning or memory effects, but close enough to avoid genuine changes in 
the underlying dimension of health (61,121). Consequently the most appropriate 
interval will depend on the nature of the questionnaire and the constructs that it 
measures, as well as the population for which the questionnaire is designed. There is 
considerable variation described in the literature. Some authors have used a two hour 
test-retest interval (181) and some a median time interval of three weeks (37). It was 
considered that breast lymphoedema was not so labile that the breast lymphoedema 
would be likely to change significantly in 24 hours. Also the logistics of longer 
follow up were taken into account. Considering these principles, a 24 hour interval 
was used to determine reliability of the BLYSS questionnaire. 
 
6.2.2 Validity 
The BLYSS questionnaire signifies a validated measure of the overall effect of breast 
lymphoedema on a breast cancer patient’s life. As aspects of validity are key 
attributes of a well designed questionnaire, aspects of validity were considered an 
important inclusion in the BLYSS questionnaire development (61,112). The BLYSS 
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questionnaire has addressed face, content, construct, discriminant, convergent and 
criterion validity issues. 
 
6.2.2.1 Face and content validity 
Together face and content validity address whether the items clearly assess the 
intended subject matter and whether the range is adequately covered (121). However 
as face validity is the weakest form of measurement validity (61) and neither face nor 
content validity can be readily measured statistically, the questionnaire itself needs to 
be reviewed (121). 
 
The design approach used to create the BLYSS questionnaire; the clarity of how the 
questionnaire was developed and how the rigor of this process maximised the 
chances of constructing a useful questionnaire which then established face and 
content validity, in itself allows an informed opinion of the merit of these approaches 
(96). These approaches ensured the BLYSS questionnaire of its scientific quality 
(96,131). 
 
The design, development and validation of the BLYSS questionnaire has married 
three concepts integral to development of a health status measure; patient 
participation, scientific value and clinician acceptability. It is generally agreed that 
patient opinion needs to be taken into account when developing a health status 
measure (182). Although knowledgeable about an illness, experts cannot substitute 
completely for the direct experience that patients have of health problems (121). 
Several studies have shown the disparity between patients’, doctors’ and relatives’ 
ratings of the patients’ quality of life (132). Using measures that are not patient 
centered may not cover domains important to patients and therefore may not be valid 
measures (128,132,133). If such measures do not capture the lived experience of the 
disease they are unlikely to be responsive to change after treatment (135). This has 
implications for interpreting the validity of the measure, determining the 
effectiveness of interventions and consequently the relative quality of service and the 
allocation of resources (132). 
 
Face validity of the BLYSS questionnaire was established by generating an item 
elicitation questionnaire. The item elicitation questionnaire was based on a review of 
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the literature, interviews with clinicians and structured interviews with affected 
women.  
 
Content validity was concluded after a panel of expert clinicians who diagnose and 
treat breast lymphoedema reviewed and determined that the items within the 
instrument satisfied the content domain. Items in the BLYSS questionnaire were 
established by generating an item elicitation questionnaire based on a review of the 
literature, interviews with clinicians and structured interviews with affected women. 
Consultation with clinicians and patients has also been the approach during the 
design phase of the content of other questionnaires, to ensure capitalising content 
validity, including all appropriate concerns and items fully applicable to these 
specific groups of patients (108,111). 
 
6.2.2.2 Construct validity 
Construct validity is whether a questionnaire is able to measure an abstract concept 
(61,112). It has been described as the most rigorous approach to establishing validity 
(113) but it can be difficult to determine whether a questionnaire is actually 
measuring the intended concept. Again the questionnaire itself needs to be assessed. 
The BLYSS questionnaire addresses four separate aspects of breast lymphoedema- 
appearance and experience, memory, investigations and the weather. The scope and 
assortment of items contained in the BLYSS questionnaire contributes to the 
credence that the BLYSS questionnaire represents a meaningful approximation to 
breast lymphoedema. 
 
Discriminant and convergent validity were considered in the validation of the 
BLYSS questionnaire. These forms of validity were examined by considering the 
associations between the BLYSS questionnaire and two other forms of assessment, 
the modified Harris score and the GHQ-12. 
 
6.2.2.2a Discriminant validity 
The cosmetic result of BCT is an important outcome and one that is conceptually 
different from health status. Therefore cosmetic outcome was selected as the variable 
to examine discriminant validity. In view of its subjective nature, grading the 
cosmetic outcome of BCT is difficult. One method that is considered useful (80) and 
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is widely used in breast cancer research as measure of breast aesthetics (150), is the 
four-point Harris score. This has previously been used in validity studies of the 
breast symmetry index (81) and the Breast Cancer Conservative Treatment Cosmetic 
software (82, 150). 
 
A modified version of the Harris score was used in this project. Words in the original 
Harris score (as shown in Appendix 22, page 186) were added and changed to be the 
same as the BLYSS questionnaire.  
 
Despite reports of disparity in regards to comparison of observer ratings for the 
cosmetic outcomes after breast conserving therapy (74,76,80), the inter-rater 
agreement between assessors using the modified Harris score in this study showed 
high agreement. This may be due to the assessors’ extensive experience and skills, as 
it is documented that previous experience in BCT treatment should be a prerequisite 
for evaluation of aesthetic result (79).  
 
Correlations between the BLYSS questionnaire scores and the clinicians’ modified 
Harris scores were poor. This provided evidence of discriminant validity as the 
BLYSS questionnaire and the modified Harris score are measures of different traits 
(61).  
 
6.2.2.2b Convergent validity 
Although the serious emotional and psychological effects of breast lymphoedema are 
addressed in the literature (35,55), these consequences have not been explored by 
using previously established psychological tools. The GHQ-12 is a widely used 
measure of mental health. Although it is typically used as a one-dimensional tool it 
has been shown to be multidimensional addressing three factors; anxiety and 
depression, social dysfunction and loss of confidence (183). These factors reflect 
feelings and experiences expressed by women with breast cancer. Although the 
underlying phenomenon measured by the GHQ-12 is not identical to that measured 
by the BLYSS questionnaire, it does address a number of similar constructs. 
Furthermore, the GHQ-12 has established validity, reliability and good internal 
consistency (184). Not only is this the shortest of the three types of GHQ (taking four 
minutes to complete) and is recommended for research use (184), the GHQ-12 has 
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been used in other studies of patients with breast cancer (1,68). Consequently it was 
selected as an appropriate comparator to examine convergent validity. 
 
The significant correlation between the BLYSS questionnaire and GHQ-12 scores 
(see Chapter Four, Results, page 55) provide evidence of convergent validity of the 
BLYSS questionnaire and indicate that the BLYSS questionnaire is measuring some, 
but not all of the aspects of health indicated by the GHQ-12. If the association was 
too strong it would suggest that both questionnaires were measuring almost the same 
entity and therefore there would be no need for the BLYSS questionnaire, as the 
GHQ-12 could be used. These findings considered in the light of the poor 
correlations between the Harris score and the BLYSS questionnaire (discriminant 
validity) also help to define “health status” as measured by the BLYSS (61). 
 
6.2.2.2c Criterion validity 
Criterion validity reflects whether a questionnaire is valid insofar as its results 
correspond to those of a criterion standard, or another measure generally accepted as 
more accurate or an established “gold standard” (61,112,121). This is difficult to 
establish for the BLYSS questionnaire as there is no perfect criterion available to be 
used for comparison.  
 
6.3 Strengths and weaknesses 
To date the BLYSS questionnaire is the only questionnaire to specifically measure 
the health status of women with breast lymphoedema. The methodology employed in 
this project underpinned the development of a valid questionnaire. This project has 
provided the template for a definition for breast lymphoedema that can be used for 
future deliberation. This format of developing a definition of breast lymphoedema 
and then a condition-specific outcome measure increases confidence in the validity 
of the BLYSS questionnaire to be considered as the primary measure of outcome in 
subsequent studies (96). 
 
Eighty-nine women with breast lymphoedema participated in this study. While these 
numbers may be considered small for studies of questionnaire design, 
(61,96,100,112) they are typical for studies of breast lymphoedema (43). Reasons 
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such as the lack of a definition for breast lymphoedema, unclear incidence and 
prevalence of the condition and/or a lack of standardised diagnostic criteria may be 
account for small sample sizes associated with breast lymphoedema studies. The 
development and validation of established questionnaires were reviewed to identify 
any further strengths and weaknesses of this study (104-106,111). No further 
information was able to be retrieved using this process. 
 
Strengths of the project design included the clarity of the purpose of the project, 
creation of a definition of breast lymphoedema to be applied in the study and the 
high degree of methodological precision and research rigor throughout all aspects of 
the project. The BLYSS questionnaire considers multiple dimensions of breast 
lymphoedema, including physical, emotional, investigational and weather, whilst 
basing item content on the literature, clinicians and patients’ perspective. Inclusion of 
different aspects of breast lymphoedema has been identified as not only furthering 
knowledge of the physical aspects of lymphoedema, but also cognitive and affective 
components related to this disease (144). 
 
A potential limitation of this project is the definition of breast lymphoedema. As the 
definition was created whilst the project was underway, it was only applied to Part B 
of the project. However retrospective examination of the characteristics of the 
participants in Part A of the studies showed that 57 of the 59 patients (97%) would 
have met this criteria of breast lymphoedema. Timing and differential diagnosis were 
the only two items in the definition where two of the patients did not meet the 
selection criteria. 
 
A limitation of the definition of breast lymphoedema may be the panel of experts. 
The limited number of experts, their relationship to the author and the lack of random 
selection could potentially introduce bias to the project, and limit generalisability. 
Nevertheless the panel of experts that participated in the consensus group to define 
breast lymphoedema work in the field of lymphoedema, are recognised for their 
contributions and achievements in this field, and therefore provide credibility to not 
only the group, but the outcomes proposed by the group. However the ultimate 
success of this definition (172) does require a broader consensus and more 
widespread uptake among those working with breast lymphoedema (157).  
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Important characteristics of useful questionnaires are that they are psychometrically 
robust, whilst also being brief enough to be of practical use in clinical settings (98, 
185). Although reported in the literature that questionnaires are not widely used in 
lymphoedema related research (33), this may be because there are no questionnaires 
specifically developed for breast lymphoedema, let alone psychometrically 
evaluated. Therefore one aim of the project was to establish the reliability and 
validity of the BLYSS questionnaire. The BLYSS questionnaire was also designed 
for ease of administration and respondent and administrative burden is minimal. 
These issues are germane to evaluating comparative treatments (97). The value of an 
accurate health status assessment such as the BLYSS questionnaire is that gives an 
immediate insight into an individual patient’s current status, making it a useful 
outcome tool (97). The capacity of the BLYSS to indicate a patient’s current status 
has been evaluated comparing the results of BLYSS with those of the GHQ-12 and a 
modified Harris scale. The responsiveness of the BLYSS has not yet been tested, as 
that was beyond the scope of this current project. Indeed the demonstration of 
responsiveness, requires the availability of an effective treatment delivering 
clinically discernible improvements. Nevertheless, the demonstrable reliability and 
validity of the BLYSS questionnaire are encouraging and are a prerequisite for 
embarking on future studies of questionnaire responsiveness. 
 
6.4 Future development of the BLYSS questionnaire 
6.4.1 Determining the responsiveness of the BLYSS questionnaire.  
 
This could be investigated by introducing the BLYSS questionnaire as a pre-post- 
manual lymphatic drainage treatment assessment protocol for patients to run parallel 
with other questionnaires such as the Short Form 36 questionnaire (186) and a global 
improvement scale. It is anticipated that patients receiving treatment would respond 
favourably enabling responsiveness to be assessed. 
 
6.4.2 Validity assessment of the breast lymphoedema definition 
The definition created for breast lymphoedema could also provide a basis for future 
development. The definition created could be delivered to a wider audience, either 
nationally and/or or internationally. This could follow the approach used in the thesis 
or a different approach, such as what is suggested in the literature. The validity of the 
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created definition of breast lymphoedema could be assessed by comparing against 
clinicians’ classifications of breast lymphoedema according to their current practices.  
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Chapter 7.0 
Conclusion 
 
Although the incidence and prevalence of breast cancer have increased, survival rates 
have increased. Such interventions as screening and awareness programmes, new and 
further refined treatments have contributed to this increased survival. Whereas 
mastectomy was the traditionally prescribed treatment option, BCT now gives 
equitable survival chances, with women still retaining their breast. A consequence of 
more women surviving breast cancer, is the development of breast lymphoedema. 
This condition is a common, important and distressing phenomenon, with physical, 
psychosocial and functional consequences. 
 
However information regarding breast lymphoedema is difficult to collate, due to a 
lack of standard measuring procedures, reporting criteria, and a definition for breast 
lymphoedema. This is a significant impediment when evaluating the effectiveness of 
treatments for breast lymphoedema.  
 
These limitations also impact on the diagnosis of breast lymphoedema. Breast 
lymphoedema is difficult to diagnose as its presentation can mimic many other 
conditions; two of the major concern being breast cancer recurrence (in a primary, 
secondary or inflammatory context), and infection. At the present time a diagnosis of 
breast lymphoedema, in a patient with features of the condition, is often made by 
excluding any competing alternative diagnoses.  
 
 In recognition of the lack of a definition for breast lymphoedema, a consensus group 
was established to create a definition. Although applicable to this study, this 
definition could be applied in clinical practice. The definition now provides a 
template for further discussion and further works, and supports the need identified in 
the literature. 
 
The emergence of BCT, with reported and anecdotal increased rates of breast 
lymphoedema, encouraged this study. Using a standardised approach and utilising an 
extensive literature review and key informants (both clinical specialists and patients 
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with breast lymphoedema), a prototype BLYSS questionnaire was developed. 
Through a re-iterative process, the validity, reliability and feasibility of the BLYSS 
questionnaire were evaluated.  
 
The end result was a sophisticated, valid, reliable and feasible patient reported 
outcome measure for the evaluation of patients with breast lymphoedema. The 
BLYSS questionnaire needs to be disseminated will need continued use and testing 
for ongoing validation. However the demonstratable reliability and validity of the 
BLYSS questionnaire are not only encouraging, but are necessary requirements 
before embarking on the further development of the BLYSS questionnaire, and 
evaluation of its responsiveness, in an appropriate interventional setting.   
 
The results of this project add to the body of information on breast lymphoedema. 
The BLYSS questionnaire and the definition will be useful for any clinician treating 
breast lymphoedema. Both will also be useful as a condition specific outcome 
measure in research projects, and in clinical practice applications.  
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Appendix 4 
 
 
   
 
ROYAL PERTH HOSPITAL 
    
     
18 February 2008 
 
«Name» «Surname» 
«Address» 
«Suburb» 
 
Dear «Name», 
 
Breast lymphoedema is a complication for women following breast conservation 
treatment for breast cancer. In order to monitor the benefits of treatment for breast 
lymphoedema it is important to be able to measure the severity of the condition and 
changes that occur with treatment. The aim of this study is to develop a questionnaire, 
specifically designed for this. Due to your clinical specialisation in treating patients with 
breast cancer, I am inviting to you participate in this research. 
This study has been approved by the Royal Perth Hospital Human Research Ethics 
Committee and Curtin University Human Research Ethics Committee. 
 
 
Your role in the trial 
If you agree to be involved in this study you will be asked to attend the Physiotherapy 
Department once for an interview. During the interview you will be asked about the 
symptoms associated with breast lymphoedema. You will also be asked to rank the 
symptoms from most important to least important to you. The interview will take 
approximately an hour. Your responses will be collated with responses from other 
professionals who volunteer for the study. These responses will then be put to previously 
treated breast lymphoedema patients to create a questionnaire, specifically for breast 
lymphoedema. Although notes will be taken during the interview, these will be 
completely anonymous. The only record of your involvement will be the signed consent 
form. 
 
Participation in the study is entirely voluntary.  You do not have to join the study and 
choosing not to volunteer will not affect any future physiotherapy service provision. 
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If you would like to be involved in the study please return the enclosed form in the 
replied paid envelope and we will contact you to make an appointment for the interview.  
If you would like to talk to me in regards to any questions or concerns about this project, 
please ring me on 9224 2076, Monday to Friday, 8am-430pm. 
 
If you are not interested, please do not reply to this letter. 
Thank you for taking the time to read this letter and considering helping with this 
research. 
 
Yours sincerely, 
 
 
 
Christine Smith 
Senior Physiotherapist      
Oncology/Lymphoedema      Masters student 
Royal Perth Hospital      Curtin University 
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Appendix 5 
 
 
 
 
CONSENT TO AGREE TO BE CONTACTED AND PARTICIPATE IN THE 
DEVELOPMENT OF A BREAST LYMPHOEDEMA QUESTIONNAIRE 
 
 
 
 
 
 
 
I,……………………………………………… agree/disagree to be contacted and 
participate in the study described above. I have read and understood the attached 
Information Sheet and I have retained a copy of the signed document. I have been given 
the opportunity to ask questions about the study by the investigator. I understand that I 
may withdraw from the study at any time without affecting any future physiotherapy 
service provision. 
 
 
 
Signed……………………………………………………………..   Date…………. 
 
Time, day and number to contact you to make an appointment……………………. 
 
……………………………………………………………………………………… 
 
 
Signature of Investigator………………………………………….    Date…………. 
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Appendix 6 
 
Demographic Information- Professionals 
 
Please answer the following questions. Please tick responses for questions one and two. 
 
 
1. Gender:      Male    Female  
 
 
 
2. Profession:     Breast physician 
 
      Breast surgeon 
 
      Radiation Oncologist 
 
      Physiotherapist 
 
  Occupational Therapist 
 
  Other _______________ 
  
 
 
3. How many years have you been working in your profession?____________________ 
     
 
4. How many patients with breast cancer do you treat per year? ____________________ 
 
 
5. How many patients with breast lymphoedema do you treat per year? ______________ 
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Appendix 7 
 
Professional Interviews 
 
(Interviewer to read to professional) 
 
I am Christine Smith, a senior physiotherapist working in Lymphoedema/Oncology at 
Royal Perth Hospital, Western Australia. I am developing a questionnaire to measure the 
health status of women with breast lymphoedema, as a result of breast cancer treatment. 
 
As the first step in this process, I am asking clinicians from a variety of professions who 
currently treat patients with breast lymphoedema to help me to identify items to include 
in the questionnaire.  Clinicians working in the area should be particularly well placed to 
provide ideas and insights into the condition and its effects on physical, psychological 
and daily functioning of affected women. 
 
The next step will be to conduct interviews with women who have previously been 
treated for breast lymphoedema to gather similar information from their perspective.  
Items you have identified, will be collated with information from the literature to 
develop an item elicitation questionnaire for patient interviews. The item elicitation 
questionnaire provides structure to further explore the dimensionality of symptoms 
associated with breast lymphoedema.  
 
Firstly I am going to ask you to complete this demographic profile. 
(Hand to clinician. Once completed, check that all responses are answered. If any 
questions remain unanswered, check if the professional as to why the question is not 
answered and correct/modify as necessary).  
 
 
• Tell me how much of a problem you think breast lymphoedema is? 
- Clinically 
- For the patients? 
• Are you commonly seeing patients with breast lymphoedema? If yes, why and if no, 
why not?  
• Is this to do with your position in the progression of treatment, or your specific areas 
of interest and expertise?  
• At what stage of breast cancer treatment do you see breast lymphoedema? Have you 
noticed a change in incidence/prevalence? 
• Do you have any ideas why this might be? 
- Change in overall approach to treatment 
 - Better diagnosis of breast lymphoedema 
 
What are the symptoms the patients most commonly complain of? 
 
 
Which appear to be the symptoms they find most distressing? 
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What are the symptoms you see as being the most indicative of breast lymphoedema? 
After symptoms, then ask the signs, physical dysfunction, psychosocial and functionality 
factors.  
(a) ____________________________________________________________________ 
(b) ____________________________________________________________________ 
(c) ____________________________________________________________________ 
(d) ____________________________________________________________________ 
(e) ____________________________________________________________________ 
 
 
For each response e.g. (a)- 
• How would you normally assess this with your patient? 
• Does (a) vary? 
• How severe do you think (a) is? If requires prompt offer not, somewhat, very or 
extremely. You may have to explain what you mean by severe, and your prompt 
responses might not be appropriate for some factors. 
• How severe do you think (a) is to the patient? 
• How frequently does (a) occur? If unable to answer, suggest constant, daily, weekly, 
fortnightly, less than monthly or monthly. 
How many patients with breast lymphoedema have it? 
 Is something that has the propensity to become chronic? 
 
• How important is (a) to you? If requires prompt offer not, somewhat, very or 
extremely. 
• Is it an important diagnostic characteristic? Is it an important prognostic 
characteristic? Does it indicate the need for specific therapy? 
• How important is (a) to the patient? If requires prompt offer not, somewhat, very or 
extremely. Does it vary between patients? Is it related to other factors like age, 
cancer prognosis, body image, pain etc…? 
• What constraints currently make (a) difficult to assess in breast lymphoedema 
patients? 
• You have not mentioned… (something off the closed ended list). Is this something 
you associate with breast lymphoedema? 
 
 
 
Is there anything else you would like to add? 
 
Thank for you participating in the interview. 
Please leave your details with the interviewer, if you would like to know the final 
outcomes of the BYLSS development. 
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Appendix 8 
           
 
 
ROYAL PERTH HOSPITAL 
 
     
  
Dear «Name»,         20 June 2008 
     
RE:  Breast Lymphoedema Research. 
 
Breast lymphoedema can occur in some women following breast conservation treatment 
for breast cancer. In order to monitor the benefits of treatment for breast lymphoedema it 
is important to be able to measure the severity of the condition and changes that occur 
with treatment. The aim of our study is to develop a questionnaire, specifically designed 
for this. As you have been treated at Royal Perth Hospital for breast lymphoedema 
following breast cancer treatment in the past, we are inviting to you participate in our 
research. 
This study has been approved by the Royal Perth Hospital Human Research Ethics 
Committee and the Human Research Ethics Committee, Curtin University, Western 
Australia. 
 
Your role in the trial 
If you agree to be involved in this study you will be asked to attend the Physiotherapy 
Department once for an interview. During the interview you will be asked about the 
symptoms you have experienced associated with your breast lymphoedema. You will 
also be asked to rank the symptoms from most important to least important to you. The 
interview will take approximately an hour. Your responses will be collated with 
responses from other ladies who volunteer for the study to create a questionnaire, 
specifically for breast lymphoedema. Although notes will be taken during the interview, 
these will be completely anonymous.  
If you live in the country and travelling to Perth is not possible, you maybe able to have 
a tele-interview. This would involve attending your local hospital for a telephone and 
television hook up, made from your local hospital, with myself at Royal Perth Hospital. 
There will be some re-embursement for the cost of travel and parking to attend the 
interview at Royal Perth Hospital. Ten dollars ($10) will be provided to you for this.  
As Curtin University is providing this money, I will need you to sign a form that says 
you received this money from me. This form and the signed consent form will be the 
only records of your involvement. 
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Participation in the study is entirely voluntary. You do not have to join the study and 
choosing not to volunteer will not affect any future physiotherapy that you might need. 
 
 
If you would like to be involved in the study please return the enclosed form in the 
replied paid envelope and we will contact you to make an appointment for the interview.  
If you would like to talk to me in regards to any questions or concerns about this project, 
please ring me on 9224 2076, Monday to Friday, 8am-430pm. 
 
If you are not interested, please do not reply to this letter. 
Thank you for taking the time to read this letter and considering helping with this 
research. 
 
 
Yours sincerely, 
Christine Smith 
Senior Physiotherapist      Masters student 
Lymphoedema/Oncology      Curtin University 
Royal Perth Hospital 
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Appendix 9 
 
 
CONSENT TO AGREE TO BE CONTACTED AND PARTICIPATE IN THE 
DEVELOPMENT OF A BREAST LYMPHOEDEMA QUESTIONNAIRE 
(PART A) 
 
 
 
 
 
 
 
I,……………………………………………… agree/disagree to be contacted and 
participate in the study described above. I have read and understood the attached 
Information Sheet and I have retained a copy of the signed document. I have been given 
the opportunity to ask questions about the study by the investigator. I understand that I 
may withdraw from the study at any time without affecting any future physiotherapy 
treatment, or the treatment of the condition which is the subject of the study. 
 
 
 
Signed……………………………………………………………..   Date…………. 
 
Time, day and number to contact you to make an appointment……………………. 
 
……………………………………………………………………………………… 
 
 
Signature of Investigator………………………………………….    Date…………. 
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Appendix 10 
 
          
 
 
     ROYAL PERTH HOSPITAL 
 
 
<Subject’s name> 
<Subject’s address> 
<Suburb, Post code>       12 October 2008 
 
Dear <Subject’s name>, 
 
Earlier this year you were contacted by myself in regards to participating in an interview 
in regards to your breast lymphoedema.  
Due to a poor response, I am writing to you again. There may have been a problem with 
you not receiving the initial letter. So far 28 women have agreed to be involved, but 50 
women are needed to make this research scientifically sound.  
In the past you have been treated for breast lymphoedema due to breast cancer treatment 
at Royal Perth Hospital. 
At that time, the physiotherapist would have explained to you that not much is known 
about the symptoms of breast lymphoedema. 
Now more women are having surgery (only removing part of their breast), followed by 
radiotherapy to treat breast cancer. Due to this and as more women are surviving from 
breast cancer, it is important that there is a greater understanding what breast 
lymphoedema includes. 
 
The Ethics Committee of Royal Perth Hospital has allowed me to access your notes, and 
to contact you again to ask if you would be interested in being involved in a study. This 
study involves interviewing you once to find those symptoms of breast lymphoedema. 
Only your answers to these questions will be recorded, but no other details. If you are 
not interesting in taking part, there will be no further contact from myself. This will not 
affect any future physiotherapy that you might need.  
Once 50 women are interviewed, a questionnaire will be written. This will be given to 
another 10 women to check its structure and how clear it reads. 
If you would like to be involved in the study, please read the consent form. If you are 
interested, please sign and send the consent form back in the replied paid envelope. The 
physiotherapy receptionist will ring you to book an appointment. 
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If you are not interested, please sign and send the consent form back in the replied paid 
envelope. I will not contact you again on this matter.  
Thank you for taking the time to read this letter and considering helping with this 
research. 
If you would like to talk to me in regards to any questions or concerns about this project, 
please ring me on 9224 2076, Monday to Friday, 8am-430pm. 
Thanks again, 
 
Yours sincerely, 
 
 
 
 
Christine Smith 
Senior Physiotherapist      Masters student 
Lymphoedema/Oncology      Curtin University 
Royal Perth Hospital 
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CONSENT TO AGREE TO BE CONTACTED AND PARTICIPATE IN THE 
DEVELOPMENT OF A BREAST LYMPHOEDEMA QUESTIONNAIRE 
(PART A) 
 
 
 
I,……………………………………………… agree/disagree to be contacted and 
participate in the study described above. I have read and understood the attached 
Information Sheet and I have retained a copy of the signed document. I have been given 
the opportunity to ask questions about the study by the investigator. I understand that I 
may withdraw from the study at any time without affecting any future physiotherapy 
treatment, or the treatment of the condition which is the subject of the study. 
 
 
 
Signed……………………………………………………………..   Date…………. 
 
Time, day and number to contact you to make an appointment……………………. 
 
……………………………………………………………………………………… 
 
 
Signature of Investigator………………………………………….    Date…………. 
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Clinical and demographic characteristics of interview patients 
 
ID Number:                                           Date of Data Collection     /    / 2008 
Date of definitive diagnosis  
     /     /   
  
Date of surgery  
     /     /  
  
Age when having surgery  
20-29          
30-39          
40-49          
50-59  
60-69          
70-79          
80-89          
  
Menopausal state  
1.Premenopausal   
2.Perimenopausal   
3.Postmenopausal   
  
Surgery  
1.Wide local excision   
2.Other    specify   
  
Staging  
Stage  
T  
N  
M  
  
Position of incision  
1.Upper inner quadrant   
2.Upper outer quadrant   
3.Lower inner quadrant   
4.Lower outer quadrant   
5.Central   
6.Axillary tail   
  
Side of tumour  
1.Left   
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2.Right   
  
Pathological tumour size (cm)  
 0-0.9          
1.0-1.9   
2.0-2.9   
>3.0   
Unknown   
  
Tumour grade  
1.1          
2.11        
3.111      
4.Unknown   
  
Histological type  
1.Ductal   
2.Lobular   
3.Mixed ductal and lobular   
4.Special types   
5.Not reported   
  
Receptor status  
1.Oestrogen   
2.Progesterone   
3.Unknown   
  
Node status  
1.Positive   
2.Negative   
3.Unknown   
  
Axillary surgery  
1.None  
2.Axillary clearance- Grade 1   
Grade 11   
Grade 111   
Sentinel node biopsy   
Unknown    
  
Adjuvant treatment  
1.None  
2.Neoadjuvant chemotherapy  
3.Chemotherapy     
4.Radiation therapy   
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5.Endocrine therapy  
  
Post operative complications  
1.Seroma   
2.Haematoma   
3.Infection   
4.Cording   
  
Past medical history  
  
  
  
Medications  
  
  
  
Current Age  
Years  
  
Dominant side  
1.Left   
2.Right   
3.Unknown   
  
Country of birth  
1.Australia   
2.Canada  
3.China   
4.Greece   
5.Hong Kong   
6.India   
7.Italy    
8.Malta   
9.Malaysia   
10.Middle East (Turkey, Lebanon)   
11.New Zealand   
12.Other Asia   
13.Other European   
14.Philippines   
15.Poland   
16.UK   
17.US  
18.Vietnam   
19.Other specify  
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Indigenous status  
Aboriginal  
Torres Strait Islander  
  
Marital status  
1.Single   
2.Married   
3.De facto   
4.Divorced   
5.Widow   
  
Child bearing  
1.Nulliparous  
Number of births       specify  
Breast fed  
Unknown  
  
Level of education  
1.No school certificate or other qualifications   
2.School or intermediate certificate  
3.High school or leaving certificate  
4.Trade/apprenticeship  
5.Certificate/diploma   
6.Undergraduate degree  
7.University degree   
8.Post graduate qualifications   
  
Employment activity  
1.Student  
2.Unemployed  
3.Home duties  
4.Not able to work  
5.Pension  
6.Voluntary work  
7.Part time work  
8.Full time work  
Occupation-  
  
Time of breast lymphoedema diagnosis (post surgery)  
Years         
Months  
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Appendix 12 
 
 
Item Elicitation Questionnaire 
 
(Interviewer to read to patient) 
 
I am Christine Smith, a senior physiotherapist working in Lymphoedema/Oncology at 
Royal Perth Hospital, Western Australia. I am developing a questionnaire to measure the 
health status of women with breast lymphoedema, as a result of breast cancer treatment.  
 
This step involves conducting interviews with women who have previously been treated 
for breast lymphoedema, to gather items to include in the questionnaire. Those items that 
you have identified as being relevant with breast lymphoedema will be collated with 
information from clinicians and the literature. This will be used to develop the final 
questionnaire. 
 
 
 
 
 
 
Interviewer- Refer to appendix one for the abbreviations used in table one. 
 
If more room is required for the open ended responses, refer to appendix two and three 
for an additional response tables. 
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Symptoms 
 
 Interviewer to read to patient- 
 
The following questions are interested in how you perceive your breast lymphoedema. 
 
What terms would you most commonly use to describe your symptoms of breast 
lymphoedema?  
 
Table One 
Symptom Occur. Frequency Importance 
 Y N C D W F ≤M N S M V E 
1. Swelling             
2. Discomfort               
3. Heaviness               
4. Pain               
5. Hypersensitive               
6. Tightness               
7. Tenderness               
8. Uncomfortable               
9. Ache             
10.                
11.             
12.             
13.             
14.             
15.             
16.             
17.             
 
 
For each symptom, to further explore the dimensionality of that symptom, ask- 
 
1. Is _____ (name the symptom) there constantly or on and off?   
If on and off, how often (using the above scale) is _____ (name the symptom)     
there?    
  
2. How important is (name the symptom) this to you? 
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For the responses volunteered by the patient, probe further with the following questions- 
 
1. Why is _____ (name the symptom) important to you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
 
2. How does _____ (name the symptom) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
 
3. When does _____ (name the symptom) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
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Additional closed ended questions to patient- 
 
Do you consider the following terms to mean the same or do they have different 
meanings?  
For either response ask the patient to explain the similarities or differences of the terms.  
 
      Table Two 
Terms Same Different Rationale 
Swelling and 
tightness 
 
 
 
  
Swelling and 
hardness 
 
 
 
  
Tightness and 
hardness 
 
 
 
  
Discomfort and  
pain 
 
 
 
  
Discomfort and 
tenderness 
 
 
 
  
Pain and  
tenderness 
 
 
 
  
Heaviness and 
tightness 
 
 
 
  
Discomfort and 
uncomfortable 
 
 
 
  
Discomfort and 
ache 
 
 
 
  
Pain and ache  
 
  
Uncomfortable 
and ache 
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Signs 
 
Interviewer to read to patient- 
 
What terms would you most commonly use to describe your signs of breast 
lymphoedema?  
 
     
Table Three 
Sign Occur. Frequency Importance 
 Y N C D W F ≤M N S M V E 
1. Redness             
2. Hardness               
3. Orange peel 
type skin on the 
L/O breast 
              
4. Increased 
warmth 
              
5. Thickened skin               
6. Pinkness               
7. Heat               
8.                
9.              
10.                
11.             
12.             
 
 
 
For each sign, to further explore the dimensionality of that sign, ask- 
 
1. Is _____ (name the sign) there constantly or on and off?   
If on and off, how often (using the above scale) is _____ (name the sign) there?     
 
2. How important is this to you? 
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For the responses volunteered by the patient, probe further with the following questions- 
 
1. Why is _____ (name the sign) important to you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
2. How does _____ (name the sign) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
3. When does _____ (name the sign) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
Additional closed ended questions to patient- 
 
Do you consider the following terms to mean the same or do they have different 
meanings?  
For either response ask the patient to explain the similarities or differences of the terms.  
 
      Table Four 
Terms Same Different Rationale 
Redness and 
pinkness 
 
 
 
  
Heat and 
increased  
warmth 
 
 
 
  
Hardness and 
thickened skin 
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Physical limitations 
 
Interviewer to read to patient- 
These next questions are interested in how your breast lymphoedema has affected the 
way you manage activities. 
 
What physical limitations do you have as a result of your breast lymphoedema?  
 
Table Five 
Physical 
Limitation 
Occur. Frequency Importance 
 Y N C D W F ≤M N S M V E 
1. Indentations of 
the bra on the 
L/O breast 
            
2. Decrease in 
shoulder 
movement 
              
3. Reaching 
above your 
shoulder 
              
4. Putting on/ 
taking off a bra 
              
5. Doing 
housework  
              
6.                
7.                
8.                
9.              
10.                
11.             
12.             
 
 
For each physical limitation, to further explore the dimensionality of that physical 
limitation, ask- 
 
1. Is _____ (name the physical limitation) there constantly or on and off?   
If on and off, how often (using the above scale) is _____ (name the physical limitation) 
there?     
 
2. How important is this to you? 
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For the responses volunteered by the patient, probe further with the following questions- 
 
1. Why is _____ (name the physical limitation) important to you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
2. How does _____ (name the physical limitation) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
3. When does _____ (name the physical limitation) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
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Emotional 
 
Interviewer to read to patient- 
The next questions are interested in how your breast lymphoedema affects your 
emotional well being. This includes such things as being happy with your life. 
 
What terms would you most commonly use to describe how your breast lymphoedema 
makes you feel? 
 
Table Six 
Emotional Occur. Frequency Importance 
 Y N C D W F ≤M N S M V E 
1. Fear of breast 
cancer recurrence 
            
2. Appearance of 
the breast 
              
3. Reminder of 
breast cancer 
              
4. Distress               
5. Anxious               
6. Fear               
7. Depressed               
8. Frustrated               
9. Embarrassed             
10. Self –
conscious 
              
11. Affects 
choice of clothing 
            
12. Tired             
13. Affect 
relationship with  
family 
            
14. Affect 
relationship with  
friends 
            
15.             
16.             
 
For each emotion, to further explore the dimensionality of that emotion, ask- 
1. Is _____ (name the emotion) there constantly or on and off?   
If on and off, how often (using the above scale) is _____ (name the emotion) there?     
2. How important is this to you? 
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For the responses volunteered by the patient, probe further with the following 
questions- 
 
1. Why is _____ (name the emotion) important to you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
2. How does _____ (name the emotion) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
3. When does _____ (name the emotion) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
Additional closed ended questions to patient- 
 
Do you consider the following terms to mean the same or do they have different 
meanings?  
For either response ask the patient to explain the similarities or differences of the terms.  
 
      Table Seven 
Terms Same Different Rationale 
Distress and 
fear of 
recurrence 
 
 
 
  
Feels self 
conscious about 
appearance and 
feels less 
feminine 
 
 
 
  
Feels self 
conscious about 
appearance and 
embarrassed 
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Social 
 
Interviewer to read to patient- 
The next questions are interested in how your breast lymphoedema affects your ability to 
interact at work, with family and/or friends. 
 
What terms would you most commonly use to describe how your breast lymphoedema 
affects how you function?  
 
 
Table Eight 
Social Occur. Frequency Importance 
 Y N C D W F ≤M N S M V E 
1. Difficulty 
wearing a bra 
            
2. Difficulty 
sleeping 
              
3. Discomfort 
wearing a bra 
              
4. Affects ability 
to do ADL’s 
              
5. Affects 
occupational 
activities 
              
6. Affects 
sporting activities 
              
7. Affects 
intimate 
relationships 
              
8.                
9.              
10.                
11.             
12.             
 
For each social response, to further explore the dimensionality of that social response, 
ask- 
 
1. Is _____ (name the social response) there constantly or on and off?   
If on and off, how often (using the above scale) is _____ (name the social response) 
there?     
2. How important is this to you? 
For the responses volunteered by the patient, probe further with the following questions- 
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1. Why is _____ (name the social response) important to you?  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
2. How does _____ (name the social response) affect you?  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
3. When does _____ (name the social response) affect you?  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
Additional closed ended questions to patient- 
 
Do you consider the following terms to mean the same or do they have different 
meanings?  
For either response ask the patient to explain the similarities or differences of the terms.  
 
      Table Nine 
Terms Same Different Rationale 
Discomfort 
wearing a bra 
and difficulty 
wearing a bra 
 
 
 
  
  
 
 
  
  
 
 
  
  
 
 
  
 
 
Is there anything else you would like to add? 
Thank you for participating in the development of the BLYSS questionnaire. 
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Abbreviations Used in the Tables 
 
Frequency- 
 
C-  constantly 
D-  daily 
W-  weekly 
F-  fortnightly 
≤M-  less than and/or monthly 
 
 
Importance- 
 
N-  not 
S-  slightly 
M-  moderately 
V-  very 
E-  extremely 
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Additional Table 
 
 
 
Group Occur. Frequency Importance 
 Y N C D W F ≤M N S M V E 
1.              
2.                
3.                
4.                
5.               
6.                
7.                
8.                
9.              
10.                
11.             
12.             
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Additional Table Two 
 
Terms Same Different Rationale 
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Probing open ended questions 
 
For the responses volunteered by the patient, probe further with the following questions- 
 
 
1. Why is _____ (name the group) important to you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
2. How does _____ (name the group) relate to your breast lymphoedema?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
3. When does _____ (name the group) affect you?  
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
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Appendix 13 
 
Symptomology 
 
 
 
Symptom Rest Activity Night 
 Yes No Yes No Yes No 
1. Swelling       
2. Discomfort           
3. Heaviness           
4. Pain           
5. Hypersensitive           
6. Tightness           
7. Tenderness           
8. Uncomfortable           
9. Ache       
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Appendix 14 
Breast Lymphoedema Symptoms Severity (BLYSS) Questionnaire                 
 
Name: _____________________________________________ Institution: ___________________________________ Date: ________________________ 
 
This questionnaire is designed for women who have breast swelling/lymphoedema as a result of breast cancer treatment. Please grade the severity of the 
following items in the affected breast. To start, please circle which breast is the swollen/lymphoedematous breast. 
  
 LEFT                    RIGHT 
 
Considering the last seven days, circle the response that best describes what you have felt in your affected breast. 
 Choose the answer that best applies to you. Circle only one box for each question.   
 
1 
 
How severe is any swelling in your breast? For 
example one breast may look larger than the other 
and/or feel larger. 
 
 
None 
 
 
 
Mild 
 
 
Moderate 
 
Severe 
 
Extreme 
 
2 
 
How severe is any discomfort in your breast? 
Words like ache or mild pain may describe this 
experience. 
 
None 
 
 
Mild 
 
Moderate Severe Extreme 
 
3 
 
How severe is any heaviness in your breast? Words 
like a weight and/or dragging down might describe 
this experience. 
None 
 
Mild 
 
Moderate Severe Extreme 
 
4 
 
How severe is any uncomfortable feeling in your 
breast? This could be considered an unpleasant 
awareness that maybe associated with clothing and/ 
or positioning. 
None 
 
Mild 
 
Moderate Severe Extreme 
 
5 
 
How severe is any hardness in your breast? Words 
like solid, firm to touch and/or a feeling of firmness 
might describe this. 
None 
 
Mild 
 
Moderate Severe Extreme 
 
6 
 
How severe is any discomfort in your breast when 
wearing a bra? 
None 
 
Mild 
 
Moderate Severe Extreme 
 
7 
 
How severe are any indentations on your breast 
from the bra?  
 
Not at all 
 
 
Mild 
 
 
Moderate 
 
Severe 
 
Extreme 
Now please turn over to complete the questionnaire 
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Breast Lymphoedema Symptoms Severity Questionnaire (BLYSS) 
 
 
 
 
Considering the last seven days, circle the response that best describes what you have felt in your affected breast.  
There are no right or wrong answers. Circle only one box for the question.   
 
1 
 
How often do your symptoms of breast 
lymphoedema cause you to remember the breast 
cancer?  
 
 
 
Never 
 
 
 
Occasionally 
 
 
 
Some days 
 
 
Every day 
 
 
Constantly 
 
 
 
 
Considering the last year, answer each question by placing a circle around the response that best describes what you have felt in your affected breast during the following events. 
There are no right or wrong answers. Circle only one box for each question.   
 
1 
 
Please grade the severity to which mammograms 
have been more uncomfortable than previously. 
 
 
Not applicable 
 
Not at all 
 
Mild 
 
 
Moderate 
 
Severe 
 
Extreme 
 
2 
 
Please grade the severity to which breast 
ultrasounds have been more uncomfortable than 
previously. 
 
 
 
Not applicable 
 
 
Not at all 
 
 
Mild 
 
 
 
Moderate 
 
 
Severe 
 
 
Extreme 
 
3 
 
Please grade the severity to which the breast 
lymphoedema is more of a problem in summer/hot 
weather. 
 
 
 
Not applicable 
 
 
 
Not at all 
 
 
Mild  
 
 
Moderate 
 
 
Severe 
 
 
Extreme 
 
 
 
Thank you for completing this questionnaire 
 
 
             174 
Appendix 15 
 
How to score the BLYSS 
 
There are four scores of the BLYSS questionnaire (BLYSS I-IV). Due to the differences 
of each domain, a single score is not suitable. Each domain is explained below. 
 
BLYSS I- “Appearance and Experience” is the score for the first domain, which are 
those signs and symptoms to be associated with breast lymphoedema. The scores range 
from 0-4, resulting in a range of responses from 0-28. 
 
BLYSS II- “Memory” is the score pertaining to the second domain. This domain asks if 
the symptoms of breast lymphoedema are a reminder of the breast cancer experience.  
The scores range from zero to four, resulting in a range of responses from 0-4. 
 
BLYSS III- “Assessments” is the score for the first two items in the third domain. These 
two items question whether investigations are now more uncomfortable as a result of 
breast lymphoedema.  The scores range from zero to five, resulting in a range of 
responses from 0-10. 
 
BLYSS IV-“Weather” is the score for the third item in the third domain. This item asks 
if summer exacerbates the patient’s breast lymphoedema. The scores range from zero to 
five, resulting in a range of responses from 0-5. 
 
 
 
Scoring table for the BLYSS questionnaire 
Date BLYSS 1 BLYSS 11 BLYSS 111 BLYSS 1V 
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ROYAL PERTH HOSPITAL 
 
 
The development of the Breast Lymphoedema Severity Symptom Questionnaire 
(BLYSS). 
 
Investigator: Christine Smith, Department of Physiotherapy 
 
Trial summary 
 
Breast lymphoedema can develop after the treatment for breast cancer. To date, there are 
no reliable or valid ways of assessing the symptoms of breast lymphoedema. The aim of 
this study is to develop a questionnaire, specifically designed for this purpose.  
 
This study has received ethical approval from the Royal Perth Hospital Ethics 
Committee and the Curtin University Human Research Ethics Committee. 
 
Your role in the trial 
 
If you agree to be involved in this study you will be contacted and ask to attend the 
physiotherapy department for an interview on one occasion with the research 
investigator.  
During this interview you will be asked to comment on the relevance of the items and 
whether the questionnaire is comprehensive.  
 
Once the interviews are finished, your responses will be collated with responses from 
other clinicians and patients to refine the questionnaire, specifically for breast 
lymphoedema. 
  
How your personal information will be handled 
 
Special arrangements are in place to ensure that your data is handled in strict confidence 
and in compliance with all privacy laws (in Australia this is the Privacy Act 1988). Your 
name will not appear on study documents and only duly authorised persons will have 
access to your data. Your name will also not appear on any publications arising from the 
study. 
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Cost of participation in the trial 
 
Participation in the study will be at no cost to you. 
If you chose not to participate in the study, this will have no consequences on future 
physiotherapy service provision. 
 
Further information 
 
There are several sources of additional information: 
 
1. Feel free to ask the interviewer questions about the study. 
2. For questions relating to ethical approval, contact the Chairman of the Ethics 
Committee, A/Professor FM van Brockxmeer, on 9224 2244. 
 
During the study you can telephone Christine Smith (Senior Physiotherapist) during 
weekdays, 8am-430pm, on 9224 2076 if other questions occur to you. 
 
If after reading this sheet you are interested in enrolling in the study you should now 
sign the CONSENT FORM. Please put this in the replied envelope provided and post.  
 
Thank you for considering participating in this study. 
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CONSENT TO BE CONTACTED AND PARTICIAPTE IN THE 
DEVELOPMENT OF A BREAST LYMPHOEDEMA QUESTIONNAIRE 
 
 
 
 
 
 
 
 
I,……………………………………………… agree/disagree to be contacted and 
participate in the above study. I have read and understood the attached Information 
Sheet and I have retained a copy of the signed document. I have been given the 
opportunity to ask questions about the study by the investigator. I understand that I may 
withdraw from the study at any time without affecting any future physiotherapy service 
provision. 
 
 
Signed……………………………………………………………..   Date…………. 
 
Time, day and number to contact you to make an appointment……………………. 
 
……………………………………………………………………………………… 
 
Signature of Investigator………………………………………….    Date…………. 
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ROYAL PERTH HOSPITAL 
 
 
The development of the Breast Lymphoedema Severity Symptom Questionnaire 
(BLYSS). 
 
Investigator: Christine Smith, Department of Physiotherapy 
 
Trial summary 
 
Breast lymphoedema can develop after your treatment for breast cancer. To date, there 
are no reliable or repeatable ways of detecting and monitoring the symptoms of breast 
lymphoedema. The aim of this study is to develop a questionnaire, specifically designed 
for this purpose.  
 
This study has received ethical approval from the Royal Perth Hospital Ethics 
Committee and the Curtin University Human Research Ethics Committee. 
 
Your role in the trial 
 
If you agree to be involved in this study you will be contacted, at a day and time suitable 
for you. You will be asked to attend the physiotherapy department for an interview on 
one occasion with the research investigator.  
During this interview you will be asked to complete the new questionnaire and then to 
provide feedback about the clarity of the questionnaire and the relevance of the 
questions. You will be asked to comment on what you believe the question to be asking, 
what they meant by your answer and the wording of the question. If necessary, the 
questionnaire will be revised according to feedback received. 
 
Once the interviews are finished, your responses will be collated with responses from 
other ladies to refine the questionnaire. If necessary, the questionnaire will be revised 
according to feedback received. 
 
How your personal information will be handled 
 
Special arrangements are in place to ensure that your data is handled in strict confidence 
and in compliance with all privacy laws (in Australia this is the Privacy Act 1988). Your 
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name will not appear on study documents and only duly authorised persons will have 
access to your data. Your name will also not appear on any publications arising from the 
study. 
 
Cost of participation in the trial 
 
 
Participation in the study will be at no cost to you. 
If you chose not to participate in the study, this will have no consequences on future 
physiotherapy treatments. 
 
 
Further information 
 
There are several sources of additional information: 
 
1. Feel free to ask your physiotherapist questions about the study. 
2. For questions relating to ethical approval, contact the Chairman of the Ethics 
Committee, A/Professor FM van Brockxmeer, on 9224 2244. 
 
During the study you can telephone Christine Smith (Senior Physiotherapist) during 
weekdays, 8am- 430pm, on 9224 2076 if other questions occur to you. 
 
If after reading this sheet you are interested in enrolling in the study you should now 
sign the CONSENT FORM. Please put this in the replied envelope provided and post. 
 
Thank you for considering participating in this study. 
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CONSENT TO AGREE TO BE CONTACTED AND PARTICIPATE IN THE 
DEVELOPMENT OF A BREAST LYMPHOEDEMA QUESTIONNAIRE 
 
 
 
 
I,……………………………………………… agree/disagree to be contacted and 
participate for the above study. I have read and understood the attached Information 
Sheet and I have retained a copy of the signed document. I have been given the 
opportunity to ask questions about the study by the investigator. I understand that I may 
withdraw from the study at any time without affecting any future physiotherapy 
treatment, or the treatment of the condition which is the subject of the study. 
 
 
 
Signed……………………………………………………………..   Date…………. 
 
Time, day and number to contact you to make an appointment……………………. 
 
……………………………………………………………………………………… 
 
 
Signature of Investigator………………………………………….    Date…………. 
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Pilot testing Interview of the BLYSS Questionnaire 
 
The items within the BLYSS questionnaire are based on a literature review, interviews 
with clinicians (working in the assessment and treatment of patients with breast oedema/ 
lymphoedema) and interviews with patients with breast oedema/lymphoedema.  
 
Those items elicited from the literature and clinicians formed the template interviews 
with patients. 
The responses from patients formed the items contained in the BLYSS. 
 
The BLYSS is designed only for women who have developed breast oedema/ 
lymphoedema as a result treatment for breast cancer.  
At this stage, the BLYSS questionnaire is only designed for use in women with 
unilateral breast oedema/lymphoedema.  
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Content 
 
Generally, do you think the content is relevant to the topic? 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
Does the second sentence make sense i.e. which is the lymphoedematous breast?  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
 
Do I need to make this clearer e.g. please circle which breast is affected? 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
Items 
As a clinician, are these items representative as those items associated with breast 
lymphoedema? Yes/No. Please elaborate. 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
What else could be included? Please elaborate. 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
Should any of these items be excluded? Please elaborate. 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
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Does the explanation attached to each item make sense to you? Yes/ No 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
How would you describe – 
(1) Swelling-
_________________________________________________________________ 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
(2) Discomfort-
_________________________________________________________________ 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
(3) Heaviness-
_________________________________________________________________ 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
(4) Uncomfortable_____________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
(5) Hard-
_________________________________________________________________ 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
(6) Discomfort in the breast when wearing a bra-_____________________________ 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
Are the descriptors (not at all – extremely) sufficient to describe the items? 
Yes/No______________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
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Structure 
 
 
What do you like about the layout of the questionnaire? 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
 
 
What could be improved in regards to the layout of the questionnaire? 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
 
 
In regards to the size of the text, is it easy to read? Yes/No. 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
  
 
Are two pages sufficient for the questionnaire? Yes/No. 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
 
Additional comments 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
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Modified Harris Score 
 
1. None-  excellent aesthetic result. At first sight no visible therapy related 
  sequelae. Both breasts have similar appearance 
 
2. Mild-   treated breast nearly identical to untreated breast.  
 
3. Moderate-  treated breast slightly different than untreated. 
 
4. Severe-  treated breast clearly different from untreated but not seriously 
  distorted 
    
5. Extreme-  treated breast seriously distorted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             186 
Appendix 22 
 
Harris Score 
 
 
1. Excellent- treated breast nearly identical to untreated breast.  
 
2. Good-   treated breast slightly different than untreated. 
 
3. Fair-    treated breast clearly different from untreated but not seriously 
  distorted 
 
4. Poor-   treated breast seriously distorted 
 
 
         (Harris et al 1979) 
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Appendix 24 
 
           
   SIR CHARLES GAIRDNER HOSPITAL 
 
 
 
ROYAL PERTH HOSPITAL 
 
 
The development of the Breast Lymphoedema Severity Symptom Questionnaire 
(BLYSS). 
 
Investigator: Christine Smith, Department of Physiotherapy 
 
Trial summary 
 
Breast lymphoedema can develop after your treatment for breast cancer. To date, there 
are no reliable or repeatable ways of detecting and monitoring the symptoms of breast 
lymphoedema. The aim of this study is to develop a questionnaire, specifically designed 
for this purpose.  
 
This study has received ethical approval from the Royal Perth Hospital Ethics 
Committee and the Curtin University Human Research Ethics Committee, Curtin Health 
Innovation Research Institute. 
 
Your role in the trial 
 
If you agree to be involved in this study you will be contacted, at a day and time suitable 
for you. You will be asked to attend the Breast Clinic at Royal Perth Hospital for an 
interview on one occasion with the research investigator, Breast Clinic Nurse and Breast 
Clinic Physiotherapist of the Royal Perth Hospital Breast Clinic.  
During this interview your breasts will be viewed by the nurse and then the 
physiotherapist to grade the severity of breast lymphoedema. You will also be asked to 
complete the new questionnaire (the BLYSS) and a general health questionnaire (the 
GHQ-12).  
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Twenty four hours later you will fill in the BLYSS questionnaire again, at home. The 
researcher can ring you to remind you to do this.  You will then mail the completed 
questionnaire in the supplied reply paid envelope to the researcher.  
 
 
 
How your personal information will be handled 
 
Special arrangements are in place to ensure that your data is handled in strict confidence 
and in compliance with all privacy laws (in Australia this is the Privacy Act 1988). Your 
name will not appear on study documents and only duly authorised persons will have 
access to your data. Your name will also not appear on any publications arising from the 
study. 
 
Cost of participation in the trial 
 
Participation in the study will be at no cost to you. 
If you chose not to participate in the study, this will have no consequences on future 
treatments. 
 
 
Further information 
There are several sources of additional information: 
 
1. Feel free to ask your physiotherapist questions about the study. 
2. For questions relating to ethical approval, contact the Chairman of the Ethics 
Committee, A/Professor FM van Brockxmeer, on 9224 2244 at Royal Perth Hospital or 
Sir Charles Gairdner Hospital Human Research Ethics Committee, on 9346 2999. 
 
During the study you can telephone Christine Smith (Senior Physiotherapist) during 
weekdays, 8am-430pm, on 9224 2076 if other questions occur to you. 
If after reading this sheet you are interested in enrolling in the study you should now 
sign the CONSENT FORM. Please put this in the replied envelope provided and post. 
 
Thank you for considering participating in this study. 
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CONSENT TO AGREE TO BE CONTACTED AND PARTICIPATE IN THE 
DEVELOPMENT OF A BREAST LYMPHOEDEMA QUESTIONNAIRE 
 
 
 
 
 
I,……………………………………………… agree/disagree to be contacted and 
participate in the study described above. I have read and understood the attached 
Information Sheet and I have retained a copy of the signed document. I have been given 
the opportunity to ask questions about the study by the investigator. I understand that I 
may withdraw from the study at any time without affecting any future physiotherapy 
treatment, or the treatment of the condition which is the subject of the study. 
 
 
 
Signed……………………………………………………………..   Date…………. 
 
Time, day and number to contact you to make an appointment……………………. 
 
……………………………………………………………………………………… 
 
 
Signature of Investigator………………………………………….    Date…………. 
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    Breast Lymphoedema Definition 
Location 
The adult female breast lies between the second and sixth ribs in the vertical axis and 
between the sternal edge and the midaxillary line in the horizontal axis (187)(p929-930).  
The average breast measures 10 to 12cm in diameter, and its average thickness centrally 
is 5 to 7cm. Breast tissue also projects into the axilla as the axillary tail of Spence. The 
contour of the breast varies but is usually dome-like, with a conical configuration in the 
nulliparous woman and a pendulous contour in the parous woman. 
The shape of the breast may be altered due to aging, surgical removal of the tumour and 
surrounding tissue, radiotherapy, and oedema and/or breast lymphoedema. 
Main part of the breast is superficial to the deep fascia covering Pectoralis Major, 
several digitations of Serratus Anterior and External Oblique and upon the upper part of 
the latters’ aponeurosis forming the rectus sheath (187)(p929-930). 
 
The breast can be divided into quadrants to consistently identify location of breast 
lymphoedema. This is illustrated in Table One and Diagram One. 
 
Table One: Breast quadrants 
1.  Lateral superior  
2.  Lateral inferior  
3.  Medial inferior  
4.  Medial superior  
 
Nature 
Secondary lymphoedema post breast cancer breast is “characterised by an abnormal 
accumulation of lymph fluid in the interstitial spaces, leading to persistent swelling in 
the breast” (for breast definition see location section above)(35)(48).   
 
Table two, based on the ISL grading for peripheral lymphoedema, grades the stage of 
breast lymphoedema.  
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Diagram One: Breast quadrants 
 
 
 
 
 
 
Medial Superior     
   Lateral Superior 
  
Medial Inferior  Lateral Inferior 
 
 
 
 
Timing 
Breast lymphoedema consists of swelling in the breast that persists equal or greater to 
three months post surgery and/or radiotherapy.  
  
Differential diagnosis 
Diagnoses other than breast lymphoedema must be taken into account and excluded 
before a diagnosis of breast lymphoedema should/can be considered. 
 
Other conditions include- 
• Primary or secondary breast cancer 
• Inflammatory breast carcinoma 
• Breast lymphoma 
• Thymic carcinoma 
• Angiosarcoma 
• Congestive Cardiac Failure (CCF) 
• Infection including cellulitis 
• Mastitis 
• Subclavian or innominate vein occlusion (such as from arteriovenous 
haemodialysis complications) 
• Trauma 
• Post irradiation  
• Fat necrosis 
• Granulomatous diseases 
• Pemphigus and other skin conditions 
• Aseptic inflammatory process 
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Table Two: ISL Grading 
 
ISL Grading 
I.    Latent or at risk 
II.   Intermittent with pitting 
III. Persistent with pitting/or fibrotic 
IV. Fibrotic and skin changes 
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   Definitions for Differential Diagnoses 
 
Primary breast cancer- “a malignant neoplastic disease of the mammary gland” 
(188)(p.242-43). 
 
Secondary breast cancer- “most patients with a locoregional recurrence of breast 
cancer following breast conservation therapy (BCT) present with symptoms. Ipsilateral 
breast tumour recurrence following BCT is experienced by five years in approximately 
seven percent of patients with whole breast irradiation and 26% of patients without 
whole breast irradiation. Most recurrences occur in the prior tumour bed, and positive 
pathologic margins, younger age, higher grade tumour, negative oestrogen receptor 
status and involvement of axillary nodes have all been reported to increase the risk of 
ipsilateral tumour recurrence.  Detection of ipsilateral breast tumour recurrence is often 
difficult because of post surgical and postradiotherapy changes to the breast” (189)(p 
824). 
 
Inflammatory breast carcinoma- “is a type of locally advanced breast cancer which 
arises rapidly, typically over weeks, less than six months, not years. Clinical features 
include discolouration ranging from red to purple, and affecting at least one third of the 
breast, thickening or fine dimpling (peau d’orange), oedema or warmth and a palpable 
ridge present at the margin of induration” (190)(p762). 
 
Breast lymphoma- “has been defined used the following criteria: (a) no prior 
diagnosis of extramammary lymphoma and the breast is the primary site of disease; (b) 
mammary tissue and lymphomatous infiltrate are in close association with no evidence 
of concurrent widespread disease; and (c) pathology is confirmed by technically 
adequate specimens” (191)(p803-804).  
“Radiographic imaging features of breast lymphoma are non-specific, with the exception 
that calcifications are rare. Diagnosis is typically made by core biopsy of a palpable 
breast mass. High-grade lymphoma needs to be separated from melanoma and poorly 
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differentiated carcinoma because curative treatment differs radically among these 
tumour types” (191)(p803-804). 
 
Thymic carcinoma- “a rare, aggressive neoplasm that has a poor prognosis. It is an 
epithelial tumour but cytologically it demonstrates malignant features. This cancer is 
most often located in the anterior mediastinum, although other sites have been reported” 
(192)(p872).  
 
Angiosarcoma- “an aggressive, usually deadly neoplasm of vascular cells. Four 
variants of cutaneous angiosarcoma have been identified, including angiosarcoma 
associated with lymphoedema (Stewart-Treves syndrome), and radiation induced 
angiosarcoma” (193)(p1624-1625). 
“Lymphoedema angiosarcoma presents as a violet coloured plaque or nodule 
superimposed on brawny, nonpitting oedema. Ulceration may develop soon after. The 
pathogenesis of lymphoedema angiosarcoma is not completely understood but could be 
related to imbalances in local immune regulation or angiogenesis, leading to 
proliferation of neoplastic cells” (193)(p1624-1625).. 
“Radiation-induced angiosarcoma has been reported to occur after radiation therapy. 
Lesions appear at sites treated with radiation as a violaceous to red ill-defined plaque, 
often appearing like a bruise. As the cancer progresses, lesions increase in size, become 
indurated, and may eventually ulcerate. Satellite lesions are common” (193)(p1624-
1625).  
 
Congestive Cardiac Failure (CCF) – “heart failure is a complex clinical syndrome 
that can result from any structural or functional cardiac disorder that impairs that ability 
of the heart to function as a pump to support physiological circulation. CCF is similar to 
the above but with features of dyspnoea, increased fatigue and circulatory congestion 
(fluid retention) such as jugular venous distension, rales, peripheral oedema and ascites” 
(194)(p691-692).  
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Infection including cellulitis and mastitis- “this can affect the skin overlying the 
breast (cellulitis, with or without abscess formation), and occurs either as a primary 
event or secondary to a lesion in the skin, such as a sebaceous cyst, or a more 
generalised condition, such as hidradenitis suppurativa. The most appropriate antibiotics 
associated with the organisms responsible for the infection should be prescribed. If the 
infection or inflammation fails to resolve after one course of antibiotics, then abscess 
formation or an underlying cancer should be suspected” (195)(p47-50). 
 
Subclavian or innominate vein occlusion (such as from arteriovenous 
haemodialysis complications)- “obstruction of the subclavian veins can occur due 
to thrombotic obstruction, spontaneously or develop as a result of trauma, extrinsic 
compression or most frequently in association with catheters used for venous access” 
(196)(p47- 48).  
 
Trauma- “most breast trauma is self-limited and is manifested by pain, ecchymosis and 
oedema of the breast. The sequelae of breast trauma are haematoma and fat necrosis. 
The mammographic appearance of a haematoma can include poorly defined margins 
suggesting the possibility of carcinoma. Also the opacity of the haematoma may obscure 
other abnormalities in the breast, so mammography is not usually helpful in the 
evaluation of acute posttraumatic breast problems” (197)(p43-44). 
 
Post irradiation- “skin reactions associated with radiation that can include post 
treatment oedema that may persist many months” (198)(p518). 
 
Granulomatous diseases- “are focal chronic inflammatory responses to tissue injury 
manifested by a histological picture of an accumulation and proliferation of leukocytes, 
principally of the mononuclear type and its family of derivatives, the mononuclear 
phagocyte system” (199)(p168-171). 
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Fat necrosis- “is a benign condition significantly correlated with trauma or surgical 
intervention, resulting from lipase-induced aseptic saponification of adipose tissue that 
can create mass like lesions that are difficult to distinguish from carcinoma” (200)(p39). 
 
Pemphigus and other skin conditions- “in this group of immunobullous diseases 
pemphigus and other skin conditions are characterised by blisters that form within the 
epidermis with distinct subgroups with many autoantigens identified” (201)(p40.3). 
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